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PROLOGUE   
 2 
BACKGROUND AND RESEARCH GOALS 
 
INTRODUCTION 
Stress and the HPA axis 
Stress is the disruption in an organism’s homeostasis caused by physiological or 
psychological deviations (1). To maintain well-being, all organisms require the ability to 
re-establish homeostasis in the presence of stress. The brain responds to stress by 
activating the sympathetic nervous system (SNS) and the hypothalamic-pituitary-adrenal 
(HPA) axis. The HPA axis is a system of interactions between the hypothalamus, 
pituitary gland and adrenal gland that regulates hormonal responses to internal or external 
stimuli. Stress activates the HPA axis, causing the secretion of corticotropin-releasing 
hormone (CRH) and vasopressin (AVP) from the paraventricular nucleus (PVN) of the 
hypothalamus to activate corticotroph cells in the anterior pituitary (1). There, both 
hormones induce synthesis of adrenocorticotropic hormone (ACTH), which causes 
glucocorticoid (GC)) secretion from the adrenal cortex into the bloodstream (Figure 1). 
Cortisol is the GC in humans, while corticosterone (CORT) is the GC in rodents. 
Secreted CORT binds to glucocorticoid receptors (GR), expressed in peripheral organs 
and limbic brain regions such as the amygdala, thereby facilitating responses aimed at 
adapting to the stressor (1). As a mechanism of control in the stress response, after GR is 
occupied by CORT, the sustained increase in levels of plasma CORT cause it to 
negatively feedback at the level of the PVN and anterior pituitary to inhibit its own 
secretion, and thus return the system to homeostatic levels (1). This negative feedback 
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prevents unnecessary prolongation of the stress response and thus averts maladaptive 
responses that may increase susceptibility to affective disorders.  
Generally, the biology of the stress response is characterized by an initial rapid 
response, followed by a secondary slow, sustained response. The rapid response occurs 
seconds after stress exposure and consists of SNS activation of catecholamines, 
epinephrine and norepinephrine, and PVN release of CRH into the hypophyseal portal 
system (2). These hormones are fast-acting, driving second messenger signaling 
pathways to initiate changes necessary for stress mediation. HPA axis function can 
increase the release of epinephrine in order to mediate autonomic functions to increase 
arousal, vigilance and a decision to ‘fight or flight’ (3, 4). The secondary slow response is 
driven by secretion of glucocorticoids that mediate genomic functions that are protracted, 
such GC-induced increase in CRH mRNA in the amygdala (5) (Figure 1). 
GC secretion occurs in a diurnal manner, with levels rising during the onset of an 
organism’s active phase and decreasing during the inactive phase. The GCs present 
before a stressor, act in a permissive manner ready to initiate defense mechanisms in the 
event of stress. Within the first few minutes of stress exposure, there is an increase in 
energy mobilization, cardiovascular tone, immune activation, cerebral blood flow and 
memory consolidation (necessary for stress modulation), and a decrease in appetite and 
reproductive behavior (unnecessary for stress modulation) (Review (2)).  Stress-induced 
increases in GCs levels further enhance this initial rapid stress response. The excess 
glucocorticoids in the first few hours are usually beneficial to survival of the organism. 
Stress-induced increase in GCs also causes delayed functions that serve to restrain the 
stress response and prevent exaggerated deviations from homeostasis This is through 
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negative feedback on GCs on GR in the PVN and anterior pituitary (Figure 1) as well as 
hippocampus and prefrontal cortex (6, 7). After the immediate stress response, GC 
signaling prepares the system to better respond to subsequent stressors. However in the 
event of chronic or repeated stress, the hormonal response of the HPA axis is 
hyperactivated causing an aberrant rise in CORT that is resistant to negative feedback, 
further disrupting homeostasis (8, 9). GR is pivotal in governing the actions of GCs in an 
organism, and represents an essential target to study in the understanding stress 
adaptation. 
 
 
 
Figure 1. Hypothalamic-Pituitary-Adrenal (HPA) Axis Circuitry: Left panel: Normal 
circadian regulation of HPA axis. Right panel: Chronic stress can cause HPA axis hyperactivation 
and impaired negative feedback. GR, glucocorticoid receptor; HPC, hippocampus; CeA, central 
nucleus of the amygdala; BLA, basolateral amygdala; CRH, corticotropin releasing hormone; 
ACTH, adrenocorticotropic hormone, CORT, corticosterone. + activation, - inhibition 
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Glucocorticoid receptor 
The GR gene, NRC31, after alternative splicing, alternate translation start sites, 
and post-translational modifications has many protein isoforms. The processing events 
result in the formation of at least five alternatively spliced isoforms and eight 
translational isoforms of GR. Post-translation modifications such as phosphorylation and 
acetylation also produce a variety of tissue-specific localizations and differential GC 
sensitivities that allow for the plethora of GR functions (Review (10)).  For instance, 
while CORT acts on GR in the PVN to inhibit CRH and thus the cascade that results in 
its secretion, it acts in the amygdala to increase CRH mRNA and activate the HPA axis 
(11).  This makes it important to evaluate the function of GR in specific regions of the 
brain to understand it’s site-specific role in modulating stress. 
The effects of genetic GR disruption throughout the brain was first studied by 
Tronche et. al using Nestin-Cre mice, expressing Cre-recombinase in neural progenitor 
cells, to excise the exon 3 region of GR in GR floxed mice (GRNesCre) (12). These mice 
display GR deletion during embryonic development in the entire central nervous system 
including the PVN (Figure. 2B). As a result, the GRNesCre mice display extreme 
hyperactivity of the HPA axis that causes Cushing-like symptoms and decreased anxiety 
and despair-like behaviors (12).  
Limiting GR disruption specifically in forebrain neurons during adulthood 
(FBGRKO) (Figure 2C) in male mice, on the other hand, demonstrated increased basal 
and stress-stimulated CORT and despair behavior in male mice, although there are 
differences between studies (Table 1) (9, 13, 14). For instance, whereas Boyle et al 
revealed increases in plasma CORT at nadir and peak in FBGRKO mice, Furay and 
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colleagues do not observe changes in peak CORT between control and FBGRKO mice. 
Moreover, whereas stress increases CORT levels of FBGRKO in both studies, the time 
line of this increase differs between studies. Given ultradian fluctuations in 
glucocorticoid secretion, the differences in these studies may be due to the time when 
blood samples were collected. However, both studies implicate a role for forebrain GR in 
negative feedback regulation in adult male mice (9, 13, 14). The fact that male FBGRKO 
mice displayed elevated levels of CORT despite intact GR in the PVN and pituitary 
confirmed the existence of extrahypothalamic negative feedback sites. Indeed, lesion 
studies as well as GR inhibition studies in the hippocampus and prefrontal cortex both 
disrupt HPA axis activity, identifying these regions as sites of GC feedback regulation in 
the CNS (6, 15–21). The despair behavior observed in male FBGRKO mice was reversed 
after chronic antidepressant treatment, with consequent increases in hippocampal MR 
expression (9). There are overlapping regions of MR and GR expression in limbic 
forebrain regions such as the hippocampus, prefrontal cortex, and amygdala, where MR 
has a role in appraisal processes and response selection (1, 22). The data in FBGRKO 
mice supports a role for MR in compensating for GR loss in the hippocampus to mediate 
therapeutic responses to antidepressants.  
In contrast to male mice, female FBGRKO mice do not show any changes in HPA 
axis activity compared to controls despite the fact that they had the same level of GR 
deletion observed in males (23). Moreover, female FBGRKO mice do not exhibit the 
despair-like behaviors in the forced swim or sucrose preference tests that were observed 
in the males. These gender differences may be due to the influence of gonadal hormones 
on the HPA axis and stress sensitivity, or the possibility that the GR sites targeted in the 
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forebrain are differentially regulated in males and females. Differences in gender-specific 
glucocorticoid actions have been exemplified in the evaluation of GC effects on gene 
expression in the rat liver (24). The authors found unique sets of genes regulated by GR 
that were male-specific or female-specific genes that were induced to a higher degree in 
males than females or vice versa, and genes that were repressed to a higher degree in 
males than females or vice versa. When the pathways regulating some of these genes 
were evaluated, it was determined that GC-mediated anti-inflammatory actions were 
more effective in males than females, and this was caused by ovarian hormones 
suppressing GC-mediated anti-inflammatory faction. The data from this paper presents 
evidence for differential GC signaling in males and females that results in distinct gene 
expression patterns (24). Although this data explored gender differences in liver GR-
mediated gene regulation, it is conceivable that the underlying concept can be 
extrapolated to other tissues as well. 
The effects of global GR loss, as well as disruption in the CNS and forebrain, 
have been reviewed in detail in many articles (25–29). This dissertation will serve to 
evaluate studies of GR targeting along major regulatory sites of the HPA axis and 
comparisons of phenotypes between the different transgenic mice. 
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Figure 2. Glucocorticoid Receptor Expression in Genetic Mouse Models. Sagittal brain 
sections depicting areas of GR mRNA expression and deletion in mice with targeted GR deletion. 
Orange circles (●) represent GR targeted regions are in yellow highlight and blue font). (A) Adult 
control mice ubiquitously express GR mRNA in the entire brain and pituitary, with higher 
expression in limbic regions. (B) Adult GRNesCre mice have GR loss in the entire brain. (C) 
FBGRKO mice have GR loss in forebrain nuclei during adulthood. (D) At postnatal day 6 GR 
expression is low and limited to few brain region (blue font). GRCaMKCre mice have GR loss in 
most of the brain and the pituitary at P6. Abbreviations: Anterior pituitary, A Pit; Basolateral 
nucleus of the amygdala, BLA; Bed nucleus of the stria terminalis, BnST; Central nucleus of the 
amygdala, CeA; Hippocampal areas, CA1, CA2, CA3; Cerebellum, Cereb; Cingulate cortex, 
Cing Ctx; Dentate gyrus, DG; Frontal cortex, Fr Ctx; Inferior colliculus, InfC; Locus coeruleus, 
LC; Medial nucleus of the amygdala, MeA; Occipital cortex, Occ Ctx; Periaqueductal gray, PAG; 
Parietal cortex, Par Ctx; Paraventricular hypothalamic nucleus, PVN; Raphe nucleus, RN; 
Septum, Sep; Supraoptic nucleus, SN; Superior colliculus, SupC; Thalamus, Thal;  
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Corticotropin-releasing hormone 
As a central stress hormone in the HPA axis pathway, CRH has been implicated 
in stress-induced psychiatric disorders, reproductive and cardiac function, as well as 
energy metabolism. In the context of psychiatric disorders, pathological increases in 
extrahypothalamic CRH expression is associated with the occurrence of post-traumatic 
stress disorder, major depression, anorexia nervosa, and anxiety disorders. One 
extrahypothalamic source of CRH is the central nucleus of the amygdala (CeA). Studies 
have provided evidence that CORT binding to GR in the CeA increases CRH mRNA 
synthesis there (30). Effects of CORT on CeA CRH expression have been further 
demonstrated in studies where CORT pellet implantation (5, 31) or repeated CORT 
injections (32) increases CRH mRNA in the CeA of rodent (3, 5, 31–33). Consequently, 
when GR is deleted in the CeA, it results in a subsequent decrease in the levels of CRH 
mRNA (34). The increased CRH mRNA in the amygdala leads to changes that heighten 
maladaptive emotional behavior (35).  
Numerous brain functions are sensitive to stress and can be evaluated in 
behavioral paradigms that have been validated over the years. Two such brain functions 
are learning and memory, some aspects of which are mediated by the CeA(34). CeA 
lesions in rodents impair memory retention in the inhibitory avoidance task(36), the 
defensive burying task(37), and conditioned fear test(38). Although there are other 
peptides found in the CeA, such as neuropeptide Y, neurotensin, and enkephalin(39), the 
role of CRH as the major HPA axis activator in the stress response, as well as activator of 
the SNS (1) makes it a prime target of interest. 
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Early life stress increases the risk of psychiatric disorders later in life. Therefore, 
the developmental time period that stress occurs also plays a role in the neuroendocrine 
and behavioral outcomes(40). Adults who experienced some form of childhood stress 
show elevated basal cortisol, increases in ACTH responsiveness, and heightened 
emotional responses to stressful stimuli than control patients(40). In the CSF of these 
patients, increased CRH was predicted by perceived stress during pre-school years but 
not during preteen years(40). These models of early life stress have been recapitulated by 
studies of maternal deprivation in both primate and rodent models. The maternal 
deprivation model consists of taking the young away from the mothers a few hours a day 
for 2 weeks(41) and studying the behavior of the young when they reach adulthood. 
These studies show increased anxiety and depression behavior in rodents and primates 
that were maternally deprived(40, 42). In adulthood, maternally deprived primates show 
an increase in CSF CRH and rodents show increases in anxiety behavior(40). 
Furthermore, CRH mRNA in the amygdala and hypothalamus, and CRH 
immunoreactivity in the median eminence are increased due to maternal deprivation (41). 
This indicates that the time period during which one is exposed to a stress can affect the 
CRH system’s response later in life. There is a need for animal models to explore 
temporal effects of CRH over-expression in the CeA. 
The aforementioned evidence provides a solid basis for investigating the role of 
amygdalar CRH early in life. Isolating the effects of CeA CRH represents an avenue to 
discover its effects on neuroendocrine and behavioral correlates of stress to enhance 
understanding of CeA CRH in stress and psychiatric disorders. 
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RESEARCH OBJECTIVES 
GR and CRH are important molecular regulators of an individual’s ability to 
respond to stressful stimuli in an adaptive manner. Impaired signaling of both GR and 
CRH often leads to dysfunction of the hypothalamic-pituitary-adrenal axis, which 
underlies the etiology of many affective disorders such as anxiety and depression.  
Studies focusing on how GR and CRH influence the stress response are generalized to 
broad brain regions, thus hindering identification of how specific CNS nuclei contribute 
to maladaptive stress responses. Our research goals are to distinguish the site-specific 
involvement of GR and CRH in the stress response.  
Part 1 of this dissertation focuses on the regulation of GR by the HPA axis 
activity during the stress response. The paraventricular nucleus (PVN) is a major site of 
negative feedback to coordinate the degree of the HPA axis activity with the magnitude 
of the exposed stressor. To define the function of endogenous PVN GR, we used Cre-
loxP technology to disrupt different GR exons in Sim1-expressing neurons of the 
hypothalamus. Part 2 focuses on the use lentiviral (LV) vectors in combination with 
tetracycline transactivation system in transgenic mouse lines, to enable overexpression of 
CRH with spatial and temporal specificity.  
The complete work in this dissertation represents an exploration of the 
neuroendocrine, molecular and behavioral consequences of GR and CRH signaling in 
mediating adaptation to stress. 
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CHAPTER I 
 
 
INTRODUCTION TO GLUCOCORTICOID RECEPTOR MEDIATION OF THE 
HYPOTHALAMIC-PITUITARY-ADRENAL AXIS  
 
INTRODUCTION 
Glucocorticoids (GCs) are endogenous steroid hormones that were first identified 
circa 1929 when studies in adrenalectomized animals demonstrated that adrenal cortex 
extracts ameliorated the effects of adrenal insufficiency (1–3). Two decades later, GCs 
isolated from the adrenal cortex were shown to treat symptoms of Addison’s disease and 
rheumatoid arthritis leading to the Nobel Prize in Physiology for Edward Kendall, Tadeus 
Reichstein, and Philip Hench in 1950 (4–6). Since then, GC function has been 
demonstrated as important in the stress response for promoting coping and adaptation to 
stress as well as recovery from the stressor (7–12). In addition, GC function has been 
demonstrated in metabolism, reproduction, and inflammatory and immune responses (9, 
13). As a steroid hormone, GC synthesis begins in the adrenal gland from cholesterol. 
Specifically, in the adrenal cortex, cholesterol is transported into the mitochondria by the 
steroidogenic acute regulatory (StAR) transport protein (14). In the mitochondria, a series 
of enzymatic reactions ultimately results in the conversion of 11-deoxycortisol by 11β-
hydroxylase (CYP11B1) into cortisol (humans) or corticosterone (rodents) (15). 
Embryonic GC synthesis begins as early as E14.5 in mice (16) and at approximately 50 
days post-conception in humans (17). Secretion of GCs is regulated in a circadian 
rhythm, through the suprachiasmatic nucleus of the hypothalamus (SCN) function, and 
by stress. Secretion of GCs shows ultradian and circadian regulation as well as 
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modulation by stress. Circadian regulation of GC results in a diurnal rhythm of GC 
secretion that has a 24-hour period and is governed by function of the suprachiasmatic 
nucleus of the hypothalamus (SCN) (18, 19) 
The SCN is a located in the anterior hypothalamus just dorsal to the optic chiasm. 
It receives light input from the optic region through the retinohypothalamic tract. This 
light input synchronizes the SCN to cause the generation of the 24-hour circadian cycle 
of biological processes that regulates mammalian physiological homeostasis. One of the 
most robust endocrine processes governed in a circadian fashion is the activity of the 
hypothalamic-pituitary-adrenal (HPA) axis, the major output of which is GC production. 
Neuronal tracing has provided evidence showing that arginine vasopressin (AVP) 
neurons from the SCN project into the paraventricular nucleus of the hypothalamus 
(PVN) through the dorsal hypothalamus and regulates the circadian rhythm of 
corticotropin-releasing hormone (CRH) (20, 21). The circadian release of CRH then 
regulates adrenocorticotropic hormone (ACTH) secretion from the anterior pituitary, 
which subsequently triggers the secretion of corticosterone in rodents and cortisol in 
humans (CORT) from the adrenal cortex. This circadian rhythmicity is confirmed in SCN 
lesion studies that result in abolished CORT rhythms (22–24) as well as disrupting 
secretion of CRH and ACTH (25, 26). CORT secretion however does not occur only 
through the HPA axis drive. Studies suggest that the adrenal cortex contains its own 
endogenous clock system that regulates circadian GC secretion that is independent of 
HPA axis activity but is dependent upon the SCN (27–29). This adrenal modulation may 
be mediated by multisynaptic projections from the SCN through the autonomic nervous 
system to the adrenal cortex (30). The result is a diurnal rhythm of CORT secretion over 
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a 24-hour period that provides a basis for an organism’s daily internal homeostasis. 
Underlying this circadian regulation is an ultradian rhythm of pulsatile CORT secretion 
throughout the day that is independent of SCN or stress-inputs. This pulsatility is crucial 
for stress responsiveness and can vary in frequency and amplitude as a consequence of 
feedback latency (31, 32) 
The circadian rise in GCs occurs immediately prior to the onset of the active 
period in mammals. In humans, this increase occurs in the morning before awakening, 
while in nocturnal animals CORT rise occurs in the evening before their active period 
begins (33–35). This awakening rise is CORT may promote mobilization of necessary 
energy to begin the activity necessary to carry out daily function (7). In order to mediate 
its functions, GCs act on two major receptors, type 1 high affinity receptors, 
mineralocorticoid receptors (MR) and type 2 low affinity receptors, GC receptors (GR) 
(36). These receptors have different spatial distribution in the brain and periphery, with 
GR being more broadly distributed and serving as the main receptor in times of stress 
(37). Stress activation of the HPA axis serves to prepare an organism to respond to a 
perceived threat and then to permit adaption that reinstates homeostasis (10). This latter 
function is especially important because chronic HPA axis activation leads to constantly 
elevated GC levels, which is detrimental to an organism. Negative feedback of GCs on 
the HPA axis is therefore essential to inhibit the damaging effects of CORT. 
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GR MECHANISM OF ACTION 
Since steroid hormones such as CORT are highly lipophilic, they are able to cross 
the plasma membrane and enter the cytoplasm of a cell through simple diffusion. Once 
CORT is inside a cell, it binds to GRs that are initially inactively bound to heat shock 
protein 90 (HSP90). The binding of CORT to GR results in a conformational change that 
releases GR from inactivation and causes two major modes of GR action. One mode of 
GR action occurs through non-genomic signaling pathways, that produce fast-acting 
effects in the order of seconds to a few minutes (38, 39). This occurs through GC action 
on membrane bound receptors or cytoplasmic GR that activate rapid signaling of second 
messenger pathways (13, 40–43). The other mode is the classical GR function which 
occurs when activated GR translocates into the nucleus and functions as a transcription 
factor to modulate genomic signaling pathways, which can take a period of 15 minutes to 
several hours. GR can act as a homodimer, monomer, or heterodimer (with MR or other 
transcription factors) to regulate gene transcription. Direct binding of GR to positive or 
negative GC-response elements (GRE) on target genes serves to activate or repress 
transcription respectively (44). In certain cases some genes require DNA-bound GR to 
physically interact with another transcription factor adjacently bound to the gene of 
interest for transcriptional activity to occur. Indirect DNA binding by GR monomers 
through tethering in a protein-protein interaction to DNA-bound transcription factors, 
such as AP-1, STAT5, and NF-KB also regulates gene expression (44, 45). In general, 
dimerization of GR and its binding to GRE results in transactivation GR-responsive 
genes, while monomeric GR interactions to other transcription factors leads to 
transrepression of genes (46). Indeed, mutations in the DNA-binding domain of GR that 
 21 
prevents its ability to dimerize, disrupts GR’s transactivation function but not its 
transrepressive function (47). There is also evidence of a GR trimer bound to POMC that 
results in transrepression of the POMC gene (48). Heterodimers of GR with MR have 
been identified to bind GRE and regulate gene transactivation with different kinetics than 
GR homodimers (49–51). Elevated levels of GC have been shown to increase the 
likelihood of GR-MR heterodimerization (52).  This implies that variable levels of GC 
may result in differences in homodimer and heterodimer formation to contribute to the 
fine-tuning of regulation of GC-responsive genes (53). The variety in GR signaling, as a 
monomer, homodimer, heterodimer, or trimer, is demonstrative of the ability of GC 
signaling to modulate diverse functions in an organism (54).   
While GCs are important for the treatment of many disorders, their chronic use, 
especially systemic administration, can result in mood disorders, osteoporosis, obesity, 
metabolic syndrome, and reduced immune system function (55–58).Therefore, regulation 
of the HPA axis by CORT is extremely important in preventing maladaptive phenotypes 
and maintaining normal mammalian function. Disrupted GC regulation is observed in a 
number of psychiatric and metabolic disorders. Major sites of negative feedback 
regulation are the PVN and anterior pituitary, although the hippocampus and prefrontal 
cortex also mediate GC feedback. 
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CLINICAL EFFECTS OF IMPAIRED GC SIGNALING 
The human GR gene, NR3C1, is located on the short arm of chromosome 5, 
5q31–32 and undergoes alternative RNA splicing and translation initiation to yield 
multiple functionally distinct isoforms.  The two most abundant isoforms generated are 
GRα and GRβ, with GRα being expressed at higher levels in most tissues (44). 
Alternative translation start sites of the human GR mRNA produce translational isoforms 
of GRα, GR-A, -B, -C1, -C2, -C3, -D1, -D2, and -D3, also each have their own unique 
distribution patterns and gene targets (44, 59). This selectivity may underlie the varied 
GC responses amongst tissues and patients. The multiple GR isoforms, alternative 
processing, tissue and cell-specific expression patterns and post-translational 
modifications demonstrate how the GR gene can be modified to produce a maximum 
range of functions. In the rodent studies described in prior sections, GR disruption along 
negative feedback sites reduces GR expression in specific brain regions and is associated 
with abnormal HPA axis regulation that affects anxiety, despair, and metabolic 
phenotypes. In this section, we briefly explore studies demonstrating that GR disruption 
and its effects are translatable to human psychiatric and metabolic diseases.  
 
Psychiatric Disorders 
As the end products of the HPA axis, GCs bind to GRs at the level of the 
hypothalamus and anterior pituitary to exert negative feedback effects and maintain 
homeostasis in response to stress. Increased cortisol levels and an inability to suppress 
cortisol secretion in the DST are known hallmarks of a number of psychiatric disorders 
including schizophrenia, bipolar disorder, generalized anxiety, and major depressive 
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disorders (60–66). Individuals with major psychiatric illness often display 
hypercortisolemia (67, 68) and a down-regulation in GR mRNA in a network of regions 
including the hippocampus, amygdala, and temporal cortex (69–71).  
Major depressive disorder (MDD) is characterized by increased release of GCs 
and hyperactivity of the HPA axis (72, 73).  A primary feature of this hyperactivity is 
non-suppression of cortisol secretion in response to administration of the synthetic 
glucocorticoid, dexamethasone.   Patients with MDD display a reduction in the number 
and function of GR (69, 74–78). Many studies have addressed the role of GR 
abnormalities in the pathophysiology of MDD by examining the effects of 
antidepressants on GR expression and function and HPA axis activity (79). Indeed, 
impaired GR function has been suggested to be causal for HPA axis hyperactivity in 
depression, as GCs typically regulate the HPA axis through negative feedback inhibition 
and thereby reduce the production of GCs themselves. This effect is thought to be 
mediated in part by GR. Therefore, hyperactivity of the HPA axis has been explained by 
an impaired feedback inhibition of GCs, possibly due to an impaired or dysfunctional GR 
(“glucocorticoid resistance”) (80). In support of this, data in numerous studies of 
antidepressant treatment on rodents have demonstrated increased GR expression in the 
hypothalamic and hippocampal brain regions, which may indicate a mode for 
antidepressant mediated HPA axis normalization (81–84). 
The non-coding exon 1 of GR contains a 5’ untranslated region (UTR) that 
determines tissue specific production of GR. Epigenetic modifications such reduced 
DNA methylation of the GR promoter in this 5’ UTR have been observed in rodent 
models of low maternal care and are associated with increased risk for addiction, 
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depression, diabetes and obesity (85, 86). The mechanism of action due to increased 
methylation of NGF1-A disrupts its binding to hGR17 promoter and thus causes a 
reduction of GR transcription (87, 88). Moreover, expression of other variants, decreased 
hGR1B and hGR1C but increased hGR1H, due to increased methylation have also been 
identified (86, 89). Specifically, these GR variants are reduced and correlate with 
decreased total GR in the hippocampus of suicide victims only when they have a history 
of childhood abuse. The idea that GC excess early in life can reprogram HPA axis 
reactivity in part through decreasing GR expression in specific brain regions that are 
responsible for mediating negative feedback. In support of this concept, fetal GC excess 
in humans has been found to increase the risk for schizophrenia in adulthood (90). 
Moreover increased fetal GCs due to maternal obesity or malnutrition also increases the 
risk of schizophrenia when the child grows into an adult (91–94). Post mortem analysis 
shows GR mRNA is decreased in the brain of patients with schizophrenia and depression 
(95).  These data represent a convergence between psychiatric and metabolic diseases 
both associated with increased GC levels, potentially the result of disrupted GR 
expression hindering negative GC feedback. 
A number of single nucleotide polymorphisms (SNPs) have been identified in 
GR, namely Bcl1, N363S, and ER22/23EK, that cause changes in GC sensitivity (Review 
(96, 97)).  Bcl1 and N363S are associated with increased GC sensitivity, while 
ER22/23EK associates with reduced GC sensitivity. Moreover some of these SNPs are 
associated with HPA axis disruption, including altered cortisol and ACTH secretion after 
stress, and may modify the risk of depression (97). SNPs in genes that mediate GR 
function have also been observed to associate with psychiatric disorders. For instance, 
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FKBP5, is a GR chaperone protein that prevents nuclear translocation and reduced GR 
affinity to GC (98). An increase in FKBP5 due to a SNP results in impaired GR-mediated 
negative feedback and GC resistance and is found to be associated with PTSD and MDD 
(99–101). In patients with MDD, decreased hippocampal volume and increased 
inflammatory cytokines are associated with decreased expression of genes targeted by 
GR activation (102). These data point to a prime role of regulation of GR function in 
mediating neuroendocrine and histopathology that affect the development of psychiatric 
disorders. 
 
Metabolic Disorders 
GC activation of GR regulates a variety of important cardiovascular, metabolic 
and immunologic functions. Synthetic GCs, including prednisone/prednisolone and 
dexamethasone, are widely prescribed anti-inflammatory drugs used to treat a number of 
immune and inflammatory diseases including allergies, asthma, lupus and rheumatoid 
arthritis. Although therapeutic benefits of GCs are vast, long-term use of GCs results in 
negative side effects including muscle wasting, abdominal fat deposition, and insulin 
resistance. In addition, some patients do not respond to GC therapy and those that do may 
develop GC resistance. Moreover, discontinuation of long-term GC therapy has been 
shown to result in increased risk of delirium and depression in 10% of users (103). 
Tissue-specific GC resistance has been associated with rheumatoid arthritis, 
osteoarthritis, Crohn's disease, ulcerative colitis and asthma (104).  Impaired negative 
feedback of GC along the HPA axis that leads to excess circulating GCs may contribute 
to the development of metabolic disorders. Excess GCs have been observed in metabolic 
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syndrome cluster diseases including Cushing’s syndrome, obesity, type II diabetes, and 
insulin resistance.  
Bioactive concentrations of plasma CORT are regulated, not only by negative 
feedback, but also by the expression of the corticosteroid binding globulin (CBG) and 
11β-hydroxysteroid dehydrogenase type 1 and type 2 (11β-HSD 1/2) (105). These 
proteins have tissue-specific expression that govern tissue-specific activity of GCs. CBG 
binding to plasma CORT and sequester its diffusion into cells to facilitate transport 
through circulation, thus governing the bioavailability of CORT. Low levels of CBG 
have been identified in stress states as well as adipose tissue of obese rats (106–108). 
11β-HSD1 is the enzyme that converts the precursor 11β-deoxycortisol or 11β-
deoxycorticosterone to cortisol and corticosterone, respectively. 11β-HSD2 on the other 
hand, mediates the reverse reaction of CORT to inactive metabolites (105). Disruption of 
the availability of these regulatory proteins have been linked to obesity and insulin 
resistance (109–114). To understand how disruption of GR along the negative feedback 
sites contribute to metabolic disorders, future studies in the previously described genetic 
models will be needed to evaluate CBG, 11β-HSD1/2, and proteins involved in metabolic 
activity in more detail. 
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CONCLUSIONS  
Circadian regulation of GC signaling is necessary for maintenance of normal 
physiological function while stress regulation of GC signaling represents a pathway to 
manage disruptions in homeostasis. The paradox of stress regulation is that it can impart 
beneficial effects but it can also be detrimental when not turned off. We’ve briefly 
discussed some clinical effects of GCs on psychological and metabolic function in 
humans. The understanding of molecular activity in humans is largely governed by 
understanding in animal models. The next chapters will discuss the detrimental effects of 
stress due to impaired negative regulation of GCs in a number of genetically altered 
rodent models.  We strive to clarify the importance of glucocorticoids and the HPA axis 
in mediating stress reactivity in terms of endocrine output, behavioral activity, and energy 
balance.   
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CHAPTER II 
 
 
DISRUPTING HYPOTHALAMIC GLUCOCORTICOID RECEPTORS CAUSES HPA 
AXIS HYPERACTIVITY AND EXCESS ADIPOSITY. 
 
Gloria Laryea,  Günther Schütz and Louis J. Muglia 
 
INTRODUCTION 
The paraventricular nucleus of the hypothalamus (PVN) is a key regulator of 
metabolism, stress responses, and physiologic homeostasis. The glucocorticoid receptor 
(GR) is of specific importance in these varied functions of the PVN. GR functions as the 
primary mediator of feedback regulation in hypothalamic-pituitary-adrenal (HPA) axis 
stress response systems. The parvocellular neurons of the PVN synthesize and secrete 
corticotropin-releasing hormone (CRH) and vasopressin (AVP) in response to stress. 
CRH is secreted into the hypophyseal portal system and acts on the anterior pituitary 
where it stimulates the synthesis and secretion of adrenocorticotrophic hormone (ACTH). 
ACTH is released into the blood stream and stimulates adrenal cortex secretion of 
cortisol in humans or corticosterone (CORT) in rodents. CORT acts on peripheral tissues 
and central nervous system GRs to mediate normal circadian function as well as the stress 
response. CORT then negatively feeds back at the level of the pituitary to inhibit ACTH 
secretion, as well as at the level of the PVN to inhibit CRH secretion and restore the 
system to homeostasis. CORT binding to GR in the PVN, pituitary, and other CNS sites 
in the forebrain, mediates the negative feedback inhibition of CORT. Dysregulation of 
the HPA axis, possibly due to impaired GR signaling, has been implicated in the 
pathogenesis of affective disorders, such as major depression, in humans (1-5).  
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Several genetically altered rodent models of GR disruption have demonstrated a 
role for GR in mediating neuroendocrine, physiological, and behavioral responses (See 
(6-8) for review). Global GR deletion in mice targeting Exon 2 of GR, GRhypo (9), or 
Exon 3, GRnull (10, 11) leads to perinatal and fetal mortality due to improper lung 
maturation. Interestingly, 20% of GRhypo mice survive into adulthood, whereas all the 
GRnull mice die within hours after birth, indicating differences in penetrance depending 
on the specific nature of targeting the GR locus (12). The fetal lethality limited further 
studies on stress-related behaviors in these mice, leading to the development of region-
specific deletion models.  
Conditional deletion of the floxed GR exon 3 allele in the whole brain using 
Nestin-Cre results in mice with HPA axis hyperactivity and consequent Cushing 
syndrome phenotypes (growth impairment, altered fat distribution, obesity), as well as 
reduced anxiety-like behaviors (13). When GR disruption is limited to adult forebrain 
neurons using the CaMKIIα-Cre transgene (FB-GRko), mild HPA axis dysregulation 
occurs, as well as increased anxiety and despair-like behaviors that can be reversed with 
antidepressant treatment (14, 15). In comparison, GR disruption in embryonic forebrain 
neurons, PVN and pituitary neurons (using BAC CaMKIIα-iCre transgenic and floxed 
exon 3 transgenic mice (GRCaMKCre)) leads to severe HPA axis hyperactivation, growth 
impairments, and death before post-natal day 10 (16). Disrupting GR in the pituitary, 
GRPOMCCre, results in elevated basal CORT levels, changes in PVN CRH and AVP 
mRNA, reduced body weight, all of which normalize in adulthood, and more active 
stress-coping behavior in the forced swim test (17). As one of the primary sites of GR 
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feedback regulation, the PVN’s specific role during HPA-axis development and stress 
reactivity still needs to be analyzed.  
We set out to isolate the specific contribution of PVN GR in mediating the 
aforementioned changes in regulation of glucocorticoid synthesis. We used Sim1-Cre 
BAC transgenic mice (18) to recombine floxed GR alleles, one removing exon 1C-2, and 
the other removing exon 3. These mice drive Cre expression during embryonic and post-
natal development in the PVN, as well as the medial amygdala and nucleus of the lateral 
olfactory tract (18). This model has the unique potential to address several important 
questions in HPA-axis regulation and behavior. For instance, can other 
extrahypothalamic sites of GR negative feedback modulate glucocorticoid production and 
compensate for GR disruption in the PVN?  Does PVN loss lead to upregulation of CRH 
expression, as it remains unclear whether a functional glucocorticoid response element 
exists in CRH gene locus. Additionally, does loss of GR in the PVN affect stress-related 
behaviors?  The two major conventional GR knockouts, described earlier, differ in their 
phenotypes. Therefore, in addition to understanding these unresolved questions regarding 
PVN GR, we investigate whether there would be any differences in phenotype depending 
on what domain of GR was conditionally disrupted. To investigate this, we used mice 
that had GR floxed for the exon 1C-2 region (GRe1C-2), containing promoter elements, 
translation start site, and the transcriptional activation domain or the exon 3 region 
(GRe3), containing the zinc finger of the DNA-binding domain (19, 20), both in 
combination with the Sim1-Cre BAC transgenic mice.  
Our physiological data indicate that loss of the exon 3 region of GR in the PVN 
results in fat accumulation due to glucocorticoid excess and a more severe HPA axis 
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dysregulation phenotype than loss of exon 2. Our behavioral data indicate that PVN GR 
alone does not mediate basal changes in anxiety and despair-related behaviors. We find 
that conditional deletion of GRe3 in the PVN leads to increased PVN CRH mRNA, 
increased plasma ACTH and glucocorticoid excess. Unlike GR deletion in the pituitary 
(17), we do not find compensation, but persistent HPA hyperactivation in adulthood, 
where circadian rhythm of glucocorticoid secretion is retained. In contrast, deletion of 
GRe1C-2 region is associated with intact HPA axis regulation. These differences may be 
contributed to by altered deletion efficiency or residual production of truncated activity-
retaining GR fragments. 
 
 
MATERIALS AND METHODS 
Animals 
All animal protocols were in accordance with National Institutes of Health 
guidelines and were approved by the Animal Care and Use Committees of Vanderbilt 
University (Nashville, TN) and Cincinnati Children’s Medical Center (Cincinnati, OH). 
Mice were housed on a 12 h/12 h (Vanderbilt) or 14 h/10 h (Cincinnati Children’s 
Medical Center) light/dark cycle with ad libitum access to rodent chow and water. Mice 
used for studies were between 3-6 months old.  
Sim1Cre-GRe3∆ mice:  We mated Sim1Cre mice (18) to floxed GR exon 3 mice (13). 
Sim1Cre-GRe2∆ mice:  We bred Sim1Cre mice to floxed GR exon 1C-2 mice (21). 
Controls: Littermates that were Cre negative but had GR exon 1C-2 or exon 3 floxed 
alleles were used as controls. In figures displaying a comparison of Sim1Cre-GRe2∆ and 
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Sim1Cre-GRe3∆ mice, controls represent littermates from both types of matings. 
Sim1Cre mice were the kind gift of Dr. Brad Lowell, Beth Israel Deaconess Medical 
Center, Boston, MA.  Sim1Cre, floxed GR exon 3, and floxed GR exon 1C-2 lines have 
been maintained on an inbred C57BL/6 background. 
 
Immunohistochemistry 
We anesthetized mice with 2.5% Avertin, perfused them with DEPC 1x PBS 
followed by 4% DEPC PFA, and post-fixed the brains and pituitaries in 4% DEPC PFA 
overnight. We then immersed the brains in 70% ethanol and processed them for paraffin 
embedding. Paraffin embedded brains were sectioned, on a microtome, at 8 µm while the 
pituitaries were sectioned at 5 µm onto Superfrost+ slides (VWR). The slides were placed 
at 60ºC overnight then stored at room temperature until later use. The slides were 
deparaffinized and rehydrated in decreasing concentrations of ethanol. Next, we 
performed antigen reconstitution of sections in 10mM Citrate Buffer (pH 6.0), followed 
by PBS washes and 1 hour blocking in 3% normal goat serum/ 0.25% Triton-X-100 in 
PBS to prevent non-specific binding. GR: Primary antibodies were 1:200 rabbit m20-anti-
GR, directed against the N-terminus of GR, (Santa Cruz Biotech. Cat# sc-1004) and 
1:200 mouse anti-NeuN; Secondary antibodies were 1:250 biotinylated goat anti-rabbit 
IgG and 1:200 goat anti-mouse Alexa 488 IgG; Washed slides were incubated in 
avidin/biotin complex (Vectastain), Cyanine-3 tyramide amplified (Perkin Elmer) and 
coverslipped with DAPI (Vector Laboratories). We quantified the number of GR positive 
cells that colocalized with Dapi as a percentage of total Dapi positive cells in the PVN. 
ACTH: Primary antibodies were 1:200 rabbit m20-anti-GR (Santa Cruz Biotech.) and 
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1:200 guinea pig anti-ACTH (Bachem Cat# S-3029); Secondary antibodies were 1:250 
biotinylated goat anti-rabbit IgG and 1:100 goat anti-guinea pig FITC IgG; Slides were 
incubated with ABC, Cyanine-3 tyramide amplified and coverslipped with DAPI as 
above. We quantified the number of GR positive cells that colocalize with ACTH 
positive nuclei as a percentage of total ACTH positive cells in the anterior pituitary. 
 
Body weight, gonadal fat, and adrenal gland measurements 
We weighed mice weekly starting on weaning day, postnatal day 21 (P21) to 22 
weeks of age. We dissected and weighed intra-gonadal fat pads and adrenal glands of 
mice 3-6 months old. 
 
Corticosterone radioimmunoassay 
 Mice were single housed for a week and submandibular bleeds were performed in 
mice at nadir, peak, and 20 minutes after restraint stress, with two days between bleeds. 
The blood was centrifuged at 14000 rpm for 6 minutes and the plasma was removed and 
stored at -80ºC until a radioimmunoassay (RIA) was performed. RIA was performed 
using the Corticosterone Double Antibody - 125I RIA Kit (MP Biomedicals, Solon, OH).  
 
Plasma glucose concentration 
We used the AVIVA plus glucose meter to measure plasma glucose levels 
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Dexamethasone suppression test 
Mice were given saline or dexamethasone (0.1mg/kg) injections in the morning 
and bleeds were performed 1 hour before lights out. The blood was centrifuged at 14000 
rpm for 6 minutes and the plasma was removed and stored at -80ºC until the CORT RIA 
was performed. 
 
CRH in situ hybridization 
We anesthetized mice with 2.5% Avertin, perfused them with DEPC 1x PBS 
followed by 4% DEPC PFA, and post-fixed the brains in 4% DEPC PFA overnight. 
Brains were immersed in 20% DEPC sucrose solution for 48 hours, then embedded in 
OCT. 16um sections were obtained from brains at -15ºC in a cryostat and mounted onto 
Superfrost+ slides (VWR), vacuum-dried overnight, and stored at -80ºC until in situ 
hybridization was performed. P-33 UTP was used to label an RNA probe complementary 
to a 0.32 KB fragment on exon 2 of the CRH mRNA. Sections were hybridized to the 
labeled probe at 65ºC for 16 hours and washed in 0.1X SSC at 60ºC for 30 min. Slides 
were exposed to Maximum resonance film (Kodax BioMAx, Rochester N.Y.) for 4 days. 
We scanned the autoradiographic images at 3200 dots/inch into Photoshop on an Epson 
Perfection V600 scanner and quantified using NIH Image J software. 
 
Behavioral tests 
All behavioral tests were performed between 8:00 a.m. and 12:00 p.m. Mice were 
allowed to acclimate in the testing room for an hour prior to behavioral testing. Male 
mice between 12 and 20 weeks old were used in tests.  All behavioral tests were 
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performed in the Vanderbilt Murine Neurobehavioral lab at the Vanderbilt University 
Medical Center and the Cincinnati Children’s Hospital behavior core.  
 We evaluated anxiety using the open field (OF) and the elevated zero maze. Both 
tests pit the innate aversion of rodents to open unsecure spaces against their natural 
curiosity to explore the environment. Open Field: The OF activity was measured in 
chambers (Med Associates, 27×27×20.5 cm) that were contained within a light- and air-
controlled environment. Each trial lasted 30 minutes per mouse. During that time, the 
Activity Monitor v5.10 program (Med Associates Inc, St. Albans, VT) was used to 
measure behaviors such as time spent, distance travelled, and number of entries into the 
inner and outer zones of the chamber. Elevated Zero Maze: This maze (34 cm inner 
diameter, 46 cm outer diameter, placed 40 cm off the ground on 4 braced legs) consists of 
a round maze with opposing open and closed arms. Mice are placed in the center of the 
open arm and activity is scored for 5 minutes using ANY-Maze software (San Diego 
Instruments, San Diego, CA). Time spent in the open and closed areas, as well as number 
of entries into the open and closed areas were measured.  
Forced swim and tail suspension tests are measures of learned helplessness and 
despair (due to their predictive validity). Forced swim test: This test utilizes a 2L beaker, 
filled to 1.5L with water at room temperature (25°C). The mouse was placed in the 
beaker for 5 minutes. Every 5 seconds, the mouse’s activity was recorded by an observer 
blind to genotype. We quantified the total time inactive during the trial, where more 
inactivity is indicative of increased despair. Tail suspension tests:  The tail suspension 
test employed a platform from which mice are suspended by their tails; motion was 
scored with either an automated system with user-defined thresholds or manually with the 
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observer blinded to genotype.  Motion was scored for 5 minutes manually or for 7 
minutes in the automated system. Time spent below a specified lower threshold was 
interpreted as inactivity.  Animals excluded from analysis after behavioral testing were 
those unable to be scored due to falling off the zero maze apparatus or sinking in the 
forced swim.  These test failures did not differ in frequency between the different 
genotypes. 
 
Statistical analysis 
Results are presented as mean ± SEM. Data were subjected to Student t-test, one- 
or two-way ANOVA test (Prism 5.0 software; GraphPad Software, Inc., San Diego, CA). 
Statistical significance was analyzed using the Tukey or Bonferroni post hoc test. 
Significant difference was defined at a p value ≤ 0.05. 
 
 
RESULTS 
Deletion of GRe1C-2 and GRe3 in the PVN neurons expressing Sim1 
We bred Sim1-Cre BAC transgenic mice (18) to mice that have loxP sites 
flanking exons 1C and 2 (21) or exon 3 of the GR gene (13). We thus generated mice 
with GRe1c-2 deleted in the PVN (Sim1Cre-GRe2∆) or mice with GRe3 deleted in the 
PVN (Sim1Cre-GRe3∆). Control mice were negative for Cre-recombinase. We evaluated 
the specificity and efficiency of GR deletion by fluorescent immunohistochemistry and 
quantified the percent of GR positive nuclei in the PVN. We demonstrated a 43% 
reduction in PVN GR expression in Sim1Cre-GRe2∆ mice (p=0.03). In contrast, we 
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found 87% decrease in PVN GR in Sim1Cre-GRe3∆ mice (p=0.002) (Figure 2.1.) when 
compared to control mice (One-way ANOVA F(2,8)=15.47, p=0.0018). 
 
 
 
 
Figure 2.1. GR immunoreactivity is reduced in the PVN (outlined area) of mice with 
disrupted GR. (A) Immunofluorescent staining for GR protein in the PVN of controls, Sim1Cre-
GRe2∆, and Sim1Cre-GRe3∆ mice. GR (red), NeuN (green), Dapi (blue). (B) Quantification of 
the amount of GR in the PVN that co-localized with Dapi as a percent of total Dapi. The bars 
represent mean + SEM.  Sim1Cre-GRe2∆ mice have a 43% reduction in GR protein, while 
Sim1Cre-GRe3∆ mice have an 87% reduction compared to controls (ctrl). *p-value < 0.05* and 
**p<0.01. 
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Sim1Cre-GRe3∆, but not Sim1Cre-GRe2∆, mice have increased body weight and fat 
mass in adulthood. 
In terms of body weight, Sim1Cre-GRe2∆ mice are phenotypically 
indistinguishable from control mice. On the other hand, Sim1Cre-GRe3∆ mice display 
characteristics of a glucocorticoid excess (Cushingoid) phenotype. At birth, Sim1Cre-
GRe3∆ mice are smaller than controls (p < 0.05), but in adulthood they display increased 
weight gain, and obesity (Figure 2.2.). We observed this in females (p < 0.05) (Figure 
2.2. A) and some male Sim1Cre-GRe3∆ mice, although there was enough variability 
between the males such that differences were not statistically different (Figure 2.2. B).  
To determine contributors to increased body weight, we dissected and weighed 
perigonadal fat pads from female and male mice. Female Sim1Cre-GRe3∆ mice had a 
14-fold increase in fat pad mass, while male Sim1Cre-GRe3∆ mice had a 3-fold increases 
in fat pad mass compared to control littermates (p=0.0006, females, p=0.001 males) 
(Figure 2.2. D,E). Due to this observed increase in adiposity and predicted high CORT 
levels, we tested serum glucose concentrations at baseline and following restraint stress. 
We observed that baseline blood glucose levels did not vary between genotypes in either 
gender (p=0.12 females, p=0.48 males) (Figure 2.2. F,G). However, Sim1Cre-GRe3∆ 
mice fail to exhibit the stress-induced elevations in blood glucose levels (p=0.22 females, 
p=0.3 males) observed in controls (p=0.0007 females, p=0.002 males) and Sim1Cre-
GRe2∆ mice (p=0.0005 females, p=0.03 males) (Figure 2.2. F,G).  
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Figure 2.2. Sim1Cre-GRe3∆ mice have altered growth and fat accumulation. The mean 
(±S.E.M.) body weights of control and Sim1Cre-GRe3∆ mice over a 6-month period, females (A) 
and males (B). Images depicting phenotype differences between female control and Sim1Cre-
GRe3∆ mice at 4 months of age (C). Ovarian (D) and Testicular (E) fat pad weight in each group 
of mice. (F,G) Plasma glucose levels measured at nadir, peak, and after 20-minutes of restraint 
stress. Control and Sim1Cre-GRe2∆ mice display increase plasma glucose after stress, ***p< 
0.001, whereas Sim1Cre-GRe3∆ mice do not, p >0.05, females (F) and males (G). p-value < 
0.05* and **p<0.01, *** p < 0.001, **** p<0.0001. 
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Sim1Cre-GRe3∆ mice, but not Sim1Cre-GRe2∆ mice, display increased HPA axis 
activity 
To evaluate the cause of the Cushing-like phenotype, we measured serum CORT 
levels. We found significantly elevated basal plasma CORT levels in both female (p 
=0.07 nadir, p=0.0005 peak) and male (p < 0.0001, nadir and peak) Sim1Cre-GRe3∆ 
mice that maintained circadian rhythmicity (Figure 2.3. A,B). Twenty minutes of restraint 
stress further elevated CORT levels (Figure 2.3. A,B) in Sim1Cre-GRe3∆ mice (p=0.04 
females, p< 0.0001 males). Moreover Sim1Cre-GRe3∆ mice fail to suppress CORT 
secretion in the dexamethasone suppression test (p=0.45 females, p=0.27 males) while 
their littermate controls suppressed CORT secretion by approximately 50% after 
dexamethasone administration (p=0.02 females, p=0.05 males) (Figure 2.3. C,D).  
To determine the mechanism by which loss of GR in the PVN leads to increased 
CORT, we evaluated CRH mRNA and protein expression in the PVN of control, 
Sim1Cre-GRe2∆, and Sim1Cre-GRe3∆ mice. We observed a 3-fold increase in CRH 
mRNA expression in Sim1Cre-GRe3∆ (p=0.01) but not Sim1Cre-GRe2∆ mice (p=0.9) 
compared to controls (one-way ANOVA F(2,9)=30.22, p=0.0001) (Figure 2.4. A,B). 
Interestingly, we found a significant effect of genotype on amygdala CRH mRNA 
expression (One-way ANOVA F(2,9)=6.202, p=0.0203), where CRH mRNA in the 
central nucleus of the amygdala increased in Sim1Cre-GRe3∆ mice compared to 
Sim1Cre-GRe2∆ mice (t-test, p=0.016), with a similar trend in SimCre-GRe3∆ mice 
compared to control mice that did not achieve statistical significance (Figure 2.5. A). 
Despite the significant increase in PVN CRH expression, pituitary ACTH 
immunoreactivity did not differ and GR protein in ACTH producing cells of the pituitary  
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Figure 2.3. Loss of PVN GR results in hypercorticosterolemia and impaired negative 
feedback in female (A, C) and male (B, D) mice. (A,B) Plasma CORT levels measured at nadir, 
peak, and after 20-minutes of restraint stress. Sim1Cre-GRe3∆ mice display increased plasma 
CORT at nadir, peak and after stress compared to controls and Sim1Cre-GRe2∆ mice. (C,D) 
Dexamethasone suppression test was used to evaluate negative feedback. Control female mice 
show a 50% suppression of CORT after dexamethasone p<0.05 (C), while males show a trend 
towards CORT suppression (D). Sim1Cre-GRe3∆ mice do not show suppression of CORT after 
dexamethasone administration. #p = 0.053  *p<0.05, ***p<0.001. 
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Figure 2.4. HPA axis hyperactivity is observed in Sim1Cre-GRe3∆ mice. (A,B) CRH mRNA 
expression is increased in the PVN of Sim1Cre-GRe3∆ mice. (A) Representative images of 
pseudo-colored CRH in situ hybridization in control mice (left), Sim1Cre-GRe2∆ mice (middle), 
and Sim1Cre-GRe3∆ mice (right). (B) Quantification of pixel density showed a 3-fold increase in 
PVN CRH mRNA in Sim1Cre-GRe3∆ mice compared to controls and Sim1Cre-GRe2∆ mice. (C) 
Expression of GR in ACTH+ nuclei was quantified as a percentage of total ACTH+ nuclei (top 
panel) in the anterior pituitary. As visualized in the immunofluorescent images in the bottom 
panel, quantification revealed no differences between groups, implying intact GR in ACTH-
producing cells GR (red), ACTH (green), Dapi (blue). (D) Plasma ACTH levels measured at 
nadir, peak, and after 20-minutes of restraint stress. Sim1Cre-GRe3∆ mice display increased 
plasma ACTH at nadir. They trend towards increased peak ACTH levels with no change in stress 
levels of ACTH compared to controls and Sim1Cre-GRe2∆ mice. #p=0.06, *p=0.03, 
***p=0.0001. 
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remained intact (Figure 2.4. C). Circulating nadir ACTH levels were significantly 
elevated while peak levels had a trend towards increase in male Sim1Cre-GRe3∆ mice 
compared to controls (two tailed t-test p=0.03-nadir, p=0.06 peak) but not in Sim1Cre-
GRe2∆ mice compared to controls (Figure 2.4. D). Stress levels of ACTH (Figure 2.4. D) 
do not differ between genotypes. Female Sim1Cre-GRe3∆ mice show a trend towards 
increased adrenal weights (p = 0.059) (Figure 2.5. B), whereas male adrenal weights in 
Sim1Cre-GRe3∆ mice are significantly increased (p=0.009) compared to controls and 
Sim1Cre-GRe2∆ mice (Figure 2.5. C).  
 
 
Figure 2.5. Amygdala CRH mRNA expression and adrenal gland weights. (A) Sim1Cre-
GRe3∆ mice show significantly increased CRH mRNA compared to Sim1Cre-GRe2∆ mice (p = 
0.016) and a similar non-significant trend compared to controls. (B,C) There is a trend towards 
increased adrenal weights in Sim1Cre-GRe3∆ female mice compared to controls (B). Male 
Sim1Cre-GRe3∆ mice show increased adrenal gland weights compared to controls and Sim1Cre-
GRe2∆ mice (C). #p <0.06, *p<0.05, **p<0.01.  
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Sim1Cre-GRe3∆ mice exhibit reduced locomotor activity 
Due to the role of brain GR in mediating anxiety and despair-related activity, we 
tested mice in different behavioral paradigms. Behaviorally, locomotor activity is reduced 
in male Sim1Cre-GRe3∆ mice (in terms of distance travelled in the open field, p = 0.02) 
(Figure 2.6. A,B). However, changes in anxiety- (OF and elevated zero maze) (Figure 
2.7. A,B) and despair-like behaviors (tail suspension test and FST) (Figure 2.7. C,D) 
were not observed in Sim1Cre-GRe3∆ mice. Comparatively, Sim1Cre-2∆ mice have 
normal locomotor activity and display no anxiety- or despair –like behavior (Figure 2.8. 
A-D). 
 
 
 
Figure 2.6. Altered locomotor activity of Sim1Cre-GRe3∆ mice in the OF test. Sim1Cre-
GRe3∆ mice show reduced distance traveled in outer zone and total distance (A) as well as 
distance travelled in 5-minute blocks (B). #p<0.09, *p<0.05, **p<0.01. 
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Figure 2.7. Sim1Cre-GRe3∆ mice do not exhibit anxiety or despair-like behavior. Anxiety 
behavior is measured as the mean (±S.E.M.) time spent in the center zone of the OF test (A) or in 
the open arm of the elevated zero maze (B). Despair-behavior is measured as the time immobile 
during the tail suspension test (C) and the FST (D). In all tests, Sim1Cre-GRe3∆ mice (n= 6-9) 
show similar activity compared with control mice (n=12-19). Student’s t test; p>0.05. 
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Figure 2.8. Sim1Cre-GRe2∆ mice exhibit normal locomotor behavior and do not exhibit 
anxiety or despair-like behavior. (A) Sim1Cre-GRe2∆ show distance traveled in the open field 
similar to control mice. Anxiety behavior is measured as the mean (±S.E.M.) time spent in the 
center zone of the OF test (B) or in the open arm of the elevated zero maze (C). Despair-behavior 
is measured as the time immobile during the tail suspension test (D) and the FST (E). In all tests, 
Sim1Cre-GRe2∆ mice (n= 10-13) show similar activity compared with control mice (n=16-18). 
Student’s t test; p>0.05. 
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DISCUSSION 
In this study, we investigate the neuroendocrine, metabolic, and behavioral 
consequences of disruption of GR in the PVN. Surprisingly, we find that the phenotype 
of Sim1-Cre-mediated deletion of floxed GR gene substrates depends upon the specific 
floxed GR allele targeted. Sim1Cre-GRe3Δ mice manifest elevated serum concentrations 
of corticosterone throughout the circadian cycle and in association with a stressor, 
compared with either Sim1Cre-GRe2Δ or non-deleted control mice.  Because of the 
greater extent of deletion in the PVN of Sim1Cre-GRe3Δ compared with Sim1Cre-
GRe2Δ mice, together with the potential for truncated carboxy-terminal products in 
Sim1Cre-GRe2Δ mice, the Sim1Cre-GRe3Δ line reflects a more complete phenotype for 
PVN GR loss. Despite elevated glucocorticoid concentrations and metabolic 
derangements, we did not find evidence for behavioral alterations in the Sim1Cre-GRe3Δ 
line.  While we did not observe differences between controls and Sim1Cre-GRe2∆ mice 
in HPA axis regulation under the conditions we analyzed, it is possible that a more 
extensive time series or different stress exposures could reveal a more subtle aspect of 
glucocorticoid feedback dysregulation.  
While the Sim1Cre line also expresses Cre-recombinase in the supraoptic nucleus, 
nucleus of the lateral olfactory tract, and other hypothalamic and medial amygdala nuclei 
(18), these sites are unlikely to influence the HPA axis regulation phenotype we report 
here. These Sim1Cre transgenics are the most selective mice that have been generated 
thus far for evaluating PVN-related functions of genes. 
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Differential HPA Axis Phenotype Between Sim1Cre-GRe2∆ and Sim1Cre-GRe3∆ 
Mice 
In mice, the GR gene, Nr3c1, is greater than 110kb in length and is the splice 
product of 9 exons, of which several alternative, non-coding first exons contribute (20). 
Exon 2 of GR encodes the usual translational start sites and the transactivation domain 
while exon 3 and 4 contain the zinc-finger of the DNA binding domain. The five C-
terminal exons compose the ligand-binding domain of the receptor (20). Studies of GR 
disruption have mainly targeted the exon 2 and 3 regions.  
The differences we observe in Sim1Cre-GRe2∆ compared with Sim1Cre-GRe3∆ 
mice may be the result of the level of GR deletion between the two lines. We measured a 
43% reduction in GR immunoreactive cells in Sim1Cre-GRe2∆ PVN, whereas Sim1Cre-
GRe3∆ mice display an 87% reduction in PVN GR. This difference in deletion extent as 
being a contributor to the observed phenotypic differences is supported by previous 
findings in FBGRKO mice that at 2 months of age, when 50% of GR immunoreactive 
neurons in the hippocampus are lost, demonstrate no significant differences in HPA axis 
activity or behavior, but at 4-6 months when there is 90-100% deletion, have impaired 
HPA axis activity and increased anxiety and despair-like behaviors (14). These data 
suggest a critical threshold for GR, that when breached disrupts normal functions.  
An alternative, or additional contributor, to the differences between floxed lines 
may result from Sim1Cre-GRe2∆ mice having the capacity to produce truncated, 
function-retaining GR products. Should antibody-mediated detection of possible 
truncated carboxy-terminal products in Sim1Cre-GRe2Δ mice arise, the transcriptional 
activation abilities of these products may still be uncertain. While conventional 
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knockouts targeting exon 2, GRhypo, (9) or exon 3, GRnull, (11) both result in fetal 
lethality, there is survival of 20% of the GRhypo mice into adulthood. Evidence suggests 
that insertion of a neomycin-resistance cassette into the second exon of GR results in 
incomplete gene inactivation due to the synthesis of a truncated C-terminal GR protein 
that maintains residual binding activity (9, 10, 19, 22). Truncated products were not 
revealed when GR exon 2 was disrupted by Cre-mediated excision of exon 1C to 2 of GR 
in thymocytes (21).  Given the complexity of GR alternative exon 1 utilization and distal 
splicing, we cannot discount the existence of tissue-dependent alternative splicing that 
might yield activity-retaining GR products. In contrast to conventional GR exon 2 
deletion, disruption of exon 3 results in complete inactivation of the GR gene due to out 
of frame splicing and premature translation termination (11, 13).  We have been 
unsuccessful in identifying or generating antibodies against the C-terminus of GR 
suitable for immunohistochemistry to directly demonstrate residual GR immunoreactivity 
in the exon 1C-2 deleted lines. 
A recent study that used the same Sim1Cre transgenic mice crossed with floxed 
GR allele starting at an MfeI site 420-bp upstream of exon 2 region found that the mutant 
homozygotes die at birth(23). The difference between our PVN GR exon 2 deleted mice 
and theirs was the inclusion of additional promoter regulatory regions in our line.  Given 
the lack of mortality in either of our lines, the lethal phenotype observed by Jeannetteau 
et al. does not arise from PVN deletion effects, but rather deletion in the lung, which was 
not observed in either of our two lines. 
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Consequences of Glucocorticoid Excess in Sim1Cre-GRe3∆ Mice 
Previous generation and characterization of GRNesCre mice, with GR deletion in all 
brain regions including the PVN, revealed a glucocorticoid excess, Cushingoid phenotype 
(13). More selective GR inactivation in the PVN of our Sim1Cre-GRe3∆ mice also 
results in a Cushingoid phenotype. Sim1Cre-GRe3∆, compared to control and Sim1Cre-
GRe2∆, mice had reduced weight from weaning (P21) to the first two months of age.  
This pattern changed to increased weight gain throughout adulthood and an obesity 
phenotype, with thinning of the hair on the abdominal areas and areas of the face and 
back. We observed sexual dimorphism in dysregulation of adult body weight, with 
female Sim1Cre-GRe3∆ mice consistently weighing more than control mice.  In 
comparison, thirty percent of male Sim1Cre-GRe3∆ mice did not weigh more than 
control mice, but maintained the truncal obesity phenotype.  The obesity and increased 
body mass phenotype in Sim1Cre-GRe3∆ mice was largely contributed to by increased 
adiposity as reflected by perigonadal fat pad weights. Female and male Sim1Cre-GRe3∆ 
mice had approximately 14-fold and 3-fold increases in pelvic fat pad weight, 
respectively, compared to controls and Sim1Cre-GRe2∆ mice. This differential 
accumulation of adipose tissue may explain the differences observed in the growth curves 
of adult female and male mice.  Given that males and females typically have altered 
patterns of fat distribution and accumulation, the influence of excess glucocorticoids 
interacting with sex hormones may account for the difference in adiposity. Similar to the 
growth phenotype in Sim1Cre-GRe3∆ mice, GRNesCre mice also demonstrate reduced 
body weight in the early period of life (24). However, while Sim1Cre-GRe3∆ mice 
display increased fat accumulation, adult GRNesCre mice exhibit significantly reduced 
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body fat mass. Since CRH acts to inhibit food intake and drive energy expenditure, it was 
suggested that increased PVN CRH in the GRNesCre mice drives the reduced fat mass (24).  
As we also find substantially increased PVN CRH in Sim1Cre-GRe3∆ mice, an 
alternative explanation may be that GR deletion in other brain regions regulating 
metabolism or sympathetic tone in  GRNesCre mice account for the differences. Consistent 
with the phenotypic evidence of glucocorticoid excess, Sim1Cre-GRe3∆ mice displayed 
greater than 2.5-fold increases in nadir and peak levels of CORT with maintained 
circadian rhythmicity. The levels of CORT in Sim1Cre-GRe3∆ mice were further 
increased after restraint stress.  
Interestingly, we found that Sim1Cre-GRe3∆ mice did not increase glucose 
secretion after restraint stress. This was quite surprising since high circulating 
glucocorticoids are known to induce hyperglycemia and insulin resistance in organisms 
(25, 26). It is possible that in Sim1Cre-GRe3∆ mice, the high basal levels of 
glucocorticoids have resulted in resistance to effects of further increases in 
glucocorticoids due to existing high occupation of receptors or receptor desensitization. 
 
Consequences of GR Disruption on Hypothalamic and Pituitary Regulation 
CRH has been implicated as the initiator of circadian and stress induced increases 
in glucocorticoid production, and is subject to glucocorticoid feedback modulation. 
Consistent with this role, CRH mRNA in the PVN of Sim1Cre-GRe3∆ mice, in which we 
find high glucocorticoid levels, is 3 times higher than levels in control and Sim1Cre-
GRe2∆ mice.  
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We found no difference in GR expression in ACTH immunoreactive cells in the 
anterior pituitary between control, Sim1Cre-GRe2∆, or Sim1Cre-GRe3∆ mice. This 
intact pituitary GR, however, was not sufficient to drive feedback inhibition in the 
dexamethasone suppression test or prevent the elevated PVN CRH from increasing basal 
plasma ACTH concentrations in Sim1Cre-GRe3∆ mice. Although Sim1Cre-GRe3∆ mice 
exhibit higher basal ACTH levels than controls, they do not demonstrate the stress-
induced elevations in ACTH observed in control and Sim1Cre-GRe2∆ mice. This is in 
divergence with CORT levels, where we observe both a circadian and a stress-induced 
rise in CORT. We tested whether adrenal hypertrophy had developed that would 
exaggerate smaller changes in ACTH in Sim1Cre-GRe3∆ mice. We found that female 
mice have trends towards increased adrenal weight compared to controls. Adrenal 
hypertrophy did occur in male Sim1Cre-GRe3∆ mice, demonstrating a 65% increase in 
adrenal weights compared to control and Sim1Cre-GRe2∆ mice.  
 
 
PVN GR Disruption and Behavioral Indices of Anxiety and Despair 
In the current study, despite marked HPA axis dysregulation, we found no 
significant differences in anxiety-related behaviors measured in the OF or elevated zero 
maze tests. Neither did we observe significant differences in despair-like behavior in the 
tail suspension or forced swim tests. GR disruption in the entire brain, GRNesCre, (13) and 
forebrain only, FBGRKO mice (14, 15), result in behavioral maladaptations in mice. The 
lack of behavioral changes in our PVN GR disrupted mice supports the interpretation that 
altered GR signaling in limbic areas mediates the genesis of behavioral dysregulation.  
We did find that Sim1Cre-GRe3∆ mice have reduced locomotor behavior in the distance 
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travelled in the OF test compared to control mice. This locomotor deficit may arise from 
the sustained effects of elevated glucocorticoids on muscle function.   
In conclusion, we report here that PVN GR is needed for feedback inhibition of 
HPA axis function, but is not required for circadian rhythmicity of adrenal activity.  
Surprisingly, GR loss in the PVN, with chronically elevated circulating glucocorticoid 
levels, does not lead to heightened anxiety or despair-like behavior.  In many 
circumstances of glucocorticoid dysregulation with Cushing’s syndrome, behavioral 
changes, particularly anxiety and depression-like symptoms are common. One possibility 
our results may suggest is that loss of PVN GR in some manner prevents the induction of 
stress-related behaviors in the context of normal extrahypothalamic GR and elevated 
corticosterone. The whole brain knockout of GR using Nestin-Cre demonstrates that loss 
of GR in the context of loss of GR in other brain regions does lead to altered anxiety-
related behaviors (13), as does intact PVN GR with disrupted forebrain GR (14, 15). 
Given our findings, the most parsimonious explanation synthesizing this information 
would be that PVN GR does not play a direct role in mediating anxiety and despair 
behavior. One intriguing possibility is that the extrahypothalamic brain regions in 
Sim1Cre- GRe3∆ mice are able to accommodate the elevated glucocorticoid levels since 
they still undergo a qualitatively similar pattern of circadian regulation. 
Interesting new areas of investigation arise as a result of these studies. For 
example, given the normal anxiety and despair-related behaviors observed in Sim1Cre-
GRe3∆ mice, can the brain compensate for chronically excess glucocorticoid exposure by 
altering CORT metabolism or functional GR signaling? Potential mechanisms include 
down-regulation of GR in extrahypothalamic regions, alteration of expression of co-
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activators or co-repressors, or increases in 11β-HSD type 2 in other brain regions such 
that normalization of functional signaling occurs.  Another area of interest is to 
investigate how PVN GR loss and excess glucocorticoid attenuate stress-induced 
increases in blood glucose levels.  Future studies designed to answer these questions 
should prove informative for understanding normal glucocorticoid physiology, the 
pathogenesis of affective disorders, and the consequences of pharmacological 
glucocorticoid therapy. 
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CHAPTER III 
 
 
ONTOGENY OF HYPOTHALAMIC GLUCOCORTICOID RECEPTOR-MEDIATED 
INHIBITION OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS  
 
INTRODUCTION 
 
Glucocorticoid receptors (GR) mediate many organismal functions including 
developmental, metabolic and stress responses. GR in the paraventricular nucleus of the 
hypothalamus (PVN) is one of the sites of negative feedback for hypothalamic-pituitary-
adrenal (HPA) axis activity. During the stress response, HPA axis activity returns to 
baseline through negative feedback of corticosterone (CORT) on GR at the level of the 
PVN and anterior pituitary to turn off the stress response. In the previous chapter, we 
demonstrated in adult mice, that loss of GR exon 3 but not GR exon 2 in the PVN causes 
HPA axis hyperactivity with increased PVN CRH mRNA and elevated plasma ACTH 
and CORT. The hypercorticosterolemia subsequently led to a Cushingoid phenotype in 
the mutant mice. Moreover, we determined that despite this HPA axis hyperactivity, PVN 
GR loss did not affect anxiety or despair behavior under basal conditions in adult mice.  
During the adolescent period in humans and other animals, the brain is still 
undergoing development. There are morphological and connectivity changes in a number 
of brain regions such as the cortex, amygdala, and hippocampus that are still maturing 
during adolescence(1–6). This makes the adolescent brain more malleable to the effects 
of environmental experiences including stress, drugs and alcohol (7–11) and number of 
mental illnesses in adults have their onset in childhood or adolescence (12–15). Studies 
indicate that during development, the HPA axis in adolescent rodents undergoes 
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reorganization (16–18) thus making this developmental period of time sensitive to the 
effects of stress. Due to the propensity of the developing adolescent brain to be 
influenced by stimuli, we hypothesized that adolescent mice will be more susceptible to 
the effects of PVN GR disruption. Here we aim to define the developmental trajectory of 
PVN GR function by evaluating the effects of PVN GR loss during early adolescence 
(postnatal days 30-50) and late adolescence (postnatal days 51-70) on neuroendocrine 
and behavioral activity. 
 
 
MATERIALS AND METHODS 
Animals 
The animal protocols were in accordance with National Institutes of Health 
guidelines and approved by the Institutional Animal Care and Use Committees of 
Cincinnati Children’s Research Foundation (Cincinnati, OH).  
Mice were housed on a 14 h/10 h light/dark cycle with ad libitum access to rodent 
chow and water.  Mice were generated as previously described (19). Briefly, Sim1Cre-
GRe3∆ mice were generated by mating Sim1Cre mice (20) to floxed GR exon 3 mice 
(21), Sim1Cre-GRe2∆ mice were generated by mating Sim1Cre mice to floxed GR exon 
1C-2 mice (22), and controls are littermates that were Cre negative but floxed GR exon 
1C-2 or exon 3 positive. Floxed GR exon 3 mice were obtained from Dr. Günther Schütz, 
German Cancer Research Center, Heidelberg, Germany. Sim1Cre mice were the gift of 
Dr. Brad Lowell, Beth Israel Deaconess Medical Center, Boston, MA. 
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Immunohistochemistry 
We used 90 mg/kg ketamine (Ketaset, Fort Dodge IAO) / 10 mg/kg xylazine 
(TranquiVed, Vedco, St. Joseph MO) to anesthetize mice at P2 and perfused them with 
DEPC 1x PBS followed by 4% DEPC PFA. We post-fixed the brains in 4% DEPC PFA 
overnight and immersed the brains in 70% ethanol to process for paraffin embedding. A 
microtome was used to section paraffin embedded brains at 8 µm onto Superfrost+ slides 
(VWR). We placed the slides at 60ºC overnight and stored at room temperature until later 
use. We deparaffinized the slides, rehydrated in decreasing concentrations of ethanol, 
reconstituted the antigen in 10mM Citrate Buffer (pH 6.0). Slides were washed in PBS 
and blocked for 1 hour in 3% normal goat serum/ 0.25% Triton-X-100 in PBS to prevent 
non-specific binding. GR: Primary antibodies were 1:200 rabbit m20-anti-GR, directed 
against the N-terminus of GR, (Santa Cruz Biotech. Cat# sc-1004) and 1:200 mouse anti-
NeuN; Secondary antibodies were 1:250 biotinylated goat anti-rabbit IgG and 1:200 goat 
anti-mouse Alexa 488 IgG. We washed the slides, incubated in avidin/biotin complex 
(Vectastain), Cyanine-3 tyramide amplified (Perkin Elmer) and coverslipped with DAPI 
(Vector Laboratories).  
 
Corticosterone radioimmunoassay 
Mice between P30–50 (early adolescence) and P51–70 (late adolescent) were 
double housed for a week. Submandibular bleeds were performed in mice at nadir, peak, 
and 20 minutes after restraint stress with two days between bleeds. We centrifuged the 
blood at 14000 rpm for 6 minutes and stored the plasma at -80ºC until a 
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radioimmunoassay (RIA) was performed. The Corticosterone Double Antibody - 125I RIA 
Kit (MP Biomedicals, Solon, OH) was used to perform the RIA.  
 
CRH in situ hybridization 
Mice were anesthetized mice with a 90 mg/kg ketamine (Ketaset, Fort Dodge 
IAO) / 10 mg/kg xylazine (TranquiVed, Vedco, St. Joseph MO) solution, perfused with 
DEPC 1x PBS followed by 4% DEPC PFA, and the brains were post-fixed overnight in 
4% DEPC PFA. After 48-hour immersion in 20% DEPC sucrose solution at 4ºC, brains 
were embedded in OCT. 16um sections were obtained from brains at -15ºC in a cryostat 
and mounted onto Superfrost+ slides (VWR), vacuum-dried overnight, and stored at -
80ºC until in situ hybridization was performed. P-33 UTP was used to label an RNA 
probe complementary to a 0.32 KB fragment on exon 2 of the CRH mRNA. Sections 
were hybridized to the labeled probe at 65ºC for 16 hours and washed in 0.1X SSC at 
60ºC for 30 min. Slides were exposed to Maximum resonance film (Kodax BioMAx, 
Rochester N.Y.) for 4 days. We scanned the autoradiographic images at 3200 dots/inch 
into Photoshop on an Epson Perfection V600 scanner and quantified using NIH Image J 
software. 
 
Behavioral tests 
Behavioral tests were performed between 8:00 a.m. and 12:00 p.m. in mice ages 
P30–50 and adult mice 3-4 months old. Mice acclimated in a room adjacent to the testing 
room for an hour before behavioral testing. Behavioral tests were performed in the 
Cincinnati Children’s Hospital behavior core.  
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Open field (OF) test: Locomotor exploration/activity was measured in a 41 cm × 
41cm chamber (Accuscan Instruments, Columbus, OH). The chamber was equipped with 
a 16 LED-photocells 2 cm above the floor in x- and y-planes 2.5cm apart. Each trial 
lasted for a period of 30 minutes, and was analyzed in 5-minute interval. During that 
time, the PAS Activity program (San Diego Instruments, CA) was used to measure 
behaviors such as time spent, distance travelled, and number of entries into the inner and 
outer zones of the chamber.  
 Light dark (LD) test:  The same apparatus used in the OF test was used in this LD 
test. A rectangular black acrylic (40 cm x 20 cm) insert with an opening was placed into 
the box and provided a half light, half dark box. Mice were placed a corner of the dark 
side and allowed to explore for 10 minutes. We recorded latency to enter the light zone, 
number of entries and time spent in the different zones. 
Elevated Zero Maze (EZM) test: This maze (50cm inner diameter, 5cm lane 
width, 15cm wall height, placed 50 cm off the ground on 4 braced legs) consists of a 
round maze with opposing open and closed arms. Mice are placed in the center of the 
open arm and activity is scored for 5 minutes. Time spent in the open and closed areas, as 
well as latency and number of entries into the open and closed areas was measured.  
Tail suspension test (TST):  This test used a rectangular tabletop platform with a 
hole through which the mouse’s tail was suspended. Latency to immobile and time spent 
immobile were measured manually with the use of a computer software. 
Forced swim test (FST): This test utilizes a clear 25 cm x 20 cm acrylic cylinder 
filled ¾ full with water at room temperature (25°C). Mice are placed in the beaker for 1 
minute to acclimate to the chamber, after which we tested the mice for 5 minutes. 
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Latency to immobile and time spent immobile were measured. Mice were placed in a 
warm cage and toweled dried.  
 
Statistical analysis 
The results are presented as mean ± SEM after data were subjected to Student t-
test, one- or two-way ANOVA test (Prism 5.0 software; GraphPad Software, Inc., San 
Diego, CA). Statistical significance was defined as a p value ≤ 0.05 and was analyzed 
using the Tukey or Bonferroni post hoc test. 
 
 
RESULTS  
Deletion of GRe1C-2 and GRe3 in the PVN neurons expressing Sim1 
Sim1Cre-GRe3∆ and Sim1Cre-GRe2∆ transgenic mice were generated as 
previously described (19). To determine the when deletion of GR first occurs, we 
performed fluorescent immunohistochemistry in P2 brains. We observed a reduction in 
PVN GR expression in Sim1Cre-GRe3∆ mice compared to controls at age P2 (Figure 3.1.), 
but no changes in Sim1Cre-GRe2∆ mice (data no shown) when compared to control mice. 
 
 
Figure 3.1. Decreased GR 
expression in Sim1Cre-GRE3∆ 
at postnatal day 2. 
Immunofluorescent images of the 
PVN showing GR (red), NeuN 
(green), and Dapi (blue) in mice at 
postnatal day 2 (P2). 
Representative of 3 mice. 
 
 74 
Adolescent Sim1Cre-GRE3∆ mice display developmental HPA Axis dysregulation in 
a gender-specific manner 
 We measured serum CORT levels in controls, Sim1Cre-GRe2∆ and Sim1Cre-
GRe3∆ mice early in life to determine the developmental consequences of PVN GR 
deletion. During early adolescent period, P30–P50, we found that male Sim1Cre-GRe3∆ 
mice had significantly elevated nadir (p=0.001) and peak (p=0.005) plasma CORT levels 
compared to controls, but stress CORT levels did not differ (p=0.299) (Figure 3.2.A). In 
late adolescence P51–P70, male Sim1Cre-GRe3∆ mice show elevated plasma CORT at 
nadir (p=0.001), peak (p<0.0001) and after 20 minutes of restrain stress (p<0.0001) 
compared to controls (Figure 3.2.B), similar to what was observed in adult male mice 
(19). On the other hand, early adolescence in female Sim1Cre-GRe3∆ mice was 
characterized by no changes in basal and stress-induced plasma CORT levels compared 
to control mice (Figure 3.2.C). In late adolescence, nadir plasma CORT levels in female 
Sim1Cre-GRe3∆ mice were significantly higher than controls (p=0.011) but peak and 
stress-induced CORT did not differ (Figure 3.2.D). Interestingly, adolescent male 
Sim1Cre-GRe2∆ mice (P30 – P50) have elevated plasma CORT levels at peak compared 
to controls (p=0.001), but no differences at nadir and stress. This increase is transient and 
does not last in late adolescence (Figure 3.2.B) or adulthood (19). The circadian rhythm 
of CORT secretion was apparent by P30-50 in all groups, controls, Sim1Cre-GRe3∆ and 
Sim1Cre-GRe2∆ and both genders, and was maintained in the transgenic mice (Figure 
3.2.). 
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Figure. 3.2. Loss of PVN GR results developmental and gender-specific differences in HPA 
axis regulation. (A,B) Plasma CORT levels measured at nadir, peak, and after 20-minutes of 
restraint stress. Sim1Cre-GRe3∆ mice ages P30-P50 display increased plasma CORT at nadir and 
peak and after stress compared to controls and Sim1Cre-GRe2∆ mice. (C,D) Dexamethasone 
suppression test was used to evaluate negative feedback. Control female mice show a 50% 
suppression of CORT after dexamethasone (C), while males show a trend towards CORT 
suppression, (D). Sim1Cre-GRe3∆ mice do not show suppression of CORT after dexamethasone 
administration. #p=0.053*p<0.05, ***p<0.001. 
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Adolescent Sim1Cre-GRE3∆ mice have reduced locomotor activity and increased 
anxiety behavior  
In order to evaluate how HPA axis disruption in adolescence affected stress-
related behavior, we evaluated anxiety behavior in the Open field test (OF), the light-dark 
test (LD) and the Elevated zero maze (EZM). Male mice were tested between the ages of 
P30–P50, with two days between tests. In the OF test, adolescent Sim1Cre-GRE3∆ mice 
have reduced locomotor activity identified in the distance traveled in the open field maze 
(Figure 3.3.A, p< 0.0001) and reduced entries into the center of the open field which is 
characteristic of increased anxiety (Figure 3.3.C, p= 0.002). However, the amount of time 
spent in the center and the latency to enter the center of the open field did not differ in 
adolescent Sim1Cre-GRE3∆ mice compared to controls (Figure 3.3. B). In the LD tests, 
there were no differences in the time spent, entries, and latency to enter the light zone 
(Figure 3.4. A,B). In the EZM test, adolescent Sim1Cre-GRE3∆ mice compared to 
controls spent less time (p=0.012) and made fewer entries (p=0.004) into the open arm of 
the maze (Figure 3.3. E, F), indicative of increased anxiety-like behavior, but there were 
no differences in latency to enter open arm (Figure 3.3. D). 
 
Adolescent Sim1Cre-GRE3∆ mice have no despair-like behavior  
We evaluated the effects of PVN GR loss in adolescence on despair-like behavior. 
Two major tests of despair are the tail suspension tests (TST) and the forced swim test 
(FST). In the both the TST and FST, adolescent Sim1Cre-GRE3∆ mice did not differ in 
the time immobile or latency to immobile compared to control mice (Figure 3.4. B – E). 
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Figure 3.3. Reduced locomotor activity and increased anxiety behavior in adolescent 
Sim1Cre-GRe3∆ mice in the OF and EZM tests. Sim1Cre-GRe3∆ mice show reduced distance 
traveled (A), no change in time spent in center (B), and decreased entries into the center of the OF 
(C). In the EZM tests, Sim1Cre-GRe3∆ mice have no difference in latency to enter the closed arm 
(D), spend less time spent in the open arm (E), and have reduced number of entries into the open 
arm (F). *p<0.05, ** p<0.01, ****p<0.0001. 
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Figure 3.4. Adolescent Sim1Cre-GRe3∆ mice do not exhibit anxiety behavior in the LD test 
or despair behavior in the TST and FST tests. Sim1Cre-GRe3∆ mice show no change in time 
spent, (A), or entries, (B), into the light zones. Sim1Cre-GRe3∆ mice show no differences in time 
spent immobile (C) or latency to immobility, (D), in the TST test. Sim1Cre-GRe3∆ mice show no 
differences in time spent immobile, (E), or latency to immobility in the FST test, (F). 
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Retesting in adulthood shows anxiety behavior in Sim1Cre-GRe3∆ mice that was 
not previously observed 
Our previous data demonstrated that adult Sim1Cre-GRe3∆ mice had no anxiety 
or despair phenotypes (19). Given that we observe anxiety-like behavior in the OF and 
EZM tests in adolescent mice, we sought to determine whether the behaviors observed in 
adolescence were transient and lost in adulthood. We therefore retested some of the 
previously tested adolescent mice again when they were 3-4 months old. In adulthood, 
the Sim1Cre-GRe3∆ mice have the expected reduction in locomotor activity (Figure 3.5. 
A, p< 0.001), but to our surprise, these Sim1Cre-GRe3∆ mice entered into the center of 
the OF test significantly less than controls (Figure 3.5. D, p=0.004). Moreover the 
Sim1Cre-GRe3∆ mice retested in adulthood showed a decreased distance traveled in the 
LD test (p=0.04), trend towards reduced entries into the light zone in the LD test (p=0.09) 
(Figure 3.5. E,F). No significant differences were found in the EZM test compared to 
controls (Figure 3.6. A-C). Furthermore no differences in despair-like behavior in the 
TST and FST were observed between Sim1Cre-GRE3∆ and control mice (data not 
shown). Since anxiety behavior was not previously observed in adult Sim1Cre-GRe3∆ 
mice, we questioned whether the current behavioral results were due to the fact that the 
mice had been previously tested in adolescence. We thus tested naïve adult mice in the 
anxiety and behavioral tests. 
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Figure 3.5. OF and LD tests show reduced locomotor activity and increases anxiety 
behavior in Sim1Cre-GRe3∆ mice retested in adulthood. OF test Sim1Cre-GRe3∆ mice show 
reduced distance traveled (A), no change in time spent in center (B), or latency to enter the center 
of the OF (C), and decreased entries into the center of the OF (D). LD test Sim1Cre-GRe3∆ mice 
show reduced distance traveled (E), and a trend towards decreased entries into the light zone (F). 
There was no change in time spent or latency to enter light zone (data not shown). #p=0.09, 
*p<0.05, **p <0.01, ***p<0.001. 
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Naïve adult Sim1Cre-GRE3∆ mice tested in the CCRF behavior core have increased 
anxiety in the OF and LD, but not the EZM and no despair behavior 
In contrast to our previous data in adult mice demonstrating no trace of anxiety 
behavior (19), this study in adult Sim1Cre-GRE3∆ mice demonstrated increased anxiety 
behavior in all measures in the OF and LD tests (Figure 3.7.). There were no significant 
differences in the EZM, TST or FST in these adult mice (Figure 3.8.), similar to previous 
data in adult Sim1Cre-GRe3∆ mice (19). There are no differences in any of the behaviors 
measured in Sim1Cre-GRE2∆ mice compared to control mice (data not shown).  
 
Figure 3.6. Retested Sim1Cre-GRe3∆ 
mice display no changes in behavior in 
the EZM test. Sim1Cre-GRe3∆ mice 
show no changes in time spent (A) or 
entries into open arm (B) and no changes 
in latency to closed arm (C). 
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Fig 3.7. Increased anxiety behavior in adult Sim1Cre-GRE3∆ mice in OF and LD tests. 
Adult male Sim1Cre-GRE3∆ mice tested in the CCHMC behavior core show increased anxiety in 
the open field (A-F) and light-dark (G-I) tests.  
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Fig 3.8. Adult Sim1Cre-GRE3∆ mice display no anxiety or despair behavior in the EZM, 
TST, and FST tests. Adult male Sim1Cre-GRE3∆ mice tested in the CCHMC behavior core 
show no anxiety behavior in the EZM test (A,B), or despair behavior in the TST (C,D) and FST 
tests (E,F). 
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DISCUSSION 
 
HPA axis regulation in adolescence 
 
Early life experiences can result in developmental changes in stress reactivity and 
behavior.  Our data indicates that in Sim1Cre GRe3∆ mice, PVN GR loss occurs by as 
postnatal day 2. The early disruption of PVN GR leads to elevated nadir and peak plasma 
CORT levels during early adolescence (P30-P50) in male Sim1Cre GRe3∆ mice. 
However stress-induced increases in CORT are not different between control and 
Sim1Cre GRe3∆ mice at that age, and only appear after P51. This indicates that during 
the early adolescent period of life in males, PVN GR is important for maintaining basal 
regulation of glucocorticoid secretion, but it is not necessary for regulating stress-induced 
glucocorticoid secretion until late adolescence/ early adulthood. We propose that early in 
life glucocorticoid feedback is primarily regulated through pituitary GR and PVN GR 
feedback dominates later in development.  
  In females, concentrations of plasma CORT do not vary between control and 
Sim1Cre GRe3∆ mice in early adolescence. In late adolescence/ early adulthood, nadir 
levels of plasma CORT are increased in Sim1Cre GRe3∆, but peak and stress levels do 
not differ from controls. In contrast to males, PVN GR in female mice is not necessary 
for maintaining basal regulation of glucocorticoid secretion during adolescence, and does 
not become necessary until adulthood. The gender difference in CORT secretion between 
male and female Sim1Cre GRe3∆ mice is suggestive of modulation of GR function by 
sex hormones. There is mounting evidence for role of estrogen in affecting GR signaling 
pathways (23–25). Thus differences in GR signaling in females compared to males may 
account for the gender-specific developmental disparities that we observe in adolescent 
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Sim1Cre GRe3∆ mice. Our studies suggest that PVN GR mediation of negative feedback 
occurs earlier in development in males than in females. 
Surprisingly, we observe elevated peak plasma CORT levels in male Sim1Cre 
GRe2 ∆ mice in adolescence that is lost in adulthood. This transient developmental 
increase in CORT indicates that GR loss in Sim1Cre GRe2∆ mice does have transient 
effects on the levels of glucocorticoid secretion. The differences in that we observe in 
CORT levels at ages P51-P70 in the Sim1Cre GRe2∆ mice compared to Sim1Cre GRe3∆ 
mice are similar to what we previously observed in adult mice (19). 
 
Behavioral phenotypes of Sim1Cre GRe3∆ mice throughout development 
Many psychiatric disorders have their onset during the adolescent period (14).  
Similar to adult mice previously tested (19), adolescent mice with loss of GR exon 3 in 
the PVN display locomotor deficits in the open field and a lack of despair phenotypes. 
However, we observe increased anxiety behavior in adolescent Sim1Cre GRe3∆ mice in 
the OF and EZM tests, but not in the LD test. When retested in adulthood, these 
adolescent mice lose the anxiety phenotype in the EZM test but retain anxious 
phenotypes observed in the OF, and show trends in anxiety in the LD test. Given that 
there may be effects of prior testing in the behavior we observed, we evaluated behavior 
in a cohort of adult mice not previously tested. Surprisingly, these adult Sim1Cre GRe3∆ 
mice display increased anxiety behavior in all measures of anxiety in the OF and LD 
tests, completely the opposite of our previously published data. Similar to our previously 
published data, no anxiety behavior was observed in the EZM however, and no despair 
behaviors were observed in the TST and FST tests. One possible reason for the 
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differences between the studies is the different in institutions that behavioral testing 
occurred. The Vanderbilt neurobehavioral core was used in the studies where we saw no 
anxiety phenotypes in adult mice. This behavior core has separate testing facilities for 
mice and rats. The behavioral tests in this current study were performed in the Cincinnati 
Children’s research foundation’s (CCRF) behavior core. The CCRF core is for the testing 
of both rats and mice. In the case of the EZM, TST, and FST tests, separate equipment 
exist for mice and rats. In the case of the OF and LD tests, the same apparatus is used for 
testing both mice and rats. The OF maze is rat-sized, and there is a possibility that there is 
residual rat odor when the mice are tested. Since there is a predator-prey relationship 
between rats and mice, this testing environment, as well as the size of the maze may 
factor into the anxiety behavior of adult Sim1Cre GRe3∆ mice tested at CCRF. This is 
supported by the lack of anxiety behavior of Sim1Cre GRe3∆ mice in the EZM test, 
which is used only for testing in mice. Since Sim1Cre GRe2∆ mice show no anxiety 
behavior in this study (data not shown), the data implies that Sim1Cre Gre3∆ mice have a 
predisposition to anxiety that is environment dependent. The effect of this testing 
environment in adult Sim1Cre Gre3∆ mice makes it difficult to interpret the anxiety 
behavior in OF test observed in adolescent Sim1Cre Gre3∆ mice. We cannot discount 
other factors that may be influencing the differences in anxiety phenotypes between mice 
tested at the different institutions. A more controlled experiment would enable more 
accurate delineation of the effects of a gene x environment interaction in causing 
behavioral disruptions in Sim1Cre Gre3∆ mice. 
The adolescent period is a time of increased susceptibility to affective and anxiety 
disorders in human and (14, 17, 26–28). In our studies, the EZM test shows increased 
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anxiety during adolescence in Sim1Cre GRe3∆ mice that is lost during adulthood. This 
may indicate that during adolescence, PVN GR disruption leading to HPA axis 
hyperactivation mice increases susceptibility to anxiety. As the mice grow into 
adulthood, however, they habituate to their constantly elevated levels of glucocorticoid 
and the anxiety phenotype in the EZM test is lost. Since normal behavior is observed in 
the TST and FST tests, GR in the PVN is likely a mediator of pathways involved in 
anxiety modulation.  
Taken together, our data indicate that PVN GR is important in maintaining basal 
glucocorticoid levels from early adolescence onward and starts mediating stress-induced 
glucocorticoid secretion later during adulthood. This finding suggests that pituitary GR 
mediates stress-induced negative feedback from birth through early adolescence and then 
PVN GR picks up the task and mediates it through adulthood.  
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CHAPTER IV 
 
GLOBAL BUT NOT BRAIN-SPECIFIC BMAL1 DEFICIENCY LEADS TO 
HYPOTHALAMIC-PITUITARY-ADRENAL AXIS HYPOFUNCTION 
 
Gloria Laryea,  Shruti Vemaraju, Richard Lang and Louis J. Muglia 
 
INTRODUCTION 
Most biological processes in an organism are regulated in a circadian fashion 
using external environmental cues to synchronize daily oscillations. These regulated 
biological processes range from molecular events such as gene transcription and hormone 
secretion to functional changes in metabolic activity, reproduction and sleep (1-5). The 
main environmental stimulus regulating circadian rhythms is light, but temperature has 
also been show to regulate periodicity (6, 7). Light stimuli are transmitted through the 
retino-hypothalamic tract to the master circadian synchronizer, the suprachiasmatic 
nucleus (SCN) located in the anterior hypothalamus (8-10). As the master regulator, SCN 
controls rhythms of cells in central nervous system and the periphery.   SCN lesions 
completely abolish circadian rhythmicity of locomotor behavior and plasma 
corticosterone (CORT) (11-15) and disrupt rhythms of sleep, feeding, and drinking (12, 
16, 17).   
Clock genes underlie the oscillatory patterns of circadian rhythms. Bmal1 and 
Clock are two transcription factors that heterodimerize and induce the transcriptions of 
Period (Per1,2,3) and Cryptochrome (Cry1,2) genes. As the period and cryptochrome 
genes accumulate, they negatively feedback on the Clock on Bmal1 genes to repress their 
transcription. This negative feedback loop of clock genes causes transcription or 
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repression of other genes and thus entrain them to a diurnal rhythmic pattern thereby, 
entraining biological processes that they govern to have circadian rhythms (See (4, 18) 
for review). 
Disruption of circadian rhythmicity is associated with a number of pathologies 
including infertility, metabolic syndrome, abnormal apoptosis, retinal degeneration, 
altered sleep, and impaired memory (19-22). Animal models with different clock genes 
disrupted have proven informative regarding the individual role of these genes in multiple 
aspects of behavioral rhythms such as length of free-running periods and light-induced 
phase shifts (23, 24). Of all the clock genes however, only isolated disruption of Bmal1 
produces the complete behavioral arrhythmicity and abolished glucocorticoid rhythms 
observed in SCN-lesioned animals (25). This is mainly due to the fact that the other core 
clock genes are not exclusive in function. CLOCK mutants maintain rhythmicity because 
NPAS2 (a neuronal PAS domain protein) can substitute and heterodimerize with Bmal1. 
The individual PER and CRY genes can partially compensate for loss of related family 
members (20, 26-29). Due to this, Bmal1 represents a target crucial to the understanding 
of circadian rhythms and the pathways it regulates, one of which is the glucocorticoid 
system. 
Glucocorticoid secretion is the major output of the hypothalamic-pituitary adrenal 
(HPA) axis.  Corticotropin-releasing hormone in the periventricular nucleus of the 
hypothalamus signals the pituitary to synthesize and secrete adrenocorticotropic hormone 
(ACTH). ACTH then acts to cause the synthesis and secretion of cortisol  (humans) or 
corticosterone (rodents). The synthesis and secretion of the hormones, CRH, ACTH, and 
CORT occur in a rhythmic fashion driven by SCN clock machinery (30). Glucocorticoids 
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are important in development and through life mediating functions of many pathways 
including organogenesis, inflammation, metabolism, learning and memory, stress, and 
behavior. Thus disruption of circadian glucocorticoid rhythms has profound effects on 
these pathways and disease states associated with them. Investigating the effects of 
circadian activity on the HPA axis provides an important avenue to understand biological 
processes. 
Global Bmal1 deletion in mice disrupts a number of biological processes leading 
to arrhythmic locomotor activity, reduced total activity levels, decreased CORT 
production and hyposensitivity to ACTH, among other metabolic and reproductive 
phenotypes (25, 31). In order to determine the role of the central nervous system in these 
phenotypes, nervous-system-specific Bmal1 deleted mouse models have been developed. 
These mice demonstrate normal light-entrained locomotor rhythms but impaired food-
entrained locomotor activity as well as neurodegeneration (8, 32).  
Here we further explore the consequences of global and brain-specific Bmal1 
deletion on HPA axis signaling and behavioral activity. We find similar to other studies 
that global Bmal1 loss disrupts that circadian rhythms of CORT. However we also 
identify here that Bmal1 is necessary for the maintenance of rhythms of 
adrenocorticotropic hormone (ACTH) and acute steroidogenic protein (StAR). We also 
demonstrate that loss of brain Bmal1 does not affect diurnal CORT rhythms or circadian 
locomotor activity, but does affect the period of free-running activity. 
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MATERIAL AND METHODS 
Animals 
All animal protocols were in accordance with National Institutes of Health 
guidelines and were approved by the Animal Care and Use Committees of Cincinnati 
Children’s Medical Center (Cincinnati, OH). Mice were housed on a 14 h/10 h 
(Cincinnati Children’s Medical Center) light/dark cycle with ad libitum access to rodent 
chow and water. Mice used for studies were between 2-7 months old.  
Bmal1 null mice were generated as previously described (33). Bmal1 wild-type and 
heterozygotes mice were used as controls. NestinCre-Bmal1 ko Mice were generated by 
mating NestinCre-positive mice (The Jackson Laboratory, Bar Harbour, ME, USA) to 
Bmal1 floxed mice. Bmal1 floxed mice generated as previously described (33) were used 
as controls. 
 
Tissue Harvest 
Mice were anesthetized with carbon dioxide and cervically dislocated. Adrenal 
tissue was harvested at nadir and peak from control and Bmal1 null mice. Brains were 
harvested to obtain hypothalamus and cortex tissue, kidneys were harvested and rapidly 
frozen on dry ice from control and NestinCre-Bmal1 ko mice. All tissue was stored at -
80°C until processing. 
 
Western Blot 
Harvested tissue was homogenized for protein extraction in a lysis buffer 
comprised of 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM EDTA, protease Inhibitor, 
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phosphatase Inhibitors I and II, 1 mM DTT, and 1% NP-40. 60ug of tissue extracts were 
resolved in NuPAGE 4-12% Bis-Tris gels (Life Technologies, Carlsbad CA). Proteins 
were transferred onto nitrocellulose membranes (Perkin Elmer, Hebron KY) using 
semidry transfer method. Membranes were blocked in 5% milk (Lab Scientific Inc) in 
PBS and 0.1% Tween-20 (Sigma-Aldrich, St. Louis MO). Blots were probed with rabbit 
anti-Bmal1 primary antibody (Bethyl labs, Montgomery TX) and horseradish peroxidase 
labeled goat anti rabbit IgG (Santa Cruz Biotech, Dallas TX) secondary. After stripping 
with Stripping buffer (Thermo Scientific, Florence KY), membranes were reprobed with 
anti-actin (Sigma-Aldrich, St. Louis MO) primary and goat anti-rabbit IgG HRP (Santa 
Cruz Biotech, Dallas TX) secondary antibodies. Blots were processed with Super Signal 
West Chemiluminescent Substrate (Thermo Scientific, Florence KY, Florence KY) and 
visualized on Hyblot CL Autoradiography film (Denville Scientific, South Plainfield NJ). 
 
Radioimmunoassays (RIA) 
Control and NestinCre-Bmal1 Ko male and female mice were double housed for a week 
and bled by the submandibular method into EDTA-treated tubes. Samples were taken at 
nadir, peak, and 20 minutes after restraint stress, with two days between bleeds. The 
blood was centrifuged at 14000 rpm for 10 minutes and the plasma was removed and 
stored at -80ºC until a radioimmunoassay (RIA) was performed. Corticosterone and 
ACTH RIA were performed using the Corticosterone and hACTH Double Antibody - 
125I RIA Kit respectively (MP Biomedicals, Solon, OH).  
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Real-time quantitative PCR 
RNA was extracted from adrenal tissue harvested at nadir or peak from control 
(Bmal1 floxed mice) and Bmal1 null mice using the RNeasy Micro Kit (Qiagen, Valencia 
CA) and transcribed to cDNA using the Quantitect Reverse Transcription kit (Qiagen, 
Valencia CA). Real time PCR was performed for Steroidogenic acute regulatory protein 
(StAR) using Express SYBR Green Supermix with ROX (Life Technologies, Grand 
Island NY). Previously reported StAR forward and reverse primers (34) were used: 
forward 5’-CTGGCAGGCATGGCCACACA-3’ and reverse 5’ 
GGCAGCCACCCCTTGAGGTC 3’. StAR mRNA expression was normalized to 
GAPDH expression with primers generated using NIH Primer Blast: forward 5’-
TCAAGCTCATTTCCTGGTATGAC-3’ and reverse 5’-
TCTTGCTCAGTGTCCTTGCTG-3’.  
Applied Biosystems StepOnePlus RealTime PCR System and software (Life 
Technologies, Grand Island NY) was used for of cDNA amplification. PCR reaction 
conditions: one cycle at 50°C for 2 minutes, one cycle at 95°C for 5 minutes, and 35 
cycles at 95°C for 15 seconds and once cycle at 60°C for 1 minute. The ΔΔCT method 
was used to quantify fold change in mRNA expression normalized to control nadir 
samples.  
 
Circadian Locomotor activity 
Mice were individually housed in circadian activity chambers equipped with 
running wheels (Coulbourn Instruments, Whitehall PA). The wheels in this chamber are 
connected to a wiring system that record activity any time the mouse makes a revolution 
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on the wheel. Animals where maintained under a 12:12 hr light:dark cycle for eight days 
to measure baseline activity. The animals were then switched to constant darkness for 28 
days. Activity was recorded by Actimetrics Clocklab software (Wilmette, IL). Actograms 
and free running period data were generated using MathWorks Matlab software (Natick, 
MA). Animal care was conducted in accordance with Animal Care and Use Committees 
guidelines of Cincinnati Children’s Medical Center, with periodic equipment 
maintenance and ad libitum access to food and water. 
 
Statistical analysis 
Data were subjected to two-tailed Student t-test or two-way ANOVA with 
Bonferroni post hoc analysis (Prism 5.0 software; GraphPad Software, Inc., San Diego, 
CA). Results are presented as mean ± SEM. P value ≤ 0.05 was used to identify 
significant differences  
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RESULTS 
Bmal1 Null Mice Display Impaired Plasma CORT and adrenal StAR Rhythms  
Bmal1 null mice have been previously reported to be arrhythmic in constant 
darkness and have disrupted circadian rhythms in CORT secretion (25, 31, 35). We find 
that Control mice have elevated CORT at peak compared to nadir (p< 0.0001). No 
circadian rise was observed in Bmal1 null mice. Despite the lack of circadian rise in 
CORT secretion, the Bmal1 null mice still retain the ability for stress-induced elevations 
in plasma CORT (Figure 4.1.A).  
Steroidogenic acute regulatory protein is a rate-limiting step in adrenal 
steroidogenesis. StAR functions as a transport protein to allow cholesterol into the 
mitochondria where it is converted to the precursor of various steroid hormones including 
CORT. Previously reported data identified StAR as a clock-controlled gene whose 
transcription is regulated by the CLOCK:Bmal1 heterodimer and thus has diurnal 
variation in its expression (36). Moreover, the diurnal expression of adrenal StAR mRNA 
and protein correlate with the biosynthesis of CORT in rhythmic fashion (36). To verify 
that the cause of lack of circadian CORT rise in the Bmal1 null mice was due to its 
biosynthesis, we performed real-time quantitative PCR for adrenal StAR mRNA.   
Levels of StAR mRNA in the Bmal1 null mice had a tendency to be lower than in 
control mice at nadir (p=0.06), and were decreased significantly at peak (p=0.03) (Figure 
4.1.B). We confirm here that the significant circadian rise of StAR mRNA in control 
mice (p=0.009) is lost in Bmal1 null mice (p=0.8) (Figure 4.1.B). Indicating that the 
blunted circadian rise of CORT in Bmal1 null mice was due to disruption in diurnal StAR 
mRNA expression. 
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Figure 4.1. Effects of complete Bmal1 loss on HPA axis activity. (A) Plasma CORT levels 
measured at nadir, peak, and after 20-minutes of restraint stress. Bmal1 null mice lack circadian 
rise plasma CORT at peak but display normal stress induced increased in CORT. (B) Bmal1 null 
mice have a trend towards reduced adrenal StAR mRNA expression and lack circadian rise in 
StAR mRNA compared to controls. (C) Plasma ACTH levels measured at nadir, peak, and after 
20-minutes of restraint stress. Bmal1 null mice lack circadian rise plasma ACTH and display 
reduced stress-induced ACTH levels. #p< 0.07, *p<0.05, **p< 0.01, ***p<0.001, ****p<0.0001. 
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ACTH Regulates Adrenal StAR Expression 
In mice with adrenal-specific Bmal1 deletion, adrenal StAR and CORT diurnal 
rhythms are abolished only under constant dark conditions (36). The fact that under light-
dark conditions StAR circadian rhythms are abolished in Bmal1 null mice (Figure 4.1.B), 
but maintained in adrenal Bmal1-deleted mice suggest the influence of upstream 
hormonal regulators in its periodicity.  
Given that hypothalamus and pituitary regulate CORT secretion, we evaluated 
ACTH expression from the pituitary. We measured ACTH to identify whether plasma 
ACTH expression correlated with the abolished circadian rhythm of StAR mRNA in 
Bmal1 null mice. Indeed control mice showed a circadian rise in ACTH levels (p=0.013) 
that was absent in Bmal1 null mice (Figure 4.1.C). Interestingly, both control and Bmal1 
null mice show stress induced increases in ACTH (p<0.001, p=0.006 respectively), 
although levels in control mice were elevated to a greater extent (p=0.04) (Figure 4.1.C). 
Thus plasma ACTH is associated with diurnal circulation of adrenal StAR and 
subsequently plasma CORT. 
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Figure 4.2. Effects of brain Bmal1 loss on Bmal1 expression and HPA axis activity. (A) 
Western blot demonstrating Bmal1 protein expression in the kidney, cortex, and hypothalamus of 
control and NestinCre Bmal1 ko mice. We observe undetectable levels of Bmal1 protein in the 
cortex and hypothalamus of NestinCre Bmal1 ko mice. (B) Quantitative PCR verifies Bmal1 
mRNA lost in the cortex of NestinCre Bmal1 ko mice, but there is still residual Bmal1 mRNA in 
the SCN and no effect in the pituitary. (C,D) Plasma CORT levels measured at nadir, peak, and 
after 20-minutes of restraint stress shows only a difference in stress-induced CORT levels in 
males (C), but no differences in females (D). **p< 0.01, ***p<0.001 
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Intact CORT and Locomotor Circadian Rhythms in Bmal1-deleted Brains  
To further examine the role of Bmal1 in the hypothalamus and brain more 
generally, we generated mice with Bmal1 deleted in the CNS (NestinCre-Bmal1 ko). We 
verified loss of Bmal1 in the brain using western blot analysis. We find that NestinCre-
Bmal1 ko mice had no detectable Bmal1 protein in the cortex or hypothalamus, and this 
loss of Bmal1 was limited to the brain as the kidney of these mice had normal Bmal1 
expression (Figure 4.2.A). Evaluation of Bmal1 mRNA expression demonstrated that 
NestinCre-Bmal1 ko mice lack Bmal1 mRNA expression it the cortex but retain some 
residual expression in the SCN (Figure 4.2.B). This residual expression of SCN Bmal1 
may account for the normal circadian rhythmicity of CORT secretion in NestinCre-
Bmal1 ko mice compared to control mice (Figure 4.2.C,D). Plasma CORT levels in 
NestinCre-Bmal1 ko mice also did not differ from controls (Figure 4.2. C,D). 
Interestingly, while both genotypes exhibit significant increases in stress-induced CORT 
(p < 0.0001), levels in male NestinCre-Bmal1 ko mice were elevated to a higher extent 
compared to controls (p = 0.016) (Figure 4.2. B).  
Consistent with data in other studies, our NestinCre-Bmal1 ko mice maintain 
normal circadian locomotor activity (32, 37). We tested this using circadian activity 
chambers equipped with running wheels. Double plotted actograms confirm that in first 8 
days in light-dark cycle (12-12 hours) both groups of mice entrain to the light dark cycle 
(Figure 4.3. A). In the remaining 28 days of constant darkness, we observe that the 
NestinCre-Bmal1 ko mice retain locomotor rhythmicity similar to controls (Figure 4.3. 
A). We, however, do observe significantly reduced free-running period in NestinCre-
Bmal1 ko mice compared to control mice (p=0.048) (Figure 4.3. B).  
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Figure 4.3. NestinCre-Bmal1 ko mice have normal locomotor behavior but reduced free-
running period. (A) Actograms of representative control and NestinCre Bmal1 ko mice show no 
differences in circadian locomotor activity in LD and DD. (B) Evaluation of length of free-
running period demonstrates a reduced period in the NestinCre Bmal1 ko mice compared to 
controls. *p<0.05 
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DISCUSSION 
Bmal1 null mice display disrupted circadian rhythms in glucocorticoid secretion 
(31). We confirm this data in our studies and further demonstrate disruption of diurnal 
rhythms in plasma ACTH and adrenal StAR mRNA in a normal light-dark cycle. We 
demonstrate that brain Bmal1 is not necessary for maintenance of behavioral or CORT 
rhythmicity, but residual Bmal1 expression in SCN neurons are necessary.  
Our data show that while ACTH levels do not differ between control and Bmal1 
null mice, there is a circadian rise in the control mice, not observed in Bmal1 null mice. 
This ACTH trend correlates to our plasma CORT data where diurnal rhythm is lost but 
differs in that peak levels of CORT are significantly reduced in Bmal1 null mice compare 
to control. These disruptions in ACTH and CORT regulation in combination with the 
blunted and arrhythmic StAR mRNA suggest that CORT regulation in the Bmal1 null 
mice is in part due to arrhythmic ACTH signaling and/or reduced adrenal StAR activity. 
In vitro data from Leliavski et al. demonstrates that the adrenals of Bmal1 null mice have 
reduced sensitivity to ACTH stimulation (31), which could explain the dissociation 
between ACTH levels and blunted CORT levels in Bmal1 null compared to controls. 
Disruption in diurnal CORT rhythm has also been reported in CLOCK mutants (38, 39), 
PER1 and PER2 mutants (40, 41), as well as CRY1/2 double knockouts (42). 
Interestingly, our data and data from some these studies demonstrate that CLOCK and 
Bmal1 disruption dampens CORT secretion (31), whereas PER1, PER2, and CRY1/2 
disruption elevates CORT secretion. This indicates the direct control of glucocorticoid 
secretion by both the positive and negative arms of the clock gene network.  
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We also observe that despite blunted and arrhythmic CORT and ACTH, Bmal1 
null mice still have the ability for stress-induced elevation in both hormones. However 
while stress-induced CORT levels in Bmal1 null mice rise to the level of control mice, 
ACTH levels are still blunted in the Bmal1 null mice. One implication of this result is 
that circadian disruption has no effect on stress-mediated glucocorticoids release. This is 
substantiated by similar data found in PER2 knockout mice, where basal CORT rhythms 
are disrupted but stress-induced CORT is intact (41). One possible reason for this may be 
due to autonomic nervous system stimulation of CORT under stressful conditions, 
leading to CORT dissociation from ACTH.   Interestingly in two days of constant 
darkness, a mild acute forced swim stressor causes a 3-fold increase in control CORT 
levels but no increase in Bmal1 null mice (31). Moreover, Bmal1 null mice display 
similar stress-induced increases in plasma ACTH as do control mice in DD (31). 
However, in our studies, a 20-minute acute restraint stressor causes greater than 19-fold 
elevation of CORT in control mice and 8-fold elevation of CORT in Bmal1 null mice. 
While we observe significant elevation in plasma ACTH levels after 20-minute restraint 
stress, the elevations in control mice are twice as high as those in Bmal1 null mice. These 
data indicate that the type of stressor as well as the presence or absence of light cues can 
influence ACTH and glucocorticoid signaling. In general, the data does point to 
diminished HPA axis sensitivity in Bmal1 null mice and affirms the notion of different 
neuroendocrine pathways mediating basal versus stress-mediate glucocorticoid secretion. 
Adrenal specific Bmal1 deletion was accomplished by using the ACTH receptor 
(MC2R) promoter to drive expression of an antisense Bmal1 gene. In these transgenic 
mice, adrenal StAR expression as well as both plasma and adrenal CORT rhythms are 
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normal in the presence of light cues (36). In constant darkness, adrenal CORT rhythms 
are abolished while the plasma CORT rhythms are retained but attenuated (36). This data 
suggests that adrenal Bmal1 affects the peak levels of CORT secretion but not the 
circadian rhythm of CORT.  
Consistent with other studies (32, 37), we observed in our NestinCre-Bmal1 ko 
mice that loss of Bmal1 in neurons is associated with normal circadian locomotor 
activity, however the free-running period is significantly reduced by approximately 7 
minutes (Figure 5.3. B). Interestingly, when brain-Bmal1 is rescued in mice on a Bmal1 
null background, circadian rhythmicity is restored, but the free-running period is reduced 
by one hour compared to control mice (35). Reduced free running period when Bmal1 is 
lost in the brain and when it is expressed only in the brain indicates peripheral Bmal1 also 
plays a role in determining the period of locomotor activity.  
Complete Bmal1 loss in mice abolishes both circadian locomotor and CORT 
rhythms (at least under normal light/dark conditions). Given that both brain- and adrenal-
specific Bmal1 loss do not affect normal CORT rhythms, the findings together suggest 
that intact Bmal1 expression in the pituitary may compensate to mediate circadian 
rhythmicity in NestinCre-Bmal1 ko mice. This is not surprising since glucocorticoid 
pathways at the level of the pituitary and the adrenal cortex have their own endogenous 
clock systems to regulate in the absence of brain Bmal1 input (43-45).  A Cre-mediated 
Bmal1 deletion targeting the pituitary or hypothalamic neurons may help to elucidate the 
inherent source of diurnal CORT synthesis in more detail. However, the incomplete 
Bmal1 deletion in the SCN of NestinCre-Bmal1 ko mice is a potential source for the 
maintained circadian CORT rhythms. We conclude that SCN, but not brain, Bmal1, is 
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necessary for maintaining the circadian rhythm of locomotor activity and plasma CORT 
levels. 
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CHAPTER V 
 
 CONCLUSIONS AND FUTURE DIRECTIONS 
 
SUMMARY AND CONCLUSIONS 
Part 1 of this dissertation determines the consequences of disrupting the 
glucocorticoid receptor (GR) in the paraventricular nucleus of the hypothalamus (PVN) 
from adolescence through adulthood. Negative feedback regulation of glucocorticoid 
(GC) synthesis and secretion by the GR along the hypothalamic-pituitary-adrenal (HPA) 
axis coordinates basal and stress-induced increases in glucocorticoid secretion. This 
chapter describes the effects of loss of the GR along major sites of negative feedback in 
the brain and pituitary, particularly focusing on the PVN.  Utilizing genetically-altered 
mouse models, we evaluate circadian regulation of HPA axis, the stress-stimulated 
response neuroendocrine and behavioral activity, as well as the integrated response of 
organism metabolism.  
 
GR disruption in the hypothalamus 
In the HPA axis, the PVN is the site of corticotropin-releasing hormone (CRH) 
synthesis that drives GC synthesis. Circadian regulation of PVN CRH activity is 
mediated by suprachiasmatic nucleus (SCN) synchronization. Neuroanatomical studies 
have provided evidence for SCN neuropeptide input to the PVN. For instance, 
vasopressin (AVP) neurons originating from the SCN project into the dorsal 
hypothalamic nuclei which then relay information to CRH neurons in the PVN (1). 
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Physiological data has also demonstrated that the SCN evokes both inhibitory and 
excitatory postsynaptic potentials in PVN neurons and in this way directly targets PVN 
CRH neurons (2). This SCN control would therefore drive the canonical HPA axis 
pathway of GC synthesis and secretion by synchronizing PVN CRH to induce the 
secretion of pituitary adrenocorticotropic hormone (ACTH) that leads to the synthesis 
and secretion of corticosterone (CORT). It is of note, however, that both the pituitary and 
adrenal cortex have endogenous clock pathways that can be activated independently of 
HPA axis rhythmicity. Furthermore, GC action via GR does not have a direct effect on 
SCN clock gene expression, but does cause phase shifts in peripheral clock gene-driven 
circadian functions peripherally, indicating a reciprocal relationship between SCN and 
GC, in which diurnal GC is able to coordinate SCN driven circadian functions in 
peripheral oscillators (3). 
To specifically investigate the impact of GC feedback at the level of the 
hypothalamus, we generated mutant mice using a Sim1Cre transgene that expresses Cre-
recombinase in Sim-1 neurons, primarily in the PVN, as well as sparsely in other nuclei 
(4). The Sim1Cre transgene was used to remove exon1C-2 (Sim1Cre-GRe2Δ) or exon 3 
(Sim1Cre-GRe3Δ) (Figure 5.1. A) in floxed GR mice. We demonstrated in the resulting 
mutant mice that loss of 50%-90% of PVN GR protein does not disrupt circadian CORT 
or ACTH release (5). In control mice, Sim1Cre-GRe2Δ and Sim1Cre-GRe3Δ mice, basal 
evening CORT and ACTH levels were elevated significantly above morning levels. This 
retention of diurnal CORT and ACTH rhythms occurred in spite of significantly 
increased CORT and ACTH secretion in Sim1Cre-GRe3Δ mice. This is evidence that 
PVN GR is not involved in regulating the qualitative pattern of diurnal secretion of GCs.  
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Adult Sim1Cre-GRe3Δ mice have augmented HPA axis activity with increased 
PVN CRH, and increased ACTH and CORT secretion compared control mice. A 
different PVN GR knockout mouse generated by Jeanneteau and colleagues showed a 
different phenotype in that the homozygous mutants (GRflox+/+;Sim1Cre+) are embryonic 
lethal due to possible residual Cre-recombinase expression in the lung (6). The 
heterozygous mice (GRflox+/-;Sim1Cre+), which are hypomorphic for GR in the PVN 
however, also demonstrate increased plasma CORT ACTH levels. The elevated plasma 
CORT and ACTH levels are a reflection of increased CRH transcripts in the PVN of 
GRflox+/-;Sim1Cre+ and Sim1Cre-GRe3Δ mice (5, 6) (Table 5-1.). Interestingly, none of 
these HPA axis changes were observed in adult Sim1Cre-GRe2Δ mice, but adolescent 
males show a transient increase in peak CORT levels. The level of GR loss, 47% in 
Sim1Cre-GRe2Δ mice vs. 87% in Sim1Cre-GRe3Δ mice, is likely a contributing factor 
to the difference in phenotype. This is supported by data in GR null heterozygous mice 
which have 50% loss of GR and display no changes in glucocorticoid secretion under 
basal conditions (7) as well as in FBGRKO mice, which do not show HPA axis 
abnormalities when less than 60% GR is loss (8).  An alternate explanation for the 
differences between Sim1Cre-GRe2Δ and Sim1Cre-GRe3Δ mice might be the influence 
of the distinct exons deleted and the potential for residual production of portions of GR. 
The exon 3 of GR contains the zinc-finger of the DNA binding domain while the exon 2 
contains the transcriptional activation domain. Genetically altered mice with site specific 
mutations along the GR gene, such as in the GR dimerization-deficient mice (9), may 
provide more intricate analysis of importance of exon/domain functions. In fact, GRdim 
mice, have elevated CORT levels at nadir and peak compared to control mice (10), 
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indicating that the dimerization and/or DNA binding function of GR is necessary for 
negative feedback regulation of HPA axis activity. The developmental function of PVN 
GR was exposed in data from adolescent Sim1Cre-GRe3Δ mice. Early in adolescence, 
male Sim1Cre-GRe3Δ mice display augmented basal CORT levels but not stress-induced 
CORT, indicating that PVN GR plays a role in mediate negative feedback during 
adolescence. This role is gender specific since it is not observed in female Sim1Cre-
GRe3Δ mice (Table 5-1.). By late adolescence, PVN GR appears to be necessary for 
negative feedback of CORT at both the basal and stress-induced levels in males, but only 
at the nadir level in females. Therefore, there is not only gender-specific activity of PVN 
GR, but also developmental progression of PVN GR function.  
Negative feedback in the hypothalamus occurs when CORT binds to GR in the 
PVN. Activated GR translocates to the nucleus of parvocellular neurons where it may 
bind to a negative GRE in the CRH promoter gene, causing repression of CRH 
transcription (11, 12), though this remains controversial. Malkoski and colleagues 
identified a GC-responsive cis-regulatory element on the CRH promoter, which is 
stimulated by cAMP. GR was shown to mediate greater than a 50% reduction in CRH 
promoter activity through direct binding to a negative GRE on the CRH promoter in a 
region that is highly conserved (12). However, many other studies have found a lack of 
direct GR interaction with the CRH gene. For instance, studies of GRdim mice, which 
have a mutation in the DNA-binding domain, demonstrate no changes in CRH expression 
(9). Moreover, hypothalamic chromatin immunoprecipitation of the CRH promoter 
demonstrated no GR interaction or GRE detected near the promoter (13). Further 
exploration of the CRH gene indicated that GCs act on GR to promote DNA methylation 
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and histone acetylation of the CRH promoter to repress CRH expression (14, 15). In vitro 
studies show that GR repression of CRH can occur through its disruption of second 
messenger signaling pathways (16). Studies also indicate that GCs act on G-protein 
coupled membrane receptors in PVN neurons to increase endocannabinoid signaling. The 
activated endocannabinoids cause retrograde suppression of glutamate secretion onto 
PVN neurons, thereby reducing the frequency of miniature excitatory post-synaptic 
currents (17–19). This results in GC-mediated fast-feedback inhibition of CRH neurons 
in the PVN and thus inhibition of ACTH and CORT secretion (20–24). These data 
collectively indicate the existence of multiple mechanisms for GC-mediated repression of 
PVN CRH activity that does not depend on direct GR interaction with the CRH gene. 
Data from our lab demonstrates that loss of ~50% of GR in the PVN does not 
affect HPA axis activity or behavior in adulthood but causes transient changes in 
adolescence. When levels of GR are reduced below 20% deleterious effects due to CORT 
excess are observed (5). Indeed, adult Sim1Cre-GRe3Δ mice show a 3-fold increase in 
CRH mRNA levels in the PVN as a result of 87% GR loss, whereas Sim1Cre-GRe2Δ 
mice have only 43% of GR PVN loss. Thus, the level of GR loss in the PVN directly 
influences alterations in CRH transcripts in the PVN and subsequent plasma ACTH and 
CORT levels. 
In addition to having elevated basal nadir and peak levels of CORT, adult 
Sim1Cre-GRe3Δ mice respond to restraint stress with greater increases in CORT release 
than controls (5). Our data indicate that the stress-induced regulatory activity by PVN GR 
is low or absent during early adolescence, indicating that pituitary GR may be more in 
control of stress mediation during that time in development. In contrast to CORT, stress-
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induced ACTH levels in adult Sim1Cre-GRe3Δ mice did not differ from that of control 
mice. This dissociation of elevated stress-induced CORT with normal stress-induced 
ACTH expression implies a possible increase in adrenal cortex sensitivity to ACTH 
under stressful conditions. Indeed, increased adrenal sensitivity to ACTH is observed in 
GRNesCre mice (25), but not in FBGRKO, resulting in elevated CORT secretion in 
response to exogenous ACTH injections (26, 27) (Table 5-1.). A role for PVN GR 
mediating this increased adrenal sensitivity during stress is therefore possible.  
At the onset of a stress response, GCs are known to mediate metabolic activity by 
enhancing glycogenolysis, lipolysis, and proteolysis to produce substrates of glucose, 
fatty acids, and amino acids, respectively, that can be diverted for use in specific tissues 
depending on need (28). Given the involvement of GR in metabolic activity as well as the 
hypothalamus being a center for regulation of energy metabolism, (Kellendonk 2002, 
endocrinology), Sim1Cre-GRe3Δ mice present an opportunity to evaluate the influence 
of loss of PVN GR on several metabolic phenotypes. 
At birth, the Sim1Cre-GRe3Δ mutants appear similar to control littermates. 
During postnatal development, Sim1Cre-GRe3Δ mice show stunted growth (5). 
Phenotypic differences start manifest at P20, and there is significantly reduced body 
weight. In contrast to pituitary GR loss, Sim1Cre-GRe3Δ male and female mice begin to 
catch up to their control littermates beginning around P70 and surpass controls in weight 
from P100 onward. This increased weight included the accumulation of adipose tissue in 
the gonadal region of the mutants, and a truncal obesity phenotype. Given the chronically 
high levels of GCs in the mutants, this result is consistent with Cushing’s syndrome in 
these mice. Compared to Sim1Cre-GRe3Δ mice, the excess GCs in GRNesCre and GRflox+/-; 
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Sim1Cre+ mice do not result in increased adiposity; in fact these mice have reduced 
weight in adulthood. GCs regulate expression of hypothalamic peptides, such as leptin, 
insulin, and neuropeptide Y, which govern growth and energy homeostasis (29). Leptin, 
which signals the hypothalamus to decrease hunger and therefore food intake as well as 
fat storage, is elevated in young GRNesCre mice. Adult GRNesCre mice have reduced levels 
of insulin-like growth factor 1 (IGF-1) which is involved in stimulating growth in many 
organs (29). Thus, excess GCs may induce decreased body weight by regulation of leptin 
and IGF-1. Since Sim1CreGRe3Δ mice become obese and have increased adiposity, this 
finding is suggestive of a difference in CORT function during early development 
compared to adulthood in mediating growth signaling. This ramification is supported by 
rat studies showing that prenatal dexamethasone application causes low birth weight (30), 
but dexamethasone application into adult rats causes an increase in enzymes responsible 
for synthesis of lipids, and thus increased visceral adiposity (31). The cause of 
discordance in weight between adult Sim1Cre-GRe3Δ and GRflox+/-; and Sim1Cre+ mice 
is unclear, given that excess GCs also occurs in these lines. The influence of increased 
PVN CRH in mediating some of the growth phenotypes in these mutants cannot be 
discounted, as CRH signaling also regulates feeding and energy balance (32, 33). 
 
GR disruption in the pituitary 
The anterior lobe is the target of PVN CRH and arginine vasopressin input that 
stimulates the synthesis and secretion of ACTH. CRH activates the synthesis of ACTH 
through the function of an orphan nuclear receptor, Nur77 (11). When activated by CRH 
signaling through its receptors, Nur77 induces the transcription of POMC by binding to 
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DNA-response elements on the POMC gene. Prohormone convertase 1 and 2 enzymes 
process the POMC precursor polypeptide to generate ACTH and β-lipoprotein, which can 
be further processed into α-melanocyte-stimulating hormone, β-endorphin, 
corticotrophin-like intermediate peptide and γ-lipotrophins (34). It is important to note 
that Nur77 deficient mice display normal HPA axis signaling, and there is evidence that 
closely-related members of the Nur77 nuclear receptor family can compensate in its 
absence (35, 36). Diurnally secreted ACTH binds to type 2 melanocortin receptors 
(MCR2) on the surface of the adrenal cortex. Activation of MCR2, a G-protein coupled 
receptors, triggers cAMP second messenger activity that results in immediate and chronic 
synthesis of StAR and other steroidogenic enzymes (34) to cause CORT synthesis and 
secretion (37).  
GC negative feedback at the level of the pituitary begins at E16.5 (38) when 
CORT acts on pituitary GR. Rapid and delayed feedback inhibition of pituitary ACTH by 
GC have been demonstrated to occur through both genomic and non-genomic pathways 
in a number of studies (39–43). A negative GRE has been previously identified proximal 
to the POMC gene responsive to dexamethasone suppression in vitro, indicating direct 
GR genomic effects (44). Indirect effects have also been suggested in that activated GR 
homodimer can represses Nur77 activity, thereby decreasing POMC mRNA expression 
and inhibiting ACTH production (11). Studies also indicate that GC-mediated fast-
feedback inhibition of ACTH occurs through non-genomic pathways, dependent on 
endocannabinoid receptor activity (20, 21). To evaluate negative feedback regulation at 
the level of the pituitary, Schmidt and colleagues generated mice with pituitary GR 
deletion. This was accomplished by the crossing of GR floxed exon 3 mice to a POMC-
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Cre transgenic line (GRPOMCCre). GR expression was lost in the POMC-expressing cells of 
the pituitary and arcuate nucleus of these mice (Figure 5.1. B) (45). Morning levels of 
plasma CORT and ACTH under basal conditions were extremely elevated by P6. This 
excess GC is particularly interesting because it occurred despite reduced PVN CRH. It 
could be argued that this excess CORT is actually mediating negative feedback at the 
level of the PVN, hence the reduced CRH mRNA. However this is unlikely due to the 
fact that GR mRNA in these mice is also reduced at that age and levels of plasma ACTH 
are increased. While PVN CRH mRNA is decreased, expression of AVP transcripts in 
the PVN is increased and may contribute to the increase in plasma ACTH levels. These 
effects of pituitary GR deletion only happen developmentally, because by P30, the HPA 
dysregulation phenotypes were normalize in GRPOMCCre mice (Figure 5.2.) (Table 5-1.), to 
levels similar to control mice (45). Development of the HPA axis in mice includes a 
stress hyporesponsive period (SHRP) established from postnatal day 1 (P1) through P12 
(46). During this time, neonates have low basal CORT, and high PVN CRH transcript 
levels. The alterations in GRPOMCCre mice during SHRP but not in adulthood, confirm as 
previously identified that pituitary GR function is indispensable for HPA axis control 
during the SHRP (46). 
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Figure 5.1. Glucocorticoid Receptor Expression in Genetic Mouse Models. Sagittal brain 
sections depicting areas of GR mRNA expression and deletion in mice with targeted GR deletion. 
Orange circles (●) represent GR, targeted regions are in yellow highlight and blue font). A. Adult 
Sim1Cre-GRe3∆ mice have GR loss primarily in the PVN. B. GRPOMCCre mice have GR loss in 
the anterior pituitary throughout life. Abbreviations: Anterior pituitary, A Pit; Basolateral nucleus 
of the amygdala, BLA; Bed nucleus of the stria terminalis, BnST; Central nucleus of the 
amygdala, CeA; Hippocampal areas, CA1, CA2, CA3; Cerebellum, Cereb; Cingulate cortex, 
Cing Ctx; Dentate gyrus, DG; Frontal cortex, Fr Ctx; Inferior colliculus, InfC; Locus coeruleus, 
LC; Medial nucleus of the amygdala, MeA; Occipital cortex, Occ Ctx; Periaqueductal gray, PAG; 
Parietal cortex, Par Ctx; Paraventricular hypothalamic nucleus, PVN; Raphe nucleus, RN; 
Septum, Sep; Supraoptic nucleus, SN; Superior colliculus, SupC; Thalamus, Thal;  
 
 
 
Developmental GC excess in GRPOMCCre mice impaired GR-mediated negative 
feedback in adulthood, as GRPOMCCre mice took longer to decrease their CORT levels 
after restraint stress and in the dexamethasone suppression test (DST) (45). While the 
initial study of GRPOMCCre mice demonstrated no basal anxiety phenotype (45), a 
subsequent study revealed a more anxious phenotype of GRPOMCCre mice in the elevated 
zero maze test (47). This anxious phenotype was abolished with a chronic social defeat 
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stress, leading the authors to infer that in the initial study, the mice were inadvertently 
exposed to a stressor that masks their basal anxiety phenotype. Adult GRPOMCCre mice 
display decreased despair in the forced swim test compared to control mice. The reduced 
despair behavior was inhibited if GRPOMCCre mice were treated with a GR antagonist 
during the developmental period when CORT levels are high. This finding indicates that 
transient increases in GR activation early in development have differing effects on 
anxiety and despair behaviors later in adulthood. This data also suggests that when 
increased GR activation is persistent, as observed in Sim1Cre-GRe3Δ mice (5), it results 
in habituation to anxiety and despair behavior under basal circumstances. The data 
reviewed here is part of a larger body of evidence on the programming effects of early 
life experience (48–54). The observations described in these studies have strong 
implications for the role of MR and GR in the predictive adaptive capacity, 
match/mismatch and cumulative stress exposure theories (55–58). 
FBGRKO and Sim1Cre-GRe3Δ both fail to suppress CORT in the DST test (8, 
59), and GRPOMCCre mice suppress CORT but in a less efficient manner than observed in 
controls (Table 5-1.). This suggests differential levels of contributions to negative 
feedback regulation from these regions, with the PVN and forebrain GR contributing 
more heavily in adulthood and pituitary GR more during early postnatal life. From this 
data, we conclude that pituitary GR mediates basal HPA activity in early life (young 
GRPOMCCre mice have disrupted PVN CRH, normal plasma CORT and ACTH levels) but 
not in adulthood (Adult GRPOMCCre have normal PVN CRH, normal plasma CORT and 
ACTH levels). On the other hand, PVN GR is involved in mediating basal HPA activity 
in adulthood, (adult Sim1Cre-GRe3Δ have disrupted PVN CRH, normal plasma CORT 
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and ACTH levels).  
The data in GRPOMCCre and GRCaMKCre (Chapter 1) mice demonstrate the 
importance of pituitary GR function in early postnatal development. The retention of 
negative feedback sites in the brain and PVN of GRPOMCCre mice prevents the postnatal 
death that occurs in GRCaMKCre mice (60). This finding suggests that CORT elevations in 
excess of a certain threshold are lethal. At least one site of negative feedback regulation 
must be retained for life. This conclusion is supported by the fact that when pituitary GR 
is the only negative feedback site retained in GRNesCre mice, the mice survive similar to 
controls. While GRPOMCCre mice do show decreases in PVN GR early in life, the level of 
this GR deletion may not be enough to completely avert negative feedback, and 
furthermore PVN GR mRNA levels normalize in adulthood while pituitary GR loss is 
retained (45). Given data in from our group that indicates that 50% loss of PVN GR does 
not affect HPA axis activity or behavioral phenotypes (5), it seems unlikely that the level 
of GR loss in GRPOMCCre mice is influential in the observed phenotypes. Thus, one 
question that arises is, when PVN and pituitary GRs are both lost, is GR feedback in the 
forebrain sufficient to maintain viability? 
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Figure 5.2. Schematic of CORT levels in GR-targeted Mice. This figure depicts the relative 
levels in plasma CORT depending on the nature of the mutation in GRNesCre, GRCaMKCre, 
GRPOMCCre, and Sim1Cre-GRe3∆ compared to control mice at postnatal day 6 and in adulthood. 
Values represent estimates of plasma CORT values provided from respective articles. Controls 
are averaged values of from individual studies. 
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After the SHRP, basal plasma CORT levels increase and PVN CRH mRNA levels 
decrease beginning from P12, while plasma ACTH levels remain constant (61). 
Moreover, before P9, the stress of a novel environment has no effect on plasma CORT or 
ACTH levels, but after P12 levels of both hormones increase in response to novelty stress 
in control mice. The data in GRPOMCCre mice indicate that developmentally, pituitary GR 
is sensitive to stimuli. Generally, GR is known as being responsive to circadian peak or 
stress-induced but not nadir changes in HPA axis activity (62, 63). However the studies 
described in GRPOMCCre and Sim1Cre-GRe3Δ mice suggest that in early postnatal 
development, pituitary GR is sensitive to basal HPA axis changes and along development 
there is a switch to PVN GR becoming sensitive to basal changes in HPA axis activity. A 
comparison of GRPOMCCre and Sim1Cre-GRe3Δ mice also shows that whereas loss of 
pituitary GR increases anxiety in the EZM and causes stress coping in the FST during 
adulthood, loss of PVN GR had no effect (Table 5-1.). This outcome is possibly due to 
lower plasma CORT concentrations early in development of Sim1Cre-GRe3Δ mice than 
GRPOMCCre mice. A closer evaluation of the ontogeny of the HPA axis in Sim1Cre-
GRe3Δ mice would better enable this to be resolved.  
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Chronic social defeat stress in GRPOMCCre mice not only prevented anxiety 
phenotypes but also abolished increases in basal CORT that occurred in control stressed 
mice. There is much evidence of early life stress being protective later in life. The data in 
GRPOMCCre mice supports the notion that the resilience to social defeat stress occurs due 
to the transient GC excess that mimics the neuroendocrine effects of early life stress (47). 
It appears though, that while genetic defects that produce a brief period of GC excess 
postnatally have no effect on HPA axis dysregulation later in adulthood, genetic defects 
that produce long-term GC excess completely disrupt HPA axis activity. 
GRPOMCCre mice have stunted growth until during the first two weeks of life (45). 
Early postnatal growth deficits also occur in GRNesCre, GRCaMKCre and Sim1Cre-GRe3Δ 
mice, all of which have elevated levels of CORT during that developmental period. In 
GRPOMCCre mice, weight returns to similar levels as that of controls from P28 onwards, 
and coincides with normalization of HPA axis dysregulation. In contrast to normalized 
HPA axis in adult GRPOMCCre mice, the HPA axis is still hyperactive in GRNesCre and 
Sim1Cre-GRe3Δ mice in adulthood and leads to a differential impact on growth. These 
data suggest that GR in the brain and pituitary are required to maintain normal growth 
processes in mice. Loss of GR early in development leading to GC excess reduces 
growth, while in adulthood GC influence on growth is region dependent. Pituitary GR, 
however, does not have a major influence in mediating growth pathways in adulthood. 
Taken together, these data suggest differential involvement of GR in regulating growth 
during early development versus during adulthood, as well as differential involvement of 
GR in specific brain regions in terms of the level of involvement in growth regulation. 
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Numerous studies in animal models and humans clarify the importance of 
glucocorticoids and the HPA axis in mediating stress reactivity in terms of endocrine 
output, behavioral activity, and energy balance. Here in part 1 of the dissertation, we 
primarily focus on studies in sites of GC negative feedback in the brain and pituitary of 
genetically targeted mice. In all of the genetic models addressed, diurnal rhythmicity of 
CORT secretion is maintained indicating that GR in negative feedback sites are not 
important for circadian regulation of GC synthesis and secretion. During periods of GC 
excess, increased PVN CRH and/or AVP lead to increased plasma ACTH and CORT. In 
terms of physical development, it seems that excess GCs during early life cause growth 
deficits that normalize if GC levels normalize. Early postnatal GC excess impairs growth 
and may reprogram HPA axis reactivity to stress later in life. Moreover, the effects of this 
GC excess are dependent on the site where GR is lost. Brief GC elevations during 
postnatal development, due to pituitary GR loss, slow dexamethasone suppression while 
increasing anxiety and stress-coping behavior. GC excess due to PVN GR loss results in 
age and gender-specific differences in impaired negative suppression of CORT and 
causes a Cushing’s phenotype. There is increased anxiety behavior in the EZM during 
adolescence that is lost in adulthood, perhaps due to habituation of chronically elevated 
glucocorticoids. There are no basal differences in anxiety or despair behavior in adult 
Sim1Cre-GRe3Δ mice. However, there is a gene – environment interaction that results in 
increased anxiety in mice with PVN GR loss after exposure to anxiogenic environment. 
GR loss in both PVN and pituitary as well as in the brain is incompatible with sustained 
life, primarily due to the necessity for pituitary GR function early in life.  
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FUTURE DIRECTIONS 
There are a number of lingering questions that can be address with the Sim1Cre-
GRe3Δ model. Excess glucocorticoid levels can act on a number of brain regions such as 
the amygdala, hippocampus, and prefrontal cortex and alter cortical activity (64, 65). 
Changes in neurocircuitry as a result is increased GC activity have been shown due to GC 
altering synaptic dendrite morphology (66–68). These changes can lead to dysregulation 
of excitatory – inhibitory signaling. Our preliminary data demonstrated impaired spatial 
memory in the Morris water maze test in Sim1Cre-GRe3Δ mice. However, the reductions 
in speed and locomotor activity and that these mice display confound evaluating the 
Morris water maze data. Using behavioral tasks that are not influenced by locomotor 
activity would be beneficial in evaluating learning and memory in Sim1Cre-GRe3Δ mice. 
Also, functional studies in the brain of Sim1Cre-GRe3Δ mice can reveal the effects of 
PVN GR disruption role of throughout development.  
There remains much to be learned from Sim1Cre-GRe3Δ mice regarding elevated 
GC levels on metabolic activity. We have already described the Cushingoid phenotype in 
Sim1Cre-GRe3Δ mice, the growth impairments and altered adipose distribution. We also 
observed altered stress-induced glucose secretion in Sim1Cre-GRe3Δ mice. The effects 
of PVN GR on metabolism could prove valuable in uncovering hypothalamic function in 
metabolic activity. There is also the question of how PVN GR functions depending on 
gender. Investigations into the influence of gonadal hormones on HPA axis and behavior 
in Sim1Cre-GRe3Δ mice will prove beneficial in this area. Lastly, the possibility of 
epigenetic modifications in the GC signaling pathways during development as a result of 
PVN GR disruption is an attractive area of investigation. Overall, these studies will 
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provide further insight in understanding HPA axis dysregulation and the molecular basis 
of psychiatric and metabolic disorders in different genders. 
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CHAPTER I 
 
INTRODUCTION TO CORTICOTROPIN-RELEASING HORMONE MEDIATION OF 
THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS 
 
Gloria Laryea, Melinda G. Arnett and Louis J. Muglia 
 
INTRODUCTION  
Corticotropin-releasing hormone (CRH) is a 41 amino acid peptide that was 
first isolated and characterized by Wylie Vale in 1981 (1). It belongs to a family of 
peptides that has subsequently been found to include Urocortin1, 2, and 3 (Ucn1, 2, 
3). This family of peptides shares 18% to 43% sequence homology, and its members 
are expressed in largely non-overlapping regions of the central nervous system and 
periphery. They function to maintain physiological activities ranging from appetite 
control to immune system modulation and mediation of the stress response (2). To 
understand the endogenous role of CRH in organisms, several genetic rodent models 
have been established and used to address a number of questions. These questions 
deal with understanding the neuroendocrine and behavioral function of CRH and 
signaling molecules that mediate CRH neurocircuitry. In this chapter, we begin by 
discussing CRH circuitry and reviewing the associated genetically altered models. 
Then we present findings regarding human genetic polymorphisms in CRH pathway 
genes that are associated with stress and psychiatric disorders. We finish by 
discussing a role for regulators of CRH activity as potential sites for therapeutic 
intervention aimed at treating maladaptive behaviors associated with stress. 
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CRH synthesis 
CRH is synthesized as a larger inactive preprohormone that undergoes 
proteolytic cleavage in the Golgi, mainly by prohormone convertase 2 (PC-2), and in 
some cases PC-1 (3, 4) to generate mature active CRH. The major site of CRH 
synthesis is the parvocellular neurons of the paraventricular nucleus of the 
hypothalamus (PVN). Other brain regions that show high expression of CRH mRNA 
are the central nucleus of the amygdala (CeA), the bed nucleus of the stria terminalis 
(BnST), and other limbic areas including the hippocampus (Figure 1). In the PVN, 
CRH is packaged into secretory vesicles and released in a circadian rhythm or in 
response to stress. The packaged hormone is released from neurons in the PVN into 
the hypophyseal portal system that links the hypothalamus to the anterior pituitary 
gland. CRH binds to receptors on corticotroph cells in the anterior pituitary and 
stimulates the synthesis and secretion of the adrenocorticotropic hormone (ACTH), 
which ultimately activates adrenal glucocorticoid (GC) synthesis and secretion. These 
GCs (corticosterone in rodents, cortisol in humans) function to enable adaptation to 
the stressor and negatively feedback in the hypothalamus and pituitary (to suppress 
CRH and ACTH production) to establish homeostasis. In extra-hypothalamic parts of 
the brain, CRH acts in a neuromodulatory capacity on target neurons. 
Arginine vasopressin (AVP) is a non-peptide hormone involved in water 
homeostasis, HPA axis regulation, and behavioral and vascular tone. In HPA axis 
regulation, AVP is recognized as an important ACTH secretagogue that functions 
synergistically with CRH. As such, AVP has been shown to compensate for loss of 
basal, but not stress-activated, CRH-induced secretion of ACTH in CRH KO (5) and 
CRH-R1 KO mice (6, 7). Detailed AVP involvement in mediating HPA activity and 
stress-related behavior (see (8, 9) for review) is beyond the scope of this review. 
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However, it should be considered that in some studies described here in which HPA 
axis activity remains normal in the absence of CRH or CRH-R1, AVP may contribute 
to maintaining normal HPA axis activity. 
 
  
 
 
 
Figure 1. Expression of Corticotropin-releasing hormone (CRH), CRH-R1 and CRH-R2 
mRNA in a normal mouse brain. CRH is synthesized in the PVN and shows high 
expression in the CeA, BnST and the hippocampus. CRH-R1 mRNA is highly expressed in 
the cortex, cerebellum, A Pit, hippocampus, BLA, MeA and the DMH. CRH-R2 displays 
high expression in the L Sep, SN, VMH, P Pit and the RN. Abundance of mRNA is shown as 
the density of representative symbols in an area. Abbreviations: Anterior pituitary, A Pit; 
Barrington’s nucleus, BAR; Basolateral nucleus of the amygdala, BLA; Bed nucleus of the 
stria terminalis, BnST; Central nucleus of the amygdala, CeA; Hippocampal areas, CA1, 
CA2, CA3; Cerebellum, Cereb; Cingulate cortex, Cing Ctx; Dentate gyrus, DG; Dorsomedial 
hypothalamus, DMH; Frontal cortex, Fr Ctx; Inferior colliculus, InfC; Inferior Olive, IO; 
Locus coeruleus, LC; Lateral dorsal tegmental nucleus, LDT; Medial nucleus of the 
amygdala, MeA; Medial septum, M Sep; Nucleus tractus solitarii, NTS; Occipital cortex, Occ 
Ctx; Olfactory bulb, OB; Posterior pituitary, P Pit; Periaqueductal gray, PAG; Parietal cortex, 
Par Ctx; Paraventricular hypothalamic nucleus, PVN; Raphe nucleus, RN; Supraoptic 
nucleus, SN; Superior colliculus, SupC; Thalamus, Thal; Ventromedial hypothalamus, VMH.  
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CRH receptors 
CRH has two receptors, CRH-R1 and CRH-R2. These receptors share almost 
71% amino acid sequence similarity (10), but are distinctly different in localization 
and affinities for CRH. In rodents, CRH-R1 displays widespread expression in the 
cortex and cerebellum, with higher expression in the anterior pituitary, hippocampus, 
basolateral and medial amygdala, dorsomedial hypothalamus, and parts of the 
pons/medulla and mesencephalon (Figure 1) (10, 11). CRH-R2, in contrast, is found 
in more discrete locations in the brain but displays abundant expression throughout 
the periphery. It is highly expressed in the lateral septum, supraoptic nucleus, 
ventromedial hypothalamus, cortical amygdala nucleus, raphe nucleus, choroid 
plexus, and the nucleus tractus solitarii (Figure 1). Regions of overlap between CRH-
R1 and CRH-R2 include the olfactory bulb, hippocampus, superior and inferior 
colliculus, BnST, periaqueductal gray, and medial septum (10, 11). CRH-R1 has a 
much higher affinity for CRH than CRH-R2 and is the principle receptor involved in 
the hypothalamic-pituitary adrenal (HPA) axis mediated stress response. Ucn2 and 3 
bind selectively to CRH-R2 (2, 12) while Ucn1 binds both receptors with high 
affinities (13).  
In monkey brain, CRH-R1 immunoreactivity is most abundant in the pituitary, 
cerebellum, and brain stem, with moderate expression in the cerebral cortex, basal 
forebrain, basal ganglia and thalamus and weak expression in the prefrontal cortex 
and limbic areas (14). CRH-R2 is present in the neocortex, pituitary, amygdala and 
hippocampus of monkey brain (15). This is in sharp contrast to expression in the rat 
brain where only CRH-R1 is found in the pituitary and neocortex.  
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Finally, in human brain, CRHR1 is expressed in the hypothalamus, cerebellar 
cortex, pituitary, amygdala and nucleus accumbens (16) while CRHR2 is expressed in 
the pituitary, amygdala, thalamus and hippocampus (17). 
The first splice variants of CRH-R1 were identified as CRH-R1α and CRH-
R1β (18). CRH-R1α lacks 29 amino acids of exon 6 and is the highest affinity CRH 
receptor variant. CRH-R1β contains all 14 exons of the CRH-R1 gene, including exon 
6, which decreases the affinity of CRH-R1β for CRH. Other CRH-R1 splice variants, 
including CRH-R1c-h, have been identified, all lacking exon 6 as well as other exons 
(19). All the aforementioned CRH-R1 splice variants have been identified in humans, 
while only variants analogous to CRH-R1α, CRH-R1c, CRH-R1e, and CRH-R1f 
exist in mice. CRH-R2α and CRH-R2β splice variants have been identified in rodents 
with CRH-R2α expressed mainly in neuronal regions while CRH-R2β is found 
predominantly in peripheral regions such as the heart, blood vessels and duodenum 
(13, 20, 21). In humans, both CRH-R2α and CRH-R2β are expressed in peripheral 
tissues and the brain. Both CRH-R1 and CRH-R2 receptors are G-protein coupled 
receptors (GPCR), composed of seven-transmembrane domains. Binding of CRH to 
either receptor results in a conformational change that produces activation of Gαs 
stimulated adenylate cyclase and activated cyclic AMP and protein kinase A (PKA) 
signaling pathways (18, 21). The expression of different splice variants of CRH-R1 or 
CRH-R2 therefore mediate functions associated with their locations through 
activation of cAMP-mediated pathways. 
The specific type of neurons that express the CRH receptors will also factor 
into their function. In that regard, a recent article by Refojo and colleagues identified 
the expression of mouse CRH-R1 in forebrain glutamatergic and GABAergic 
neurons, as well as midbrain dopaminergic neurons and to a lesser extent serotonergic 
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neurons (22). The functional effects of CRH within each of these neuron populations 
will be discussed in the next chapter.  
 
CRH binding protein 
The CRH binding protein (CRH-BP) is another source of regulation for CRH 
activity at the protein level. During the third trimester of pregnancy in humans, there 
is a significant increase in the release of placental CRH that predicts the relative 
timing for parturition (23). Despite this dramatic release of CRH into circulation, 
there is no increase in ACTH secretion from the pituitary (24). The most reasonable 
explanation for this came through the identification of the 37 kDa CRH-BP that 
sequesters CRH and prevents binding to its receptors (25). In primates, CRH-BP is 
expressed in the brain, pituitary, liver, placenta and plasma (26) and has a higher 
affinity for CRH than CRH receptors do (27). In rodents, CRH-BP is widely expressed 
in the cerebral cortex, lateral septum, olfactory bulb and limbic areas such as the CeA 
and the BnST as well as in pituitary corticotroph cells, with sparse expression in the 
PVN (27, 28). CRH-BP expression overlaps with CRH receptor expression and is 
therefore properly positioned to sequester CRH and inhibit its activity. Conversely, 
low levels of Ucns are also capable of binding CRH-BP and displacing CRH to 
increase levels of free CRH and thus, CRH activity (29). Whether there are internal or 
external signals that allow for displacement of CRH by Ucns is unclear, but further 
investigation may provide insights into regulation. 
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Synaptic CRH activity 
A role for CRH in modulating CNS synaptic transmission outside the HPA 
axis has become evident. Extrahypothalamic CRH may act as a modulator of 
neurotransmitters, affecting their excitatory and inhibitory activity. CRH-R1 and 
CRH-R2 are metabotropic receptors and thus, function slowly in activating signaling 
cascades, unlike the fast activation of classical neurotransmitters, such as glutamate 
and GABA, on ionotropic receptors. Synaptic CRH would function to prime post-
synaptic neurons for neurotransmitter or neuromodulator activity (30). This activity of 
CRH is both receptor- and site-specific. For instance, CRH application depresses 
glutamate-mediated excitatory postsynaptic currents (EPSCs) in the CeA while 
facilitating these EPSCs in the lateral septum (31). Application of CRH receptor 
antagonists has indicated that CRH-R1 is responsible for the changes in EPSCs in the 
CeA and lateral septum, while CRH-R2 facilitates EPSCs in the CeA and depresses 
them in the lateral septum, although Ucn1 mediates the latter. Further evidence in 
studies of mice lacking CRH-R1 in forebrain glutamatergic neurons shows that CRH 
increases excitatory field potentials in the BLA and facilitates action potential firing 
between hippocampal regions (22). CRH modulation of synaptic activity is observed 
in other brain regions and provides evidence for the mechanism by which CRH 
mediates behavior. Evidence supporting this mechanism was demonstrated in a study 
where acute stress and CRH application facilitated long-term potentiation in the 
hippocampus and was responsible for enhanced contextual fear conditioning in mice 
(32). Alterations in CRH expression and signaling are associated with a number of 
psychiatric disorders that are discussed later in this review. The interplay between 
extrahypothalamic CRH, its receptors and modulators may regulate synaptic activity 
that leads to the behavioral changes associated with these disorders. 
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CRH AGONISTS AND ANTAGONISTS 
A subpopulation of patients with major depression and post-traumatic stress 
disorder (PTSD) have elevated levels of CRH in their cerebrospinal fluid (33, 34) 
Moreover, HPA axis hyperactivity is the most commonly observed neuroendocrine 
change in major depressive disorder (MDD). Substantial evidence suggests that 
normalization of the HPA axis might be a requirement for successful treatment of 
some individuals with MDD (35). It should be noted that there is biological variation 
that occurs within these disorders and while some patients do exhibit CRH 
abnormalities, others do not (36, 37). Furthermore, the presence of CRH 
abnormalities may relate to the severity of the illness, or to the presence of 
melancholic features in patients with MDD (35). The hyperactive CRH system and 
HPA axis abnormalities that occur in some patients suggests a potential role for CRH 
in modulating the neurocircuitry underlying mood and anxiety disorders. Animal 
studies have expanded the understanding of CRH activity in neuroendocrine and 
behavioral changes associated with stress. Important findings from these studies are 
discussed below. 
The use of intracerebroventricular (ICV) CRH has provided further insight 
into CRH-mediated stress-induced behaviors. ICV injections of CRH in rats results in 
stimulation of hypothalamic and limbic brain regions that are activated in the stress 
response (38). In animal models, several behavioral paradigms have been utilized that 
explore various aspects of anxiety, despair, fear, avoidance, and other stress-related 
behaviors. Paradigms such as the open field (OF), elevated plus maze (EPM), and 
light/dark preference (LD) tests are used as indices of anxiety. The forced swim (FST) 
and tail suspension (TST) tests are used to measure levels of despair, and fear 
conditioning is utilized as a measure of stress-induced learning and memory. These 
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tests have been extensively validated and are used frequently in rodent studies. Some 
studies have demonstrated that ICV CRH increases locomotion, anxiety, fear, despair, 
and emotionality, decreases food intake, sexual activity, exploration (39) and social 
interaction and activates the HPA axis and the autonomic nervous system (40–44). 
Furthermore, these changes can be reversed with CRH antagonists (45–47). CRH-R1 
antagonists and antisense oligonucleotides are anxiolytic in rats while CRH-R2 
antagonists and antisense oligonucleotides increase despair-like behaviors and alter 
appetitive behaviors (48, 49).  
In vitro studies using rat amygdala and hypothalamic slices suggest that CRH 
and Ucn1 act through CRH-R1 to increase GABA release (50, 51). Moreover, 
prolonged daily infusion of Ucn1 into the BLA results in the development of anxiety-
like behavior in the EPM and social interaction tests (52). The study determined that 
this anxiety-like phenotype was inhibited with the administration of NMDA receptor 
antagonists.  
Ucn2 and Ucn3, which are primarily CRH-R2 ligands, have been 
demonstrated to suppress locomotor activity when injected into the intracerebral 
ventricles of rats (53, 54). The opposite effect occurs when ovine CRH is 
administered, it increases locomotor activity. Moreover, while CRH was anxiogenic 
in the EPM, Ucn3 was anxiolytic and Ucn2 had a delayed anxiolytic effect in the 
EPM test. These data are supported by evidence in CRH-R2 null mice (discussed in 
the next chapter) and reinforce the idea that CRH-R2 has a stress-coping function 
opposite to the stress-activating function of CRH-R1. In contrast to this data, Ucn2 
administration in mice is anxiogenic in the EPM, an effect reversed by CRH-R2 
specific antagonist (55). Although much data supports an anxiolytic role for CRH-R2, 
there is still strong data supporting an anxiogenic role for the receptor. Despite the 
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lack of consistency in data, CRH-R2 does have a role in mediating behavioral 
responses to stress. The degree of interaction with CRH-R1 in mediating these effects 
is yet to be determined. These studies and others also indicate the infusion of CRH or 
Ucn1, -2, or -3 in to the cerebral ventricle reduces feeding behavior in rodents (56).  
Pharmacological manipulations have provided evidence in understanding 
central CRH system effects and continue to be important for investigating the effects 
of potential therapeutic drugs. In general, however, they are limited by the fact that 
their effects are short-lived and it is difficult to measure the degree of receptor 
activation mediating the observed effects. The generation of genetically altered 
animal models, discussed in the next chapter, has allowed for a closer examination of 
the endogenous role for CRH.  
 
 
GENETICALLY ALTERED RODENT MODELS 
CRH Mutants 
With the generation of CRH deficient mice (CRH KO) (57), the hypothetical 
role of CRH as an essential mediator of physiological responses to stress could be 
further tested. CRH KO mice from heterozygous matings are phenotypically normal 
compared to control mice (58). Their only defining feature is a marked atrophy of the 
zona fasciculata of the adrenal gland and profound glucocorticoid deficiency. CRH 
KO mice generated from homozygous parents do not survive longer than 24 hours, 
due to a lack of glucocorticoids from the mother’s placenta to aid in proper lung 
formation. The aggregate studies in CRH KO mice have demonstrated that CRH KO 
mice display behavioral responses to stressors remarkably similar to those of wild-type 
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(WT) animals (59, 60). These mice have low levels of basal plasma concentrations of 
corticosterone (CORT) that are not compensated for by other ACTH secretagogues 
such as vasopressin (58) and that do not increase with a foot shock stressor. Stress-
induced activation of the HPA axis is absent in these mice whereas stress-induced 
behavioral responses thought to be mediated by CRH in the brain remain unaffected. It 
is of note that the use of two distinct CRH-R1 specific antagonists in WT and KO mice 
attenuated stress-induced behaviors. This indicates the existence of another CRH-like 
ligand, possibly one of the urocortins, acting through CRH-R1 (59). 
 
CRH Overexpressing (CRH-OE) Mice 
General CRH-OE 
To study the role of CRH hyperactivity, transgenic mice were generated that 
constitutively overexpress CRH (Table 1-1.). Stenzel-Poore and colleagues (61) 
utilized the mouse metallothionein-I (MMT-1) promoter, expressed in the brain and 
peripheral areas such as the adrenal gland, heart, and testis, to drive CRH 
overexpression in these areas (CRH-Tg). Inserting rat CRH cDNA into Thy-1 
regulatory genes created another model of CRH overexpression (62). The Thy-1 gene 
drives neuronal expression postnatally through adulthood (CRH-OE2122). In addition, 
Lu et al. inserted a targeting allele consisting of a floxed stop codon, a CRH gene, and 
an IRES LacZ gene into the Rosa 26 allele (R26+/flop CRH) and mated them to Cre-lines 
to overexpress CRH (63). The R26+/flop CRH mice, when crossed with Deleter-Cre mice, 
overexpress CRH ubiquitously throughout the body (CRH-COEDel) (64). These three 
general transgenic lines display elevated plasma CORT and, in some cases, elevated 
ACTH levels, altered HPA axis responses and Cushingoid phenotypes. Cushing’s 
syndrome is characterized by hypercortisolemia, truncal obesity, muscle wasting, 
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thinning of the skin and hair loss (61). These phenotypes are observed in all three 
transgenic lines described, although the CRH-OE2122 mice do not show a Cushing’s 
phenotype until six months of age (61, 64, 65). 
Behavioral studies in CRH overexpressing mice show reduced locomotor 
activity in a novel environment that is further exacerbated by social defeat stress and 
increased anxiety identified by less time spent in the open arm of the EPM (64, 66), 
and increased latency to enter the light compartment of a LD preference box (64, 67) 
and black/white transition test (68). ICV injection of α-helical CRH 9-41, a CRH 
antagonist, abolished this anxiogenic response (66). Despite heightened anxiety, these 
mice displayed decreased despair, demonstrated by reduced immobility in the FST (64, 
67). CRH-OE2122 mice have decreased acoustic startle reactivity, inability to habituate 
to a startle response, and a deficit in pre-pulse inhibition, all indicative of an impaired 
ability to process sensory information (62). Moreover they have altered heart rate and 
increased food and water consumption (69). The CRH-Tg mice from Stenzel-Poore and 
colleagues also show reduced alcohol preference (70). This finding is surprising given 
that increased CRH-R1 activity is known to increase alcohol use in stressed rats and 
humans (71–73). The data from these mice support a role for CRH in stress-mediated 
coping and sensory processing.  
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Table 1-1. CRH deletion and overexpression mutants 
 
 
CRH Deletion Mutant 
 
Line Manipulation Main Phenotypes References 
CRH- KO Constitutive deletion of CRH 
by insertion of a 
phosphoglycerate kinase 
neomycin-resistant cassette 
Adrenal insufficiency 
↓ Stress CORT 
No behavioral changes 
(57–60) 
 
 
 
 
CRH Overexpression (OE) Mutants 
Line Manipulation Main Phenotypes References 
CRH-Tg Mouse metallothionein-1 (MT-
1) promoter driven CRH OE in 
brain, adrenal glands, heart, 
and testes. 
Adrenal Hypertrophy 
Cushingoid phenotype  
Attentional Impairment 
↑ Basal CORT and ACTH 
↓ Locomotion 
↑ Anxiety in OF, EPM, LD, 
and black/white transition test 
↑ Active coping in FST 
↓ Despair in FST 
↓ Sexual receptivity in females 
↓ Alcohol preference 
Gene expression changes 
(61,66,67, 
70,79,80) 
CRH-OE2122 Thy-1 promoter driven CRH 
OE in neurons postnatally 
through adulthood.  
Adrenal Hypertrophy 
Cushingoid phenotype at 6 
months of age  
↑ Basal CORT  
Dexamethasone non-
suppression 
↓ Acoustic startle reactivity 
↓ Habituation to a startle 
response 
Deficit in pre-pulse inhibition 
↑ Food and water consumption, 
and altered heart rate  
(62,65,69)  
CRH-COEDel Rosa26 (R26) promoter driven 
CRH OE in the whole body. 
Cushingoid phenotype at 3-
weeks of age 
↑ Adrenal weight, ↓ thymus 
weight 
↑ Basal CORT  
↑ Anxiety in OF, EPM, LD, 
and black/white transition test 
↓ Despair in FST 
(64) 
CRH-COEAPit R26 and POMC promoter 
driven CRH OE in the anterior 
and intermediate lobes of the 
pituitary 
Mild Cushingoid phenotype at 
5-6 months of age 
↑ Basal CORT 
(64) 
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Table 1-1. Con’t 
 
 
CRH Overexpression (OE) Mutants 
 
Line Manipulation Main Phenotypes References 
CRH-COE-Nes R26 and Nestin promoter 
driven CRH OE in neurons 
and glia from embryonic day 
10.5 
↑ Stress-induced CORT and 
ACTH in male mice 
↓ Despair in FST and TST 
tests, reversible with CRH-R1 
antagonist treatment 
↑ REM sleep 
 
 
 
 
(63,75,76) 
CRH-COE-
Cam 
R26 and CamK2 promoter 
driven CRH OE in forebrain 
glutamatergic neurons from 
postnatal day 15 
Normal HPA axis activity  
↑ REM sleep 
↑ Deficit in spatial performance 
in the MWM and Y-maze tests. 
 
CRH-COE-Dlx R26 and Dlx promoter driven 
CRH OE in GABAergic 
interneurons from embryonic 
day 10.5 
Normal HPA axis activity and 
behavior 
FBCRHOElife CamK2 promoter driven 
forebrain CRH OE from 
embryonic day 0 through life 
Cushingoid phenotype by 8 
weeks of age 
↑ Nadir CORT and ACTH 
(77)  
Crh-
COECamCreERT2 
R26 and Camk2a-CreERT2 
promoter driven CRH OE in 
forebrain glutamatergic 
neurons (OE induced by 
tamoxifen at postnatal week 8) 
↑ Anxiety in LD and EPM tests (22) 
FBCRHOEdev CamK2 promoter driven 
forebrain CRH OE from 
embryonic day 15 to postnatal 
day 21 
↑Basal CORT only during 
CRH- OE. 
↑ Despair in FST and TST test 
(↓ despair in FST with 
antidepressants treatment) 
↑ Anxiety in OF, EPM, and LD 
tests 
↑ CRH-R1 mRNA in the 
cingulate cortex, dentate gyrus 
and CA1 region of the 
hippocampus 
(77) 
CRF-OE CamK2 promoter driven 
forebrain CRH OE from 8 to 
11 weeks of age 
↑ Nadir CORT 
↓ Thymus weight in females 
↓ Locomotion in familiar 
environment 
↓ Despair in FST 
Trend towards anxiety in LD  
(78) 
 
Abbreviations: Acoustic startle response test, ASR; Adrenocorticotropic Hormone, ACTH; 
Arginine Vasopressin, AVP; Basolateral nucleus of the amygdala, BLA; Bed nucleus of the 
stria terminalis, BnST; Central nucleus of the amygdala, CeA; Corticosterone, CORT; cAMP 
response element-binding, CREB; Corticotropin-Releasing Hormone, CRH; Dentate gyrus, 
DG; Dopamine, DA; Dorsal raphe nucleus, DRN; Elevated Plus Maze, EPM; Forced Swim 
Test, FST; Lateral Septum, LS; Light/Dark Preference test, LD; Lipopolysaccharide, LPS; 
Long-term potentiation, LTP; Morris Water Maze, MWM; Open field test, OF; Open Reading 
Frame, ORF; Overexpression, OE; Paraventricular nucleus of the hypothalamus, PVN; 
Prefrontal Cortex, PFC; Proopiomelanocotin, POMC; Rapid Eye Movement, REM; 
Supraoptic nucleus, SON; Tail suspension test, TST; Urocortin, Ucn). 
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These studies demonstrate that elevated CRH alters emotional regulation. 
However, analysis of the data may be confounded by the Cushing’s phenotype of 
these mice, including muscle wasting, which may alter their behavioral output. A 
recent article investigated the effects on GABA and glutamatergic transmission in 
CRH-OE2122 (74). The study showed that constitutive overexpression of CRH reduced 
sensitivity to the anxiolytic effects of CRH-R1 antagonists, and GABAA and 
glutamate receptor agonists in response to stress-induced hypothermia. Additionally, 
mRNA levels of distinct subunits of the GABAA receptors and mGluR2/3 receptor 
were differentially altered in amygdala versus the hypothalamus (74). The data 
supports the notion that an imbalance in GABAergic and glutamatergic transmission 
may underlie the genesis of stress-related maladaptive behaviors.  
 
Spatially Restricted CRH-OE 
The general overexpression of CRH in the aforesaid studies makes it difficult 
to identify which regions are involved in mediating the different phenotypes 
observed. This section focuses on transgenic mouse models that spatially restrict CRH 
overexpression to particular brain regions (Table 1-1.). The Rosa 26 allele was inserted 
with a targeting allele consisting of a floxed stop codon, a CRH gene, and an IRES 
LacZ gene (R26+/flop CRH) (63). These mice were bred to Nestin-Cre mice to 
overexpress CRH in neurons and glia from embryonic day 10.5 through adulthood 
(CRH-COE-Nes); Cam-Cre to overexpress CRH in forebrain glutamatergic neurons 
from postnatal day 15 (CRH-COE-Cam); and Dlx-Cre to overexpress CRH in 
GABA-ergic interneurons from embryonic day 10.5 into adulthood (CRH-COE-Dlx). 
None of these mutants display Cushingoid phenotypes and all exhibit normal basal 
CORT and ACTH levels. Stress-induced CORT and ACTH are however, higher in 
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CRH-COE-Nes males compared to controls, an effect not observed in females. 
Behaviorally, CRH-COE-Nes mice show decreased despair behavior in both the FST 
and TST tests that is reversible with CRH-R1 antagonist treatment. The authors 
postulate that this is an adaptation to actively cope with stress (63). The fact that these 
behaviors are only observed in the CRH-COE-Nes mice indicates that hindbrain 
regions are important for mediating the active coping responses observed in CRH-
COE-Nes mice. Behavior in the CRH-COE-Cam mice indicates deficits in spatial 
memory in the Y-maze test and deficits in spatial learning in the Morris Water Maze 
(MWM) test (75). These spatial learning and memory deficits recapitulate what is 
observed in mice that have undergone early life stress and do not occur in the absence 
of forebrain CRH-R1. This indicates that CRH-R1 signaling is important in mediating 
stress-induced alterations in hippocampus-dependent learning and memory. Further 
proof of this will be discussed in the CRH-R1 mutants’ section (Section 3.3.1.). A 
separate study also shows that overexpressing CRH in forebrain glutamatergic 
neurons (Crh-COECamCreERT2) of mice increases anxiety in the EPM and LD tests, while 
anxiolysis is observed in the absence of forebrain CRH-R1 (22).  
Sleep impairments are observed in a number of psychiatric disorders and are 
targets of therapy when treating patients with depression, PTSD, and anxiety 
disorders. CRH-COE-Nes and CRH-COE-Cam mice display increased REM (rapid 
eye movement) sleep, indicating a role for CRH dysregulation of sleep (76).  
The R26+/flop CRH mice have also been crossed to Pomc-Cre mice to 
overexpress CRH in the anterior and intermediate lobes of the pituitary (CRH-
COEAPit) (64). CRH-COEAPit display a Cushingoid-like phenotype at 5–6 months old, 
decreased body weight but increased adrenal gland weight, increased basal CORT 
secretion that is arrhythmic, and no differences in the stress-induced CORT secretion, 
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compared to controls, in males but a blunted effect in females. Behaviorally, these 
mice spent more time in the inner zone of the OF and less time immobile in the FST, 
indicative of decreased anxiety and despair-like behaviors, respectively (64). 
 
Spatially and Temporally Restricted CRH-OE 
We have generated transgenic mice that overexpress CRH in the forebrain 
under the control of the CamKII promoter (77). These mice utilize an inducible 
tetracycline system that enables CRH overexpression to be turned off in the presence 
of dietary doxycycline (FBCRHOE). CRH mRNA expression was found to be 
elevated in all forebrain regions excluding the thalamus and PVN. Lifelong forebrain 
CRH overexpression (FBCRHOElife) resulted in a Cushingoid-like phenotype and 
elevated nadir CORT and ACTH levels. This inducible tetracycline system was 
further used to study the importance of forebrain CRH overexpression during 
development in the first three weeks of life, E15 to P21 (FBCRHOEdev). Although 
FBCRHOEdev mice have elevated basal CORT at P15 and P20, these levels normalize 
in adulthood. Behaviorally, FBCRHOEdev mice display increased despair and anxiety-
like behaviors as well as increased CRH-R1 mRNA that are reversed with 
antidepressant treatment (77). A similar mouse model overexpressing forebrain CRH 
transiently from 8 to 11 weeks of age, shows increased cortex and hippocampal CRH 
and increased basal CORT levels with a trend towards mild anxiety in the LD test and 
active coping in the FST (78). These studies demonstrate how disruption of CRH 
activity during critical developmental periods can affect behavioral outcomes. These 
studies have been invaluable in understanding the role of CRH in neuroendocrine and 
behavioral outcomes associated with stress. 
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CRH-R1 and CRH-R2 Mutants 
CRH-R1 and CRH-R2 null mutant mice have been generated to elucidate the 
role for each receptor subtype in mediating the observed behaviors. The findings from 
these studies will be discussed in details below.  
 
CRH-R1 Mutants 
CRH-R1 null mutant mice were generated by deleting exons 5–8 of the CRH-
R1 gene encoding the last 12 amino acids of the first extracellular domain through the 
fourth transmembrane domain and replacing them with a PGK neomycin-resistant 
gene cassette (79). In behavior models used to measure anxiety, these mice showed 
reduced anxiogenic-like responses compared to the littermate controls (80). A separate 
study generated CRH-R1 null mutant mice lacking the coding sequences of 
transmembrane regions V, VI, and VII, including the G-coupling protein domain and 
the intracellular cytoplasmic tail, resulting in a dysfunctional CRH-R1 unable to 
transmit any ligand-induced signals (81). These mice displayed similar reductions in 
anxiety-related behaviors in response to ethanol withdrawal. To determine if CRH-R1 
mediates anxiety-like behavior independently of the HPA axis function, Müller and 
colleagues generated conditional knockout mice with CaMKIIa driving Cre-mediated 
inactivation of CRH-R1 (Cam-CRHR1) in behaviorally relevant neuronal circuitries 
of the anterior forebrain and limbic system including the cortex, hippocampus and 
amygdala (82). Similar to the conventional mutants, these conditional knockouts 
displayed significantly reduced anxiety-related behaviors indicating that selective 
disruption of the CRH-R1 signaling pathway reduces anxiety. Furthermore, 
diminished neuronal activity in regions such as the medial amygdala and the 
prelimbic cortex of these forebrian CRH-R1 KO mice likely mediates the anxiety 
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phenotype observed (83). Chronic social defeat stress or early life stress in WT mice 
causes cognitive impairments reflected in the Y-maze and MWM tests (75, 84). In 
Cam-CRHR1 mice that undergo the aforementioned stressors, loss of CRH-R1 in 
forebrain neurons protects against impairments in spatial performance. Moreover, 
these mice are protected from atrophy in the dendritic spines of CA1 and CA3 
neurons and impaired hippocampal LTP. Interestingly, these CRH-R1 deficient mice 
appear to compensate for stress-induced impairments in synaptic transmission by 
increasing dendritic spines density and enhancing high-frequency stimulation LTPs in 
the hippocampus (75). CRH activity through CRH-R1 receptors, therefore, not only 
mediates anxiety behaviors but functions in hippocampus-dependent cognitive 
performance. In contrast to forebrain CRH-R1 deletion, deletion of CRH-R1 in all 
brain neurons, using the Nestin promoter, decreases forced swim stress-induced 
alcohol consumption in adults (85) and increases basal and stress-induce plasma 
CORT in neonates (86). Loss of CRH-R1 in all these transgenic lines results in 
differential HPA axis alterations that implicate divergent roles of forebrain and 
hindbrain regions in stress neuroendocrinology (Table 1-2) (6, 79, 81, 86–88).  
A recent study has also implicated divergent roles of CRH-R1 in different 
neurotransmitter systems. CRH-R1 was deleted specifically in forebrain 
glutamatergic neurons (Crhr1Glu-CKO) by crossing floxed CRH-R1 mice to Nex-Cre 
mice, Nex is a transcription factor that is expressed in mature glutamatergic neurons 
(22). Crhr1Glu-CKO mice display reduced anxiety in four distinct test, including EPM 
and LD preference tests. Conversely, mice with CRH-R1 deleted in midbrain 
dopamine neurons (Crhr1DA-CKO) display increased anxiety. These data indicate that 
different neurotransmitter system mediates opposite function of CRH-R1. While 
glutamatergic neurons mediate the anxiogenic properties of CRH-R1 activity, 
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dopamanergic neurons mediate the anxiolytic functions. Further analysis of the 
Crhr1DA-CKO mice showed a reduced prefrontal cortex response to stress-induced 
dopamine release. This study also demonstrated that CRH-R1 deletion in gabaergic 
and serotonergic neurons had no effect on anxiety-related behaviors. This data in 
general indicates that CRH may function in different neurotransmitter systems to 
balance CRH-R1 responses to stress (22).  
 
CRH-R2 Mutants  
In contrast to the clear reduced-anxiety phenotype in both conventional and 
conditional CRH-R1 KO mice, significant differences in the behavioral phenotypes 
are reported amongst three independently generated CRH-R2 KO mouse lines. 
Subsequently, the physiological role of CRH-R2 in mediating anxiety is still unclear. 
CRH-R2 null mice have been demonstrated to increase HPA axis reactivity to stress 
(89). Bale and colleagues generated a CRH-R2 null mutant mouse by constructing a 
targeting vector in which the portion of CRH-R2 encoding one-half of the fifth 
transmembrane domain through the end of the seventh transmembrane domain was 
deleted and replaced with a neomycin-resistant gene cassette (90). In contrast to CRH-
R1 mutants, behavioral studies revealed that these mice displayed increased anxiety-
like behaviors. Similar increased anxiety and despair-related behaviors have been 
found in separate studies of CRH-R2 null mice (91, 92). CRH-R2 null mutants have 
also been produced by homologous recombination with a targeting construct containing 
CRH-R2 and a neomycin cassette (91). Behavioral studies revealed no difference in 
anxiety-like behaviors in these mutants. Compared to control mice, these CRH-R2 
null mutant mice were also tested for despair-like behavior using the FST and showed 
longer immobility time indicating increased despair-like behaviors (93). When reared 
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in an isolated environment after weaning, CRH-R2 deficient mice displayed increased 
locomotor behavior to a greater extent than what is observed in WT mice (94).  
 
Table 1-2. CRH receptor mutants 
 
CRH Receptor Mutants 
Line Manipulation Main Phenotypes References 
CRH-R1-/- Constitutive deletion (exons 
5-8) of the CRH-R1 
Adrenal gland atrophy 
↑ PVN CRH 
↓ Basal CORT  
↓ Stress–induced CORT and ACTH 
in males 
↓ Anxiety in LD and EPM tests 
(79,80) 
CRH-R1-/- Constitutive deletion of 
CRH-R1 
(transmembrane regions V, 
VI, and VII) 
↓ CRH-induced cAMP 
↓ Basal ACTH in pituitary cultures 
↓ Basal CORT in females 
↑ PVN CRH only in neonates 
↑ Plasma and PVN vasopressin 
↓ Stress-induced CORT and ACTH  
↓ ACTH-induced CORT 
↓ Anxiety in LD test basally and 
during alcohol withdrawal 
↓ Neuronal activity (cFOS) 
(6,81,83,87
,88) 
Crhr1loxP/loxPCa
mk2a-cre 
 
Or  
 
 
Cam-CRHR1 
 
 
 
 
Or 
 
CRHR1Camk2aCre 
 
Or 
 
 
CRF1-CKO 
Camk2a promoter driven 
deletion CRH-R1 in 
forebrain 
↑ Stress-induced CORT and ACTH 
in adults and neonates 
↑ CRH mRNA in PVN in adults and 
neonates 
↓ Anxiety in LD and EPM test in 
adults 
Hyperactive in OF test in adults 
↓ Neuronal activity  
↓ Deficit in spatial memory in Y-
maze tests after chronic social 
defeat stress  
No deficit in spatial learning and 
memory in MWM or Y-maze tests 
after early life stress 
No chronic social defeat stress-
induced deficits in the novel object 
recognition test 
No stress-induced atrophy of apical 
dendrites in CA3 neurons compared 
to control mice 
No stress-induced reduction of GR 
mRNA in CA1 and CA3 neurons 
compared to control mice 
↑ Weight gain after chronic stress 
No deficit in hippocampal LTP after 
early life stress 
↑ High frequency stimulation-
induced LTP with early life stress 
(75,82,84, 
86) 
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Table 1-2. Cont’d 
 
CRH Receptor Mutants 
Line Manipulation Main Phenotypes Refer 
 
Crhr1loxP/loxPNes-
cre 
 
Nes-CRHR1 
Nes-Cre promoter driven 
deletion CRH-R1 in all 
neurons 
↓ Basal CORT in neonates 
↑ Stress-induced CORT and 
ACTH 
↓ Alcohol intake after FSS 
(85,86) 
Crhr1Glu-CKO Nes-Cre promoter driven 
CRH-R1 deletion in mature 
glutamatergic neurons 
↓ Anxiety in LD, EPM, novel 
object exploration, and modified 
hole board tests 
No effect on despair behavior in 
FST 
No effect auditory fear 
conditioning  
↑ Locomotion in LD test 
No effect on basal or stress-
induced CORT secretion 
↓ Excitatory field potentials on 
glutamatergic neurons in the 
BLA 
↓ Facilitation of action potential 
firing between hippocampal DG-
CA3-CA1 network 
(22) 
Crhr1DA-CKO Dat-CreERT2 promoter 
driven CRH-R1 deletion in 
midbrain dopaminergic 
neurons 
↑ Anxiety in LD, EPM, novel 
object exploration, and modified 
hole board tests 
No effect on despair behavior in 
FST 
No effect auditory fear 
conditioning  
No effect on basal or stress-
induced CORT secretion 
↓ Response to stress-induced 
DA release  
in PFC 
Crhr1GABA-CKO DLX5/6 promoter driven 
CRH-R1 deletion in forebrain 
GABAergic neurons 
No effect on anxiety behaviors 
No effect on despair behavior in 
FST 
No effect auditory fear 
conditioning  
No effect on basal or stress-
induced CORT secretion 
(22) 
Crhr15HT-CKO ePet-Cre promoter driven 
CRH-R1 deletion in brainstem 
seratonergic neurons 
Crhr1CNS-CKO Nes-Cre promoter driven 
CRH-R1 deletion in all 
neurons 
No effect on anxiety behaviors 
CRH-R2-/- Constitutive deletion by 
replacing 5th-7th 
transmembrane domains with a 
neomycin-resistant cassette 
↑ Stress-induced CORT and 
ACTH  
↓ Food intake after stress of food 
deprivation 
↑Anxiety in EPM and OF tests 
↑ Despair in FST 
↑ CRH mRNA in the CeA 
↑ Ucn1 mRNA in Edinger-
Westphal (EW) nucleus 
(90,93) 
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Table 1-2. Cont’d 
 
CRH Receptor Mutants 
Line Manipulation Main Phenotypes Refer 
CRH-R2-/- Constitutive deletion by 
replacing exons of the 3rd 
intracellular loop with 
neomycin-resistant cassette 
↑ Anxiety in EPM and LD tests in 
males 
↑ Locomotion in OF test in males 
↑ Stress-induced anxiety in the OF 
test in males 
↓ Neuronal activation measured 
by levels of phosphorylated CREB 
↑ Despair behavior in the FST and 
TST tests that is prevented when 
MEK/ERK pathway in the 
hippocampus is inhibited 
(91,92)  
CRH-R2-/- Constitutive deletion by 
replacing the 3rd and 4th 
transmembrane domains with a 
neomycin-resistant cassette 
↓ cAMP activity in cultured 
cardiomyocytes 
↑ Ucn1 mRNA in Edinger-
Westphal (EW) nucleus 
↑ Stress-induced CORT and 
ACTH  
↓ Cardiac function with Ucn 
administration 
Altered feeding with Ucn 
administration 
(89) 
CRH-R1-/-/ 
CRH-R2-/- 
CRH-R1-/- (79) were crossed 
to CRH-R2-/- (90) to generate 
these double knockout mice 
↑ PVN CRH  
↓ Basal CORT and ACTH  
↓ HPA axis reactivity to stress 
(7)  
 
 
CRH-R1-/-/ 
CRH-R2-/- 
CRH-R1-/-(81) were crossed to 
CRH-R2-/-(89) to generate 
these double knockout mice 
↓ Basal CORT and ACTH  
↓ Anxiety in EPM and OF tests in 
females 
↑ PVN CRH and AVP 
(95)  
 
 
 
Abbreviations: Acoustic startle response test, ASR; Adrenocorticotropic Hormone, ACTH; 
Arginine Vasopressin, AVP; Basolateral nucleus of the amygdala, BLA; Bed nucleus of the 
stria terminalis, BnST; Central nucleus of the amygdala, CeA; Corticosterone, CORT; cAMP 
response element-binding, CREB; Corticotropin-Releasing Hormone, CRH; Dentate gyrus, 
DG; Dopamine, DA; Dorsal raphe nucleus, DRN; Elevated Plus Maze, EPM; Forced Swim 
Test, FST; Lateral Septum, LS; Light/Dark Preference test, LD; Lipopolysaccharide, LPS; 
Long-term potentiation, LTP; Morris Water Maze, MWM; Open field test, OF; Open Reading 
Frame, ORF; Overexpression, OE; Paraventricular nucleus of the hypothalamus, PVN; 
Prefrontal Cortex, PFC; Proopiomelanocortin, POMC; Rapid Eye Movement, REM; 
Supraoptic nucleus, SON; Tail suspension test, TST; Urocortin, Ucn). 
 
 
 
Combined CRH-R1 and CRH-R2 Mutants 
Mice null for both CRH-R1 and CRH-R2 display adrenal cortex atrophy, 
increased PVN CRH, decreased basal CORT and ACTH levels and diminished HPA 
axis reactivity in response to stress (90). A similar phenotype is observed in CRH-R1 
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deficiency alone, indicating that CRH-R2 cannot overcome the loss of CRH-R1 (7). A 
separate study observed that CORT and ACTH levels were significantly different 
between CRH-R1/CRH-R2 double KO compared to CRH-R1 KO but both were 
significantly diminished compared to controls. Further examination indicated that, 
CRH-R1 KO male mice born from dams who were either CRH-R2 het or CRH-R2 
KO, show increased anxiety in OF and EPM, implying that there are influences of 
genetic background on behavior. Female mice showed decreased anxiety in the EPM, 
also indicating gender dimorphism and perhaps the influence of  
gender-specific hormones in mediating behavior (95). 
 
Urocortin Mutants 
Urocortins (Ucn) have a high affinity for CRH receptors. While Ucn1 and 
CRH have high affinities for CRH-R1, Ucn2 and 3 are considered to be the major 
endogenous ligands for CRH-R2 (96). CRH deficient mice do not differ from WT 
mice in their freezing response to a foot shock stressor, but CRH-R1 antagonists 
block freezing behavior in CRH-KO mice (59). This brought about the idea that 
another CRH-related peptide was compensating for loss of CRH. The most likely 
candidate was Ucn1 since it also has a high affinity for CRH-R1. Ucn1 null mice 
however, have normal HPA axis activity and anxiety phenotypes, but display 
impairments in acoustic startle response, not due to hearing impairments (Table 1-3.) 
(97). Studying the response of mice deficient for both CRH and Ucn1 to foot shock 
may better elucidate whether Ucn1 acts on CRH-R1 in the absence of CRH. A 
different Ucn1 null mouse line generated by a different group shows that Ucn1 
deficiency increases anxiety in the OF and EPM (98). However, more data on this line 
of mice is needed as the hearing impairment and reduction in CRH-R2 mRNA in the 
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lateral septum in these mice may account for the increased anxiety. These Ucn-/- mice 
also have reduced ethanol preference (99), implicating a role for Ucn1 in alcohol 
behavior.  
In contrast to Ucn1 null mice, Ucn2 null mice have altered HPA axis 
regulation of CORT and ACTH (100). Ucn2 KO female mice show higher nocturnal 
CORT and ACTH levels, not observed if the mice were ovariectomized, implicating 
estrogen mediation of this effect. The female Ucn2 KO mice also have an increase in 
hypothalamic AVP mRNA that may account for the rise in ACTH and CORT. 
Behaviorally, Ucn2 KO mice show no anxiety phenotypes but the females do display 
less despair in the FST and TST tests (100). This implicates that Ucn2 may be 
involved in mediating gender differences in relation to HPA axis function and 
depressive phenotype. 
When both Ucn1 and 2 are deleted (Ucn1/Ucn2 dKO), there is a stress-
induced elevation in CORT (males only) as well as elevated CRH mRNA in the PVN 
(101). Ucn1/Ucn2 dKO mice display reduced basal anxiety as well as reduced stress-
induced anxiety in the OF and LD tests (Table 1-3.). Since Ucn1 null mice do not 
show changes in HPA axis regulation, it is plausible that an interaction between Ucn1 
and 2 activities is necessary to influence HPA axis response.  
Ucn3 deficient mice (Ucn3tZ/tZ) only display behavioral alterations in the 
social discrimination task (102). Whereas controls show no discrimination of a 
familiar versus unfamiliar subject, Ucn3tZ/tZ are able to discriminate. This was also the 
case for CRH-R2 KO mice but not Ucn2tZ/tZ, indicating that this behavior is specific 
to Ucn3 action on CRH-R2 receptors. Ucn3tZ/tZ demonstrate no alterations in HPA 
axis activity or in tests of anxiety, despair, novel object recognition, and conditioned 
fear.  
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Table 1-3. Urocortin mutants 
Ucn mutants 
Line Manipulation Main Phenotypes REF 
Ucn-/- Constitutive deletion of 
Ucn1 by replacement of 
the coding exon of Ucn 
with an EGFP-LacZ 
fusion reporter and a 
PGKneo selection 
cassette 
Normal HPA axis activity 
No change anxiety in the EPM, OF, and LD tests 
Impaired acoustic startle response 
(97) 
Ucn-/- Constitutive deletion of 
Ucn1 by replacement of 
region encoding the 
mature peptide with a 
neomycin-resistant gene 
cassette 
Normal HPA axis activity and feeding behavior 
↑ Anxiety in EPM and OF tests 
↓ CRH-R2 mRNA in the LS 
↓ Length of hair cell in organ of Corti leading to 
hearing impairments 
(98,9
9) 
Ucn2 KO Constitutive deletion of 
Ucn2 by insertion of a 
neomycin-resistant gene 
cassette 
↑ Nocturnal CORT and ACTH in females 
↑ AVP mRNA in the PVN and SON of females - 
altered drinking habits 
↓ Despair in the FST and TST in females 
No changes in anxiety in EPM and LD tests or in 
conditioned fear tests 
↑ CRH mRNA in the BnST and CeA 
↓ Ucn3 mRNA in the median preoptic nucleus and 
perifornical area 
↑ CRH-R2 mRNA in the BnST, LS and DR 
(100) 
Ucn1/Ucn2 
dKO 
Cross breeding Ucn1 
(98) and Ucn2 (100) 
single KOs to generate 
these double knockout 
mice. 
↑ Stress-induced plasma CORT in males 
↑ PVN CRH mRNA 
Hypertrophy of the zona fasciculate 
↓ Anxiety in EPM and OF 
↓ Behavioral response to acute stress in females 
↓ CRH-R2 mRNA in the LS 
↑ Amygdala CRH mRNA 
(101) 
Ucn3tZ/tZ Ucn3 gene was 
disrupted by 
homologous 
recombination and the 
ORF was replaced by a 
tau-lacZ reporter gene 
Normal basal and stress-induced HPA axis 
responses 
No changes in anxiety-related behaviors in EPM, 
social interaction, and modified hole board tests 
compared to WT 
No difference in despair behavior in the FST 
compared to WT 
No genotype effect in the ASR test 
↑ Cocial discrimination memory 
(102) 
Ucn tKO Cross breeding Ucn1, 2, 
and 3 single KOs from 
(98,100,102) 
↓ Basal exploration in OF 24 hours post-stress 
↑ Anxiety in OF, LD and ASR tests 24 hours after 
an acute stressor 
↑ Freezing in cued fear conditioning and ASR tests 
↓ Spatial learning in MWM 
↑ CRH-R2 mRNA in the LS and DRN 
↑ CRH-R1 mRNA in amygdala compared to 
controls 24 hours post- stress 
Lack of stress-induced amygdala gene modification 
compared to controls 
(103) 
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When all three Ucn are deleted, the triple knock out (tKO) exhibit increased 
anxiety in the OF and LD tests 24 hours after stress but are no different from WT 
mice in unstressed conditions or immediately after stress (103). The tKO mice display 
an increase in the acoustic startle response 24 hours post-stress. They also increase 
freezing in cued fear conditioning but not the contextual test, and have stress-induced 
deficits in spatial learning in the MWM test. Amygdala gene expression profiles 
demonstrate that Ucn tKO mice do not have typical changes in stress-induced genes 
to aid in coping with stress. Thus urocortins appear to be essential for recovery after 
stress, by modifying expression of stress-related genes in the amygdala. This tKO line 
may be useful in studying the proposed function of CRH-R2 in reducing sensitivity to 
stress (21).  
Due to the discrepancy in two lines of Ucn1 null mice, the function of Ucn1 in 
anxiety remains unclear. However, it is clear that Ucn1 is not important for mediating 
HPA axis activity, a role more attributable to Ucn2 function. The data discussed here 
also point to a role for Ucn2 activity in mediating despair behavior and stimulating 
gender differences. The specificity of Ucn3tZ/tZ mice in affecting only social 
discrimination indicates a role for Ucn3 in processing social cues. This role of Ucn3 
is fitting as it is expressed in regions associated with the accessory olfactory system.  
 
CRH-BP Mutants 
 Mice overexpressing CRH-BP were created by inserting a fragment of the rat 
CRH-BP, between the mouse metallothionein-I promoter and a 2.1 kb noncoding 
fragment of the human growth hormone, which contains a polyadenylation sequence. 
These mice overexpress CRH-BP in the brain and pituitary as well as peripheral sites 
such as the placenta, plasma, and amniotic fluid (27). Male transgenic mice showed 
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increased weight gain, to a greater extent than females, and no HPA activity changes 
(104). Overexpressing CRH-BP only in the anterior pituitary, using the pituitary 
glycoprotein hormone promoter, similarly produced normal circadian and stress-
induced levels of ACTH and CORT (105). Further investigation demonstrated 
compensatory increases in both PVN CRH and vasopressin (AVP) as the culprits for 
lack of HPA axis alterations. The behavioral phenotype of these mice includes 
increased locomotion and a trend towards decreased anxiety in the OF (105). 
Interestingly, CRH-BP deficient mice likewise display normal circadian and 
stress-induced levels of ACTH and CORT. However, anxiety phenotypes are much 
more evident in these mice in the EPM, OF and defensive withdraw tests, with 
females exhibiting more anxiety (106). CRH-BP deficient male mice demonstrate 
reduced food intake and diminished weight gain, reflecting the defined role for CRH 
in anorexiogenic behavior. The fact that all these mutant CRH-BP mice display 
normal HPA axis activity (Table 1-4.) underscores the importance of maintaining 
homeostasis in this pathway, conceivably, through compensatory changes in PVN 
CRH and AVP transcript levels. 
Table 1-4. CRH binding protein mutants 
 
CRH-BP mutants 
Line Manipulation Main Phenotypes REF 
CRH-BP 
(transgenic) 
Mouse metallothionein-1 
(MT-1) promoter driven CRH-
BP OE in the brain and 
pituitary as well as sites such 
as the placenta, plasma, and 
amniotic fluid 
Normal CORT and ACTH 
↑ Weight gain (gender specific) 
Blunted ACTH response to LPS 
injection 
(104) 
CRH-BP 
(transgenic)  
Pituitary glycoprotein 
hormone a-subunit (a-GSU) 
promoter driven CRH-BP OE 
in the pituitary  
Normal CORT and ACTH 
↑ PVN CRH and vasopressin 
↑ Locomotion  
Trend towards decreased anxiety in 
the OF 
(105) 
CRH-BP-/- Constitutive deletion by 
replacing exons1-5 with a 
phosphoglycerate kinase 
neomycin-resistant cassette 
Normal CORT and ACTH 
↑ Anxiety in EPM, OF and defensive 
withdraw (gender specific) 
↓ Food intake and weight gain in 
males 
(106) 
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THE USE OF VIRAL VECTORS TO MODULATE CRH ACTIVITY 
In the bulk of studies thus far described, the relatively broad brain regions 
investigated constrain our ability to understand the role of CRH action in restricted 
brain nuclei in mediating behaviors. The use of lentiviral vectors has succeeded at 
overcoming this limitation by allowing for precise spatial regulation of CRH 
overexpression (Table 1-5.). Regev et al. (2010) injected a lentiviral vector, 
containing rat CRH cDNA, into the CeA of 7-week old male mice. The authors 
presented that chronic (4-month) overexpression of CRH in the CeA of male mice 
under basal conditions had minor effects on anxiety in the OF and LD preference tests 
(107). However, 30 minutes of restraint stress significantly attenuated anxiety-related 
behaviors, implying possible habituation to a stressor. In a separate study, short-term 
inducible CeA CRH overexpression increased anxiety after stress (108). Since CeA 
CRH is known to be anxiogenic, perhaps the 4-month long CeA CRH OE results in 
compensatory changes that cause the observed habituation response. In male rats, 
extended elevated CeA CRH (10 weeks) during adulthood differentially dysregulated 
HPA axis function and increased CRH in the PVN (109). Observed behaviors 
included decreased locomotion in the OF test, increased anxiety in EPM, and 
increased time withdrawing and under protection in the defensive withdrawal test. A 
similar study elevating CeA CRH levels in female rats demonstrated stress pathology 
changes including increased anxiety and despair-like behaviors, and impaired 
negative feedback of the HPA axis (110). These female rats show augmented basal 
anxiety in the acoustic startle response. It is notable that the lentiviral construct used 
in this latter study was generated to infect neurons that endogenously produce CRH. 
This may limit confounds of expressing CRH in neurons that do not normally express 
CRH, and subsequent effects of these neurons on their targets. It therefore appears 
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that short term CeA CRH OE results in anxiogenic phenotypes while longer term 
CeA CRH OE causes a blunting of anxiety behaviors. We can however not exclude 
the effects of gender and/or species differences in mediating the discrepancies in these 
studies. 
Table 1-5. Viral Vectors in Rodent Models. 
 
Line  
(viral vector) 
Manipulation Main Phenotypes REF 
CeA CRF OE 
(pCSC-SP-PW-
rCRF-
IRES/GFP) 
Long-term lentiviral 
CRH OE in the CeA of 
adult male mice. 
Behavioral testing 
began 4 months after 
lentiviral injections 
↓ Basal and stress-induced anxiety in OF and 
LD tests 
↓ Response to acoustic startle 
Habituation to startle after stress 
↑ CRH-R1 mRNA in CeA 
(107) 
CeA-CRF-OE 
(rtTA-IRES/GFP 
+  
TRE-mCRF-
IRES/RFP) 
Short-term lentiviral 
CRH OE in the CeA of 
adult male mice when 
Dox is administered. 
Behavioral testing 
began 3 days after Dox 
administration  
↑ Stress-induced anxiety in LD test  
No effects on despair in FST or TST 
No effects on fear conditioning 
(108) 
Lenti-CMV-CRF 
OE 
(LVCRFp3.CRF) 
Lentivirus-induced 
CRH OE in the CeA of 
female rats. 
Behavioral testing 
began 2 weeks after 
lentiviral injections 
Impaired negative feedback of the HPA axis  
Disrupted reproductive and sexual function. 
↑ Despair in FST  
↑ Anxiety in acoustic startle  
(110) 
CeA CRF OE 
LVCRFp3.CRF 
Lentivirus-induced 
CRH OE in the CeA of 
male rats. 
Behavioral testing 
began 4 weeks after 
lentiviral injections 
↑ CRH and vasopressin mRNA in the PVN 
↑Basal ACTH 
Dexamethasone non-suppression 
↑ Anxiety in EPM and defensive withdrawal 
tests. 
(109) 
BnST CRF OE 
(pCSC-SP-PW-
rCRF-
IRES/GFP) 
Long-term lentiviral 
CRH OE in the BnST 
of male mice. 
Behavioral testing 
began  
4 months after lentiviral 
injections 
↑ Despair in FST  
↓ CRH-R1 mRNA in BnST 
(107) 
BnST CRF OE 
(LVCRFp3.CRF) 
CRH OE in the BnST 
of adult male rats 
before or after fear 
conditioning in ASR 
tests 
No changes in anxiety measures in EPM or DW 
tests 
No HPA axis alterations 
↓ CRH-R1 binding density in the BnST 
↓ CRH-R2 binding density in the DRN 
(111) 
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Table 1-5. Cont’d 
 
Line  
(viral vector) 
Manipulation Main Phenotypes REF 
BnST CRF OE 
(LVCRFp3.CRF) 
Behavioral testing 
began  
~2 weeks after lentiviral 
injections 
CRH OE induced before conditioning to fearful 
stimulus: 
No differences in baseline ASR 
↓ Startle sensitization and shock reactivity in 
ASR  
↓ FPS, impaired acquisition of associative fear 
memory 
CRH OE induced after conditioning to fearful 
stimulus: 
↑ FPS, enhanced fear memory expression 
(111) 
BLA CRFR1 
KD 
(Lenti-
shCRFR1) 
CRH-R1 KD in the 
BLA of adult male 
mice. 
Behavioral testing 
began ~2 weeks after 
lentiviral injections 
↓ Anxiety in the LD and OF tests (112) 
CeA CRF-KD 
(Lenti-shCRF) 
CRH KD in the CeA 
of adult male mice 
 
Behavioral testing 
began ~2 weeks after 
lentiviral 
↓ Basal anxiety in the EPM test and stress-
induced anxiety in LD test 
No effects on despair in FST or TST 
No effects on fear conditioning 
↑ Basal plasma CORT levels 
↓ Ucn3 mRNA in BnST 
(108) 
GPe CRFR1 
KD 
(Lenti-
shCRFR1) 
CRH-R1 KD in the 
GPe of adult male 
mice.  
Behavioral testing 
began ~2 weeks after 
lentiviral injection 
↑ Anxiety in the LD, OF and EPM tests 
No changes in locomotion 
↓ Enkephalin protein in GPe, possible 
mechanism for increased anxiety 
(113) 
rPFA-Ucn3 OE 
(Lenti-rtTA) 
Transgenic mice with 
Ucn3 under the control 
of a TRE were injected 
in the rPFA with 
lentivirus containing 
rtTA. Ucn3 OE occurs 
when Dox is 
administered 
↑ Anxiety in the LD and OF tests 
↑ Metabolic rate, but has no effect on food 
intake 
↓ Insulin sensitivity 
(114) 
 
Abbreviations: Adrenocorticotropic Hormone, ACTH; Acoustic Startle response test, ASR; 
Bed nucleus of the stria terminalis, BnST; Basolateral nucleus of the amygdala, BLA; Central 
nucleus of the amygdala, CeA; Corticosterone, CORT; Corticotropin-Releasing Hormone, 
CRH; Corticotropin-Releasing Factor, CRF; Dorsal Raphe Nucleus, DRN; Doxycycline, 
Dox; Elevated Plus Maze, EPM; Fear Potentiated Startle, FPS; Forced Swim Test, FST; 
Globus Pallidus (external), GPe; Hypothalamic-Pituitary-Adrenal, HPA; Knock-down, KD; 
Dark/Light Preference test, LD; Overexpression, OE; Open field test, OF; Perifornical Area 
(rostral), rPFA; Tail suspension test, TST; Tetracycline Response Element, TRE; Urocortin, 
Ucn. 
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Like the CeA, the BnST is a part of the extended amygdala involved in 
anxiety and fear mediation. Two studies of CRH-OE in the BnST in rodents, using 
distinct lentiviral constructs, show no effect on anxiety behavior in the EPM and 
defensive withdrawal tests (107, 111). Both studies also demonstrate no HPA axis 
alterations and compensatory reductions in CRH-R1 mRNA in the BnST. Fear 
potentiated-startle (FPS) is a behavioral paradigm in which acoustic noise 
(unconditioned stimulus, US) is paired with a foot-shock (conditioned stimulus, CS). 
Measures of startle response and shock reactivity in response to only the US provide 
information on acquisition, retention, and expression of fear learning. CRH-OE in the 
BnST of male rats prior to fear conditioning impairs acquisition of fear, as these rats 
have attenuated startle and shock reactivity amplitudes (111). However if CRH is 
overexpressed after fear conditioning, the BnST CRH-OE mice have potentiate fear 
responses compared to controls, indicating enhanced retention or expression of fear 
memory. This abnormal enhancement of FPS is observed in individuals with PTSD, 
and points a potential mechanism in which elevated BnST CRH activity strengthens 
association of neutral cued with fear memories. 
Environmental enrichment (EE), which is known to reduce anxiety, significantly 
decreases CRH-R1 mRNA in the BLA (112). Lentiviruses containing small 
interference RNA (siRNA) were generated to knock down CRH-R1 in the BLA to 
further investigate its role in anxiety. Behavioral data indicates that siRNA 
knockdown of BLA CRH-R1 decreased anxiety in the OF and LD and a trend in 
EPM. The authors suggest the BLA as a potential target of therapeutics that mimics 
the anxiolytic effects of EE and benzodiazepines (112). Comparatively, when this 
approach was used to knockdown CeA CRH, mice show decreased anxiety in the 
EPM (108). Acute restraint stress, which was anxiogenic for control mice, had no 
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effect on CeA CRH-KD mice. Since restraint stress is known to increase CeA CRH 
and cause anxiety, knockdown of CeA CRH by the viral vector may counteract the 
effects of stress. This data indicates that CRH-R1 in both the BLA and CeA functions 
to mediate anxiety responses. 
 Limbic regions are not the only modulators of CRH activity in anxiety 
behavior. This is demonstrated in a study that used lentiviral-based siRNA to knock 
down 60% of CRH-R1 receptors in the external part of the globus pallidus of the 
striatum (GPe) (113). This increased anxiety in LD, OF and cause a trend towards 
increased anxiety in the EPM. CRH-R1 antagonist infused into the GPe also increases 
anxiety in OF and marble burying tests. These data imply that, in contrast to 
anxiogenic effects of CRH-R1 activation in the amygdala, activation in the GPe has 
anxiolytic properties. In this study, restraint stress reduced CRH-R1 mRNA in GPe, 
further verifying the anxiolytic properties of GPe (113). 
Lentiviral vectors have also been used to overexpress Ucn3 in the rostral 
perifornical area (rPFA) of the hypothalamus that projects to neurons in the lateral 
septum and ventromedial hypothalamus (114). Mice overexpressing Ucn3 in the 
rPFA display increased anxiety, which is most likely through rPFA Ucn3 acting on 
CRH-R2 neurons in the lateral septum.  
The use of lentiviral vectors also produced the added advantages of infection 
neurons and activating CRH receptors on neurons that they project to, unlike 
pharmacological methods that only act locally. Although the use of viral vectors is 
still ectopic, it provides more physiological relevance that pharmaceutical methods 
and more spatial relevance than genetically altered rodents alone. 
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HUMAN GENE POLYMORPHISMS 
CRH hyperactivity is present in several psychiatric disorders. For example, 
CRH levels are elevated in the CSF of some post-traumatic stress disorder (PTSD) 
and depressed patients (33, 34). Furthermore, this HPA axis dysregulation, which 
occurs in a subpopulation of individuals who suffer from a psychiatric disorder, is 
characterized by elevated secretion of ACTH and CORT that occurs in response to 
CRH hyperactivity. In the remainder of this review, we will discuss studies of 
previously identified human polymorphisms in the CRH pathway that are associated 
with the occurrence of psychiatric disorders (Table 1-6.).  
 
CRH  
Smoller and colleagues performed one of the first genetic association studies 
of CRH by studying children from families in which the parents were diagnosed with 
panic disorders (115). They specifically focused on behavioral inhibition in children 
as a strong predictor of later development of anxiety disorders. They identified an 
allele linked to the CRH locus (173 bp in the dinucleotide repeat marker CRH-PCR1) 
that negatively associated with behavioral inhibition, particularly in children whose 
parents had panic disorder. A subsequent study identified 3 single nucleotide 
polymorphisms (SNPs) in the CRH gene, one of which is in the coding region, and a 
haplotype comprising SNPs that also associated with behavioral inhibition (Table 1-
6.) (116). Although the sample sizes in these studies are relatively small and there 
exist potential for Type I or Type II errors, they demonstrate an important role for the 
CRH gene in mediating anxiety-like behaviors in humans. Thus suggesting that 
children with these SNPs in the CRH gene are less likely to display behavioral 
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inhibition and thus, are at a decreased risk for developing anxiety disorders later in 
life. 
 
CRHR1 
The most studied SNPs in the CRHR1gene are a T rare allele in rs7209436, an 
A rare allele in rs110402, and a T allele in rs242924, which also form the CRHR1 T-
A-T haplotype. Adults with a history of childhood abuse that were homozygous for 
either of the rare alleles had the lowest Beck Depression Inventory (BDI) scores for 
depression, while those homozygous for the common allele had the highest BDI 
scores, with the heterozygotes having BDI scores in between the two (117). 
Moreover, the CRHR1 T-A-T haplotypes were overrepresented in women with a 
history of childhood abuse that did not have MDD compared to women with no 
childhood abuse/no major MDD and women with childhood abuse and MDD. There 
was an additive effect of the rare alleles in this study (117, 118). Analysis of HPA 
axis activity in individuals with childhood abuse and the common allele SNPs of 
CRHR1 showed increased plasma CORT in response to the Dexamethasone/CRH test 
(119). The potential protective role for the aforementioned SNPs has also been 
confirmed in males (120, 121). Further examination by Grabe and colleagues 
however, showed an increased risk rather than protective effects of this T-A-T 
haplotype (122) (Table 1-6.). Taken together, the majority of data indicate that the 
rare allele SNPs and haplotypes in CRHR1 provide protection against the 
development of depressive symptoms when an individual has experienced early life 
stress. Thus, it is possible that the identified SNPs are involved in decreasing the 
activity of CRHR1 to reduce CRH hyperactivity-driven maladaptive changes. An 
additional study presented evidence suggestive of a protective role for the T-A-T 
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haplotype of the CRHR1 gene. The authors propose that the T-A-T haplotype may 
impair memory consolidation of the emotional effects of childhood abuse and thereby 
reduce risk of depressive symptoms later in life for women (121). This is a likely 
inference as studies in rodents have demonstrated CRH involvement in memory 
formation and consolidation (32, 123, 124). Further investigation of the rs110402 
SNP has shown that T common allele carriers have a younger age-of-onset for their 
first depressive episode and experience more seasonal-related episodes of depression 
(125). Functional magnetic resonance imaging (fMRI) data has demonstrated the 
MDD patients with the G allele in the rs110402 SNP have alterations in brain activity 
consistent with increased vulnerability to depression (16). The use of fMRI in 
investigating the functional effects of CRHR1 polymorphisms provides for greater 
avenues of understanding how the CRH signaling pathways affect the generation of 
psychiatric disorders.  
In a depressed population of Mexican Americans, a G-A-G haplotype from 
SNPs rs1876828, rs242939, and rs242941 in the CRHR1 gene increases treatment 
response to antidepressants, fluoxetine and desipramine (126). Two studies have 
shown that in a group of Chinese patients, a G-G-T haplotype for the same SNPs 
increases the risk of developing major depression (127, 128). These studies 
demonstrate that genetic risk for depression depends on factors such as ethnicity and 
possibly geographic location. This substantiates the need to evaluate the interaction of 
genes and environment in studies of human diseases.  
Stress is associated with an increased risk of substance abuse. A sample of 
adolescents that had experienced a number of stressful life events and had common 
variants in CRHR1 (CC rs187831 or A rs242938) demonstrated increased binge 
drinking (72) and increased risk of alcohol drinking behavior (129). A subsequent 
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independent analysis demonstrated that the more stressful life events experienced in 
adolescents homozygous for CC rs187831, the lower the age of onset for drinking (130). 
Furthermore, adolescent stress with either genotype (CC rs187831 or A carrier 
rs242938) increased the risk for young adult alcohol drinking. In addition, CRH gene 
variations that differ in corticosteroid sensitivity were found to influence the risk for 
alcohol use and dependence in rhesus macaques (131). Briefly, animals were 
genotyped for a single-nucleotide polymorphism disrupting a glucocorticoid response 
element, rhCRH - 2232 C > G. The effects of this allele on CSF levels of CRH, 
behavior and ethanol consumption were measured. Macaques carrying the G allele 
had lower CSF levels of CRH. Infant macaques carrying the G allele were more 
exploratory and bold, and in adolescent and adult male macaques, the G allele was 
associated with increased exploratory/bold behavior when responding to an 
unfamiliar male. Adults with the C/G genotype also exhibited increased alcohol 
consumption. 
These studies indicate that there exists a gene x environment interaction for 
risk of alcohol abuse, as studies that examined the effect of the SNPs alone found no 
association (132, 133). Analysis of a different CRHR1 SNP (rs110402) in 
schizophrenia patients shows that the T allele interacts with a G allele in a CRHBP 
SNP (rs3811939) to double the risk of comorbid alcoholism in these patients. 
Individuals with these SNPs also show a higher CRH-R1/CRH-BP mRNA ratio, 
indicating an increase in CRH reactivity as the plausible cause (134). Rodent studies 
have demonstrated that in alcohol preferring (msP) rats, there is an increase in CRH-
R1 transcripts in the brain and an increased risk to reinstate alcohol-seeking after a 
foot-shock stressor (71). These studies indicate that the human SNPs described may 
function to increase CRH activity mediated through CRH-R1, to increase stress-
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induced alcohol consumption. There is also evidence that low stress exposure 
increases suicidality in individuals with a rs4792887 (TT) genotype in the CRHR1 
gene (135). Studying the interaction of stress and polymorphisms in CRH pathway 
genes will enable better insight into the ability of stress to precipitate psychiatric 
diseases. 
 
CRHR2 
In depressed individuals, carriers of the G allele of the rs2270007 SNP in 
CRHR2 were slower to respond to antidepressant (citalopram) treatment at 4 weeks 
post-treatment (125) indicating a potential role for this SNP in altering HPA axis 
homeostasis and as a predictor of antidepressant treatment response. 
A separate study provided evidence for an association between CRHR2 SNPs 
and increased suicidal behavior in people with bipolar disorder (136). 
 
CRHBP 
The CRH binding protein sequesters CRH thereby preventing it from binding 
its receptors. Thus, reduced CRH-BP activity may cause CRH hyperactivity. The 
polymorphisms discussed below point to a decrease in expression or activity of 
CRHBP as the reason for the associated disorders. Patients with MDD that have a 
rs10473984 (TT) genotype in CRHBP show increase HPA axis activity, decreased 
response to antidepressant treatment, and an increased chance of relapse (35). SNPs in 
CRHBP have also been associated with vulnerability for unipolar depression (137) 
and stress-induced alcohol craving (Table 1-6.) (138). Interactions between CRHBP 
and CRHR1 polymorphism have been observed to increase suicide attempts (139) and 
alcoholism (134) in schizophrenic patients (Table 1-6.). Hyperactivation of CRH 
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signaling pathways is certainly capable of exerting these effects based on the data 
reviewed in animal and human studies. 
 
 
Table 1-6. Human gene variants in CRH pathways associated with psychiatric 
disorders 
 
GENE Polymorphism Associated Disorder Effect REF. 
CRH 173 bp in the 
dinucleotide repeat 
marker CRH-PCR1 
rs6999100 (CC) 
rs6159 (GG) 
rs1870393 (CC) 
Behavioral inhibition Risk 
promoting 
(115,116) 
CRHR1  rs7209436 (TT) 
rs110402 ((AA) 
rs242924 (TT) 
T-A-T haplotype 
Depression with adverse 
early  
life experiences 
Protective (117–121) 
CRHR1 T-A-T haplotype 
rs17689882  
rs16940674  
rs16940665 
Depression with 
childhood  
physical neglect 
Risk 
promoting 
(122) 
CRHR1 rs110402 (TT)  Depression onset and 
seasonal episodes 
Risk 
promoting 
(125) 
CRHR1 rs110402 (GG) Depression vulnerability Risk 
promoting 
(16) 
CRHR1 G-G-T haplotype 
rs1876828 (GG) 
rs242939 (GG) 
rs242941 (TT) 
Genetic susceptibility to 
major depression and 
response to 
antidepressant treatment 
Risk 
promoting 
(126–128) 
CRHR1 rs1876831 (CC)  
rs242938 (A)  
Alcohol consumption 
with life stress 
Risk 
promoting 
(72,129,130) 
CRHR1 rs4792887 (TT) Suicidality after low 
stress exposure 
Risk 
promoting 
(135) 
CRHR2 rs2270007 (GG) Decreased response to 
antidepressant treatment 
in depressed patients 
Risk 
promoting 
(125) 
CRHR2 5-2-3 haplotype (allele 3 
in GT)  
Suicidal behavior in 
bipolar disorder 
Risk 
promoting 
(136) 
CRHBP rs10473984 (TT) Remission and 
decreased depressive 
symptoms with 
citalopram treatment 
Risk 
promoting 
(35) 
CRHBP rs1875999 (TT) Unipolar depression Risk 
promoting 
(137) 
CRHBP rs10055255 (TT) Stress-induced alcohol 
craving and negative 
mood 
Risk 
promoting 
(138) 
CRHBP 
CRHR1  
rs3811939 (GG) 
rs110402 (TT) 
Comorbid alcoholism in  
Schizophrenic patients 
Risk 
promoting 
(134) 
CRHBP 
CRHR1  
rs1875999 
rs169400665 
Suicidal behavior in 
Schizophrenia 
Risk 
promoting 
(139) 
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The Potential of CRH-Pathways Genetic Studies 
CRH plays a critical role in adaptation to stress (140). Finely regulated CRH 
expression and sensitivity is required for proper function and homeostasis of the HPA 
axis (141). Chronic stress and early-life trauma can result in permanent disruptions in 
the CRH system and may lead to psychopathology in adulthood. The data 
summarized in Section 4 begins to lend support to the notion that genetic variation in 
CRH-related pathways contributes to psychiatric disorders in humans, and could 
serve as a potential target for therapeutic intervention. As each of these psychiatric 
diagnoses is likely to reflect divergent pathogenic mechanisms, the ability to 
personalize therapies based upon established risk-altering genotypes would be 
particularly valuable. 
 
 
TARGETING THE CRH PATHWAY FOR THERAPY 
The studies reviewed here demonstrate that abnormal CRH function may 
dysregulate HPA axis activity and produce maladaptive behavioral responses. Animal 
studies with CRH antagonists have shown both anxiolytic and antidepressant effects. 
Additionally, antidepressant treatment in depressed patients that normalizes HPA 
activity decreases the likelihood of relapse. In humans, CRH antagonists have been 
used in clinical trials to evaluate efficacy in treatment of MDD. A clinical trial in 20 
patients with MDD demonstrated that the CRH-R1 antagonist, R121919, is able to 
decrease anxiety and despair in multiple inventories (142). When the patients ceased 
taking R121919, their symptoms returned. Furthermore, this drug was safely tolerated 
by the patients, improved sleep (143) and did not impair normal brain activity, heart 
conductance, or HPA axis activity (144). High doses of R121919 in control 
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individuals elevated liver enzymes and resulted in discontinued production. Currently, 
only one other CRH receptor antagonist is undergoing clinical trials to evaluate 
efficacy in treating anxiety disorders ([clinicaltrials.gov;NCT01018992]). It should be 
noted that other placebo-controlled trials with CRHR1 antagonists have failed to 
show efficacy in the treatment of generalized anxiety disorder (145) or major 
depression (146). The CRB-BP also served as a potential target for therapy, but much 
more research in needed to evaluate how it can be effectively targeted to reduce or 
elevate CRH activity depending on the disorder. 
 
 
CONCLUSIONS  
The summarized data presented in this chapter provide important insights into 
a role for CRH in mediating the maladaptive behaviors associated with major mood 
disorders and demonstrate the complexity of the underlying neurocircuitries involved 
in mediating CRH activity. In addition, these studies implicate components of the 
CRH system as potential therapeutic targets for interventions aimed at treating the 
negative behavior sequelae of mood disorders.  
The CRH-CRH receptor-signaling pathway provides a consistent and robust 
series of translational studies linking basic neuroscience investigation in model 
systems to human psychiatric diseases. Initial behavioral and physiological 
experiments in rodents have reliably predicted that human variation in the CRH-CRH 
receptor and CORT pathways would influence the risk of neuropsychiatric disorders. 
In the future, these variants may serve as potential predictors of risk for the 
development of psychiatric illnesses and forecast individual responses to particular 
drug based treatments.   
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CHAPTER II 
 
 
SITE-SPECIFIC MODULATION OF BRAIN GLUCOCORTICOID RECEPTOR 
AND CORTICOTROPIN-RELEASING HORMONE EXPRESSION USING 
LENTIVIRAL VECTORS 
Gloria Laryea, Melinda G. Arnett, Lindsay Wieczorek , and Louis J. Muglia 
 
INTRODUCTION 
Defining the genes and gene networks involved in mediating the stress 
response will enhance understanding of the underlying pathophysiology of mental 
health disorders.  The hypothalamic-pituitary-adrenal (HPA) axis is a major part of 
the neuroendocrine system that responds to stress. Regulation of the HPA axis is 
critical for adaptation to environmental changes.  The principal regulator of the HPA 
axis is corticotrophin-releasing hormone (CRH), which is made in the paraventricular 
nucleus (PVN) of the hypothalamus and is an important target for negative feedback 
by glucocorticoids (GCs) – the key effector of the HPA axis. They exert their effects 
through ubiquitous nuclear hormone receptor superfamily members, in particular GR 
(NR3C1) (1). 
Disruption of normal HPA axis activity is a major risk factor for 
neuropsychiatric disorders where decreased expression of GR and altered CRH 
activation has been documented (2, 3). The use of transgenic and gene knockout mice 
has helped to define roles for particular genes in mediating altered stress 
responsiveness and neuroendocrine function (4–6). However, these data are limited 
due to their inability to regulate spatial and temporal disruption of gene expression.  
Viral vectors have become the most commonly used gene delivery vehicles due to 
their high transduction efficiencies (7). In particular, lentiviral (LV) vectors have 
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become powerful tools in basic and translational research representing one of the 
most effective gene delivery vehicles allowing for stable long-term transgene 
expression in both dividing and non-dividing cells (8, 9).    
Our lab has generated two LV vectors in an effort to investigate the role of CRH 
in specific brain nuclei.  In this paper, we will discuss their design, production and 
possible future application in mice.   
 
 
MATERIALS and METHODS 
Animals 
All animal protocols were in accordance with National Institutes of Health 
guidelines and were approved by the Animal Care and Use Committees of Vanderbilt 
University (Nashville, TN) and Cincinnati Children’s Medical Center (Cincinnati, 
OH). Mice were housed on a 12 h/12 h (Vanderbilt) or 14 h/10 h (Cincinnati 
Children’s Medical Center) light/dark cycle with ad libitum access to rodent chow 
and water. For use with the tetracycline-inducible system, some mice were given ad 
libitum access to doxycycline (doxy) chow (0.0625% doxy; Test Diets) to control 
transgene expression 
 
Generation of Tetop-CRH mice 
These mice were generated as previously described (10). Briefly, the CRH 
gene was placed under the control of a tetracycline-responsive cytomegalovirus 
minimal promoter (tetop) and inserted into a pUHC13-3 backbone vector. The 
resulting tetop-CRH plasmid was injected into inbred C57Bl/6 oocytes.  
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Generation of CaMKIIα-tTA mice 
These mice were generated as previously described (11). These mice express the 
tetracycline transactivator under the control of the CaMKIIα promoter (Jackson 
Laboratories). 
 
Lentiviral Vectors 
For each LV vector, individual plasmids were designed as described below 
and sent to the Hope Center Viral Vector Core (Washington University, St. Louis, 
MO) for packaging. Briefly, plasmids were packaged using three helper plasmids in 
293-T cells into replication deficient virions. Viral vector titers were determined by 
transduction of HT1080 cells and assayed for reporter expression using flow 
cytometry or real time PCR.  We were able to reliably obtain a titer of 107-109 
infectious units/mL for each LV. 
 
LV-rtTA Vector 
To generate the pLV-rtTA plasmid, we used a LV plasmid that is under the 
control of a modified moloney murine leukemia virus long terminal repeat (MNDU3; 
pMNDU3 plasmid generously given by M. Sands, Washington University in St. 
Louis) (12).  We directly inserted the reverse tetracycline transactivator (rtTA) from 
Clontech’s rtTA-advanced plasmid (PT3899-5) into the LV backbone with EcoRI and 
BamHI cuts.  
 
LV-tetop-CRH Vector 
We inserted tetop-CRH (10), the CRH gene under the control of the tetop 
promoter, into the XhoI and EcoRV sites of pLenti-III-EF1α  (Applied Biological 
Materials, Richmond, BC., Canada).  
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Figure 2.1. Constructs of lentiviral vectors packaged into replication deficient 
virions.  Each LV vector contains an HIV-based system including 3’ and 5’ long 
terminal repeats (LTR), a 5’ self-inactivating (SIN) element to prevent replication and 
a woodchuck post-transcriptional regulatory element to enhance protein expression 
(A) LV-rtTA (B) LV-tetopCRH. Ψ = packaging signal; RRE = Rev response element; 
cPPT = central polyurine tract; gag = group-specific antigen; EF1α, MNDU3, and 
tetop = promoters; nls = nuclear localization signal; rtTA = reverse tetracycline 
transactivator; CRH = corticotropin-releasing hormone. 
 
 
Cell Culture 
The LV-GR was transiently infected into Chinese hamster ovarian (CHO)-K1 
cells (ATCC, CCL-61). Cells were seeded in a 9-well plate at 3 x 105 cells/ml and 
maintained in Dulbecco’s modified Eagle’s medium (Gibco BRL, Merelbeke, 
Belgium) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, 
Carlsbad, CA), and 1% pen strep (Gibco, New York, NY).  Cells were cultivated at 
37°C in a humidified atmosphere containing 5% CO2.  CHO-K1 cells were infected 
with LV-GR (7 µl, 7.4 x 108 TU/ml) or LV-GFP in triplicate while control wells 
contained CHO-K1 cells only. Whole cell extracts were prepared after a 72-hour 
incubation using total protein extraction buffer (PE buffer [10mM Hepes, 60mM KCl, 
1mM EDTA], 250mM dithiothreitol, 100% NP-40 and protease inhibitor mixture [0.5 
 198 
µg/ml aprotinin, 1 µg/ml pepstatin and leupeptin). Analysis of the integrated proviral 
genome was determined by Western blotting. 
 
Western Blotting 
60 µg of whole cell extracts were resolved through sodium dodecyl sulfate 
polyacrylamide gel electrophoresis using 4–12% gradient Bis-Tris polyacrylamide 
gels (Invitrogen, Carlsbad CA), transferred to a Hybond enhanced 
chemiluminescence nitrocellulose membrane (GE Healthcare Life sciences, Pittsburg, 
PA) using a semidry transfer system (Bio Rad, Hercules, CA), and blocked with 5% 
dry milk in PBS and 0.1% Tween-20 (Sigma Aldrich, St. Louis, MO).  Blots were 
probed with anti-GR antisera (M-20; Santa Cruz Biotechnology, Santa Cruz, CA) at a 
1/2,000 dilution overnight at 4°C.  Binding of horseradish peroxidase labeled goat 
anti-rabbit antibody (sc-2004) was determined using SuperSignal West 
Chemiluminescent substrate (Pierce, Rockford, IL). Blots were stripped with Restore 
Western Blot Stripping Buffer (Pierce, Rockford, IL) and reprobed with an anti-β-
actin antibody (Sigma Aldrich, St. Louis, MO) as an internal control to ensure equal 
loading of protein. 
 
Luciferase Assay 
We transfected CHO cells with a pTetop-luciferase (pTetop-luc) plasmid in 
conjunction with pLV-rtTA.  After administering doxy at 0, 10, and 100 ng/mL 
concentrations, we used a luminometer to measure relative light units (RLU) as an 
indicator of luciferase expression.  
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CRH Immunohistochemistry 
Mice were anesthetized with 2.5% Avertin, and transcardially perfused with 4% 
paraformaldehyde. The brains were immersed in 20% DEPC sucrose solution and 
sectioned at 30 um into PBS with 0.25% Triton X-100 (PBS-T); sections were stored 
at 4ºC until use. 0.3% hydrogen peroxide in PBS was used to quench endogenous 
peroxides, and sections were blocked in 10% normal goat serum (NSG) in PBS-T to 
prevent non-specific binding. Sections were incubated in primary antibody, 1:1000 
rabbit anti-CRF (Bachem, San Carlos, CA) at 4ºC overnight. Then, sections were 
labeled with biotinylated goat anti-rabbit IgG secondary (1:200, Vector Laboratories, 
Burlingame, CA) at room temperature for an hour, followed by an hour in 
avidin/biotin complex solution (Vector Laboratories, Burlingame, CA), and detected 
with diaminobenzidine (DAB) staining. The sections were air-dried on slides 
overnight, dehydrated with ethanol and xylene, and cover-slipped with Permount 
(Fisher Scientific, Pittsburg, PA). Stained slides were visualized under a light 
microscope (Zeiss Axio Imager) and images were prepared using Adobe Photoshop. 
 
Hematoxylin and Eosin (H & E) Staining 
Sections adjacent to those used for CRH immunohistochemistry were placed on 
slides and air-dried overnight. Slides were processed as follows: 2 min wash in 70% 
ethanol; 5 min wash in distilled water; 10 min staining in hematoxylin (Polysciences 
Inc, Warrington, PA); 3 washes in distilled water; 1 min in saturated lithium chloride; 
3 washes in distilled water; 2 min in 70% ethanol; 2 min in 80% ethanol; 90 sec 
staining in eosin (Polysciences Inc, Warrington, PA); 2 min in 70% ethanol; 2 min in 
80% ethanol; three 2 min washes in 95% ethanol; three 2 min washes in 100% 
ethanol; three 2 min washes in xylene; coverslipped with Permount (Fisher Scientific, 
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Pittsburg, PA). 
 
Stereotaxic Injection 
We gave mice a 10 mg/kg dose of ketoprofen (Fort Dodge, IA) and an hour 
later, anesthetized them with a 90 mg/kg ketamine (Ketaset, Fort Dodge IAO) / 10 
mg/kg xylazine (TranquiVed, Vedco, St. Joseph MO) solution and mounted them on 
a stereotaxic frame (Kopf Instruments, Tujunga, CA). We drilled small holes at the 
coordinates provided below and injected the LV at either a rate of 0.2µl/min into the 
central nucleus of the amygdala (CeA) or 0.5µl/min into the striatum. The mice were 
monitored for recovery and given a 10mg/kg dose of ketoprofen each day for 3 days 
post-surgery. Fourteen days after the injection, brains were harvested and processed 
for immunohistochemistry. Coordinates: CeA (1.25mm bregma, ±2.75 lateral, 4.75 
ventral); striatum (0mm bregma, 2.5 lateral, 3.8 ventral). 
 
 
RESULTS AND DISCUSSION 
CRH modulation in the brain of animal models has provided extensive 
evidence for their involvement in neuroendocrine, behavioral and autonomic 
responses to stress. An important question that arises is whether CRH activity differs 
with respect to disease state and whether CRH activity in distinct brain regions 
contributes in different proportions to anxiety versus depression, or any other 
affective disorder state for that matter. Elevated forebrain CRH produced different 
neuroendocrine and behavior responses depending on the length of time of CRH 
overexpression and the specific developmental period in which this overexpression 
occurred (10, 13).  Some of the forebrain regions with altered CRH included the 
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basolateral and central amygdalar nuclei, hippocampus, striatum, PVN of the 
hypothalamus, and nucleus accumbens. The ability to define how these regions 
contribute to the observed phenotypes will help discern which regions are important 
targets for specific psychiatric disorders. We can evaluate this using LV vectors, 
directly delivered to brain nuclei of interest, in mice with specific transgenes to alter 
expression of CRH. 
 
CRH modulation 
We used the tetracycline inducible method to enable modulation of CRH 
expression along developmental periods. We generated transgenic mice with the tetop 
promoter driving CRH gene expression (tetop-CRH).  
To enable inducible expression of CRH in a site-specific manner, we 
developed an HIV-1-derived replication-defective LV vector that possesses rtTA 
(LV-rtTA) (Figure 2.1. A).  The rtTA forms a Tet-on system and when bound to a 
tetop promoter can activate expression of any downstream gene of interest.  This 
expression is inducible: turned on in the presence of a tetracycline derivative, doxy, or 
off in its absence.  The rtTA has high inducibility (within hours of doxy 
administration) and low background (14, 15).  
To determine the in vitro efficacy of the virus, we transfected CHO cells with 
a combination of pTetop-luc and pLV-rtTA (pMNDU-rtTA).  We administered doxy 
at various concentrations and detected the luciferase expression as measured by the 
relative light units (RLU) (Figure 2.2.). In the presence of both pTetop-luc and pLV-
rtTA, doxy significantly increases the RLU, which was minimal with no doxy 
present, indicating that doxy allowed rtTA to bind to tetop and drive luciferase 
expression. 
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To determine the in vivo efficacy of our virus, we performed unilateral 
stereotaxic injections into the striatum of tetop-CRH mice that were either on or off 
doxy with 3µl of LV-rtTA (7.36 x 109 infectious units/mL). Two weeks after viral 
infection, we harvested the brains and performed immunohistochemistry to evaluate 
CRH protein expression. The data indicate that CRH is expressed only in the presence 
of both LV-rtTA and doxy in mice with the tetop-CRH transgene (Figure 2.3. A). To 
evaluate the tissue in the injected region, we performed H & E staining. The H & E 
staining in Figure 2.3. B illustrates mononuclear cell infiltration and cell toxicity in 
the LV-rtTA injected region. This data raised concerns of a possible host-
inflammatory response induced by the rtTA protein.  
To eliminate this confound, we decided to use mice that express tTA during 
development and thus are inherently tolerant to it (CamKIIα-tTA mice). 
Consequently, we generated an LV delivery system, LV-tetop CRH (Figure 2.1. B), 
complementary to the CamKIIα-tTA transgenic mice, by inserting the tetop-CRH 
gene into an LV vector, pLenti-III-EF1α (Applied Biological Materials Inc., 
Richmond, BC. Canada). 
To test in vivo efficacy, we unilaterally injected the striatum of CamKIIα-tTA 
mice that were either on or off doxy with 3µl of LV-tetopCRH  (titer 8.62x107 
infectious units/ml). We chose striatum because it has no endogenous CRH 
expression and thus it is easier to visualize CRH introduced by the virus over 
background staining. We evaluated CRH protein expression two weeks after viral 
infection. In comparison to the Tet-on system – LV-rtTA in the presence of doxy 
turns on CRH gene expression – in this system (Tet-off), LV-tetopCRH binds to the 
tTA in the mice with the CamKIIα-tTA transgene and drives CRH expression only in 
the absence of doxy. Thus, placing the mice on a doxy diet would turn off CRH 
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expression. This allows us to retain the ability to spatially and temporally restrict 
CRH expression. 
 
 
 
 
Figure 2.2. In vitro analysis of pLV-rtTA. CHO cells were co-transfected with 
pTetop-luc and pLV-rtTA in the presence and absence of doxy to test the efficiency 
of the pLV-rtTA plasmid.  Luciferase expression was then measured.  pLV-rtTA 
displays robust expression in the presence of doxy with low levels of expression in 
the absence of doxy.  RLU = relative light units, doxy = doxycycline    
 
 
 
The immunohistochemistry data indicate that CRH is expressed only in the 
presence of LV-tetopCRH (Figure 2.4. A). Mice on a doxy diet or non-injected mice 
do not show this striatal CRH expression (Figure 2.4. B,C). H & E staining in Figure 
2.4. D-F illustrates that the cells in the LV-tetopCRH injected region do not display 
the same toxic effect observed in the LV-rtTA injected mice. The data support the 
functionality of this new model.   
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Figure 2.3. CRH immunoreactivity and hemotoxylin & eosin (H&E) staining in 
tetopCRH mice injected with LV-rtTA. (A) CRH protein (dark brown pigment) is 
present when mice are on doxy chow. (B) H & E staining displays inflammatory cell 
infiltration within the injected region.  
 
 
 
 
 
 
Figure 2.4. CRH immunoreactivity and hemotoxylin & eosin (H & E) staining in 
CamKIIα-tTA mice injected with LV-tetopCRH. (A) CRH protein (dark brown 
pigment) is present when mice are off doxy chow. (B ,C) CRH protein is absent when 
mice are on doxy chow or in non-injected controls. H & E staining shows normal 
cells in the (D) absence or (E) presence of doxy as well as in (F) non-injected 
controls. 
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Previous literature supports the use of LV vectors to define the role of CRH in 
brain regions such as the CeA and bed nucleus of the stria terminalis (BnST) – two 
brain regions involved in mediating anxiety and fear behaviors (See (16) for review). 
CeA CRH elevation in male mice was found to affect anxiety behavior: reduce it with 
long-term elevation (17) but increase it with short-term elevation (18). On the other 
hand, BnST CRH overexpression was involved in inducing despair behavior (17). In 
comparison, CeA CRH elevation in rats demonstrated pronounced maladaptive 
alteration in measures of anxiety and despair, as well as HPA axis function, similar to 
that observed in human disorders (19, 20). These studies indicate how different the 
effects of CRH overexpression are dependent on region, length of over-expression, 
gender and/or species of organism 
The inducibility of our tetracycline system will enable CRH overexpression 
for short periods of time during development to evaluate how CRH activity at specific 
time periods can result in different phenotypic outcomes. The strength of our model is 
the ability to terminate CRH overexpression after a length of time to allow for 
molecular and circuit changes that may occur and influence future sensitivity to 
stress. For instance, does brief CRH overexpression in amygdalar nuclei early in 
development prime and provide resilience to fearful stimuli later in life? Or does it 
predispose pathological states of anxiety or despair? Perhaps the developmental 
period during which CRH overexpression occurs will predict whether it is beneficial 
or destructive when exposed to subsequent stressors.  
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CONCLUSIONS 
One of the limitations in treatment of psychiatric disorders is the limited 
knowledge of their underlying molecular etiology. We believe that LV constructs in 
combination with transgenic mouse models provide an avenue for evaluating 
molecular pathways specific to different affective disorders. The use of this paradigm 
to study other stress-related molecules and monoamines will possibly prove beneficial 
in understanding the causation of individual differences in the manifestation and 
prognosis of mood disorders. 
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CHAPTER III 
 
BEHAVIORAL CONSEQUENCES OF CORTICOTROPIN-RELEASING 
HORMONE OVEREXPRESSION IN THE CENTRAL NUCLEUS OF THE 
AMYGDALA IN ADOLESCENT MICE 
 
 
INTRODUCTION 
Dysregulation of the HPA axis has been strongly implicated in the genesis of 
stress-related disorders such as anxiety and depression(1–3). One characteristic these 
disorders share is an increased emotional response to neutral stimuli(4). Given that 
the amygdala mediates emotional responses to stress(5, 6), it is an important structure 
to study in order to further understand predispositions of certain individuals to 
psychiatric diseases. The amygdala receives input from sensory modalities and 
integrates this information to activate behavioral and physiological responses(7). 
Functional magnetic resonance imaging (fMRI) and positron emission tomography 
(PET) studies(8) in individuals with depression and PTSD show enhanced amygdala 
activation(9). Furthermore, ablation studies of the amygdala demonstrate decreased 
fear behavior and more docile demeanor in animals(10), implicating a role for this 
limbic structure in fear potentiation.  
Among the amygdala nuclei, the CeA stands out as the major nuclei of the 
amygdala for three main reasons. First, the CeA functions as the central integration 
point for most of the other amygdala nuclei and many other brain regions(11). 
Specifically, the basolateral amygdala (BLA) receives fear memory information from 
the hippocampus and sends it to the CeA, causing output to regions involved in the 
behavioral expression of fear (12, 13). The CeA itself receives direct cortical 
innervations from the prefrontal cortex (PFC), sensory areas, brainstem and 
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hypothalamus(11). Information about the salience of danger and cognition associated 
with it is sent to the CeA directly from the mPFC or indirectly through the BLA(4). 
This sensation of danger is heightened in individuals with anxiety disorders such that 
even neutral stimuli can evoke an emotional response(4). Noradrenergic projections 
from the locus coeruleus to the CeA increases CeA activity and CRH mRNA in the 
CeA and affects autonomic activation(14). The information sent into the CeA is thus 
integrated in a process that remains to be elucidated and is expressed in the form of 
autonomic and behavioral responses in CeA outputs. 
Second, the CeA is the major amygdala output structure(11) to regions 
involved in the stress response. Efferents of the CeA go to bed nucleus of the stria 
terminalis (BNST), hypothalamus, brainstem and midbrain nuclei, and modulate 
autonomic and behavioral functions(11). The CeA mainly contains GABAergic 
output and as such, its projections to the BNST disinhibit BNST inhibition of the 
PVN(11, 15). Due to limited direct CeA to PVN projections(16), this pathway is 
believed to be the mechanism by which the CeA activates the HPA axis(6). The CeA 
activates brainstem nuclei such as the periaqueductal gray to cause freezing and 
vocalization in the conditioned fear response to shock(11), and hence generates 
relevant fear responses to aversive stimuli(17). In psychiatric diseases, stimuli can 
activate the sympathetic nervous system, possibly through CeA activation of the locus 
coeruleus(18), resulting in increased heart rate and blood pressure(19). Electrical 
stimulation of the CeA also activates the sympathetic nervous system (11, 19) and is 
believed to activate the HPA axis and lead to an increase in plasma CORT in rats(20). 
Third, the CeA is a site containing large populations of CRH neurons(13, 18) 
most of which colocalize with GAD65/67, implying their GABAergic inhibitory 
activity(18). Moreover, electrophysiological data shows that CRH application 
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increases GABA inhibitory post-synaptic currents (IPSCs) in the CeA(2, 21). Not 
only does CRH act at receptors in the CeA, but it also activates CeA targets through 
interneurons disinhibition(2). However, other studies using neuronal tract tracing 
methods demonstrate that CRH immunoreactive CeA neurons form excitatory 
synapses with locus coeruleus dendrites(22) to cause excitation of the sympathetic 
nervous system. This indicates that CeA CRH can function both through excitatory 
and inhibitory pathways to exert its function. This circuitry of the CeA identifies a 
role for it in mediating pathways involved in behavioral, autonomic, and endocrine 
responses to stimuli(23), in part mediated by CRH. The role of CRH in affecting CeA 
targets may cause changes in behavior that increase risk for psychiatric disease.  
 
Role of CRH in CeA function 
The CRH peptide is distributed throughout the brain but found more 
concentrated in the PVN, CeA, and BnST(13, 24). CRH has two receptors, CRH-R1 
and CRH-R2, which have primarily non-overlapping expressions in the brain(25, 26). 
Restraint stress in rodents significantly increases the levels of CRH and CRH-R1 
mRNA in the PVN(27).  In the amygdala, CRH-R1 receptors are the predominant 
type expressed(26). Functionally, inhibition of CRH-R1 receptors prevents the CRH-
induced increases in GABAergic IPSCs in the CeA (2) and may also affect autonomic 
and behavioral functions of the CeA.  
Studies in patients with depression and PTSD show distinct elevations in CRH 
levels in the cerebrospinal fluid(28–33). Treatment of these depressed patients with 
CRH-R1 antagonist ameliorates the symptoms of anxiety and depression(34) and 
decreases HPA axis activity(35). Many anxiety and despair symptoms can be 
recapitulated in rodent models upon intracerebroventricular CRH administration, 
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through a pathway that is thought to be HPA axis–independent(36). This observation 
leads to the implication that extrahypothalamic sources of CRH are the main source 
of CSF CRH(36). Since CeA CRH is anxiogenic(17) and CeA stimulation 
exacerbates the effects of intracerebroventricular CRH(5), the CeA is a probable 
extrahypothalamic source of CSF CRH. This hypothesis is supported in rodent 
models using both in-vivo microdialysis studies that demonstrate elevated CeA CRH 
following restraint stress(37), as well as chronic CORT administrations. Furthermore, 
elevated CeA CRH in animal models also demonstrate elevated anxiety(38) 
suggesting that changes in CeA CRH levels are a potential model of CeA dysfunction 
in psychiatric disease.  
When CeA CRH is reduced with the use of antisense oligonucleotides (13) or 
by GR deletion in the CeA (CeAGRKO)(39), memory retention in conditioned fear 
test is impaired. Furthermore, the CeAGRKO mice show rescue of conditioned fear 
behavior if intracerebroventricular CRH is administered before conditioned fear 
training(39). It appears therefore that there is a homeostatic level of CRH required in 
the CeA for normal function and any deviation above or below this level can result in 
behavioral and neuroendocrine problems. CRH receptor antagonists applied to the 
CeA reduce elevated plus maze(40) and CRH-mediated anxiety behavior(41). CRH-
R1 antagonists diminish anxiety and HPA axis response, and increases exploratory 
behavior in primates(42). Although the anxiety attenuating effects of CRH R1 
antagonist was not observed in a study looking at novelty-suppressed feeding in 
rat(43), most studies to date do suggest a role for CeA CRH in anxiogenic 
behaviors(44), fear memory consolidation(39), as well as autonomic responses (15).  
Behavioral data also shows that the CeA is involved in the psychological 
aspect of stress. Studies comparing the effects of the physical stress of treadmill 
 213 
running, to psychological restraint stress, show that the increase in CeA CRH 
throughout the restraint stress was not seen to the same extent in treadmill running 
rats (45). This implies that the CeA is more a mediator of the psychological stress 
response and this mediation may occur through modulation by CRH (17).  
Studies in transgenic mice that overexpress CRH show reduced locomotor 
activity in a novel environment and increased anxiety behaviors (36). Forebrain CRH 
overexpression in the first three weeks of life produces anxiety-like behavior and 
despair-like behavior (46). The use lentiviral vectors to specifically overexpress CRH 
in the CeA and the BNST of male mice demonstrate that chronic CRH overexpression 
in the CeA does not affect anxiety under basal conditions (47). However upon a 30 
minutes restraint stress, anxiety behavior is attenuated, implying that chronic 
overexpression can cause habituation to a stressor(47). In contrast lentiviral vectors to 
overexpress CRH in the CeA of female rats, showed increased anxiety, increased 
despair, and impaired negative feedback of HPA axis, all changes associated with 
stress pathology (6). The discrepancy in these two studies may be a result of the 
length of over-expression time, and gender and/or species differences. 
The studies describe above were all performed in adult mice, and do not 
evaluate the effects of CeA CRH overexpression early in life. Stress in early life is 
known to increase the risk of psychiatric disorders later in life, suggesting that the 
developmental time period of stress exposure affects neuroendocrine and behavioral 
outcomes. Adults who experienced some form of childhood stress show elevated 
basal cortisol, increases in ACTH responsiveness, and heightened emotional 
responses to stressful stimuli than control patients with childhood stress (48). It is 
therefore necessary to evaluate the effects of CeA CRH overexpression early in life to 
understand its development role in the stress regulation. 
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In order to test the hypothesis that CeA CRH overexpression in adolescent 
leads to maladaptive stress responses, we combine the use of a lentiviral vectors with 
the tetracycline inducible system. Our lab has developed a lentiviral vector described 
in the previous chapter that will allow for spatial and temporal CRH overexpression 
(49). Targeting the CeA in adolescent mice will allow the study of specific changes 
that occur in this brain region upon HPA-axis dysregulation and how this affects 
diseases such as anxiety and depression. 
 
 
MATERIAL AND METHODS 
Animals 
All animal protocols were in accordance with National Institutes of Health 
guidelines and were approved by the Institutional Animal Care and Use Committee at 
Cincinnati Children’s Medical Center (Cincinnati, OH). Mice were housed on a 14 
h/10 h light/dark cycle with ad libitum access to rodent chow and water. CamtTA 
mice (CaMKIIα-tTA): mice express the tetracycline transactivator under the control of 
the CaMKIIα promoter (Jackson Laboratories). 
 
LV-tetop-CRH Vector 
Tetop-CRH (46), the CRH gene under the control of the tetop promoter, was 
inserted into the XhoI and EcoRV sites of pLenti-III-EF1α  (Applied Biological 
Materials, Richmond, BC, Canada). The resulting plasmid was sent to the Hope 
Center Viral Vector Core (Washington University, St. Louis, MO) for packaging 
(described in Chapter 3). 
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Stereotaxic Injections 
We treated mice with 10 mg/kg of ketoprofen (Fort Dodge, IA) one hour 
before anesthetizing them with a 90 mg/kg ketamine (Ketaset, Fort Dodge IAO) / 10 
mg/kg xylazine (TranquiVed, Vedco, St. Joseph MO) solution.  Mice were mounted 
on a stereotaxic frame (Kopf Instruments, Tujunga, CA) and drilled small holes for 
CeA coordinates (1mm bregma, ±3 lateral, 4.3 ventral). We injected control or 
CamtTA mice at postnatal day 28-31 (P28-31) with 1µl of LV-tetop CRH (titer: 6.8 x 
108 IU/ml) at a rate of 0.25µl/min into the CeA. We monitored the mice for recovery 
and gave them a 10mg/kg dose of ketoprofen each day for 3 days post-surgery. 
Behavioral testing in mice occurred two weeks post-surgery. 
 
CRH in situ hybridization 
Mice were anesthetized mice with a 90 mg/kg ketamine (Ketaset, Fort Dodge 
IAO) / 10 mg/kg xylazine (TranquiVed, Vedco, St. Joseph MO) solution, perfused 
with DEPC 1x PBS followed by 4% DEPC PFA, and the brains were post-fixed 
overnight in 4% DEPC PFA. After 48-hour immersion in 20% DEPC sucrose solution 
at 4ºC, brains were embedded in OCT. 16um sections were obtained from brains at -
15ºC in a cryostat and mounted onto Superfrost+ slides (VWR), vacuum-dried 
overnight, and stored at -80ºC until in situ hybridization was performed. 33P UTP was 
used to label an RNA probe complementary to a 0.32 KB fragment on exon 2 of the 
CRH mRNA. Sections were hybridized to the labeled probe at 65ºC for 16 hours and 
washed in 0.1X SSC at 60ºC for 30 min. Slides were exposed to Maximum resonance 
film (Kodax BioMAx, Rochester N.Y.) for 4 days. We scanned the autoradiographic 
images at 3200 dots/inch into Photoshop on an Epson Perfection V600 scanner and 
quantified using NIH Image J software. 
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Behavioral Testing 
All behavioral testing was performed in mice two weeks after lentiviral 
injections when the mice were between postnatal day 53 – 73  (P53-P73). Behavioral 
tests were performed between 8:00 a.m. and 12:00 p.m. Mice acclimated in a room 
adjacent to the testing room for an hour before behavioral testing. Behavioral tests 
were performed in the Cincinnati Children’s Hospital behavior core.  
 
Open field (OF) test: Locomotor exploration/activity was measured in a 41 cm × 
41cm chamber (Accuscan Instruments, Columbus, OH). The chamber was equipped 
with a 16 LED-photocells 2 cm above the floor in x- and y-planes 2.5cm apart. Each 
trial lasted for a period of 30 minutes, and was analyzed in 5-minute interval. During 
that time, the PAS Activity program (San Diego Instruments, CA) was used to 
measure behaviors such as time spent, distance travelled, and number of entries into 
the inner and outer zones of the chamber.  
  
Light dark (LD) test:  The same apparatus used in the OF test was used in this LD 
test. A rectangular black acrylic (40 cm x 20 cm) insert with an opening was placed 
into the box and provided a half light, half dark box. Mice were placed a corner of the 
dark side and allowed to explore for 10 minutes. We recorded latency to enter the 
light zone, number of entries and time spent in the different zones. 
 
Elevated Zero Maze (EZM) test: This maze (50cm inner diameter, 5cm lane width, 
15cm wall height, placed 50 cm off the ground on 4 braced legs) consists of a round 
maze with opposing open and closed arms. Mice are placed in the center of the open 
arm and activity is scored for 5 minutes. Time spent in the open and closed areas, as 
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well as latency and number of entries into the open and closed areas was measured.  
 
Tail suspension test (TST):  This test used a rectangular tabletop platform with a hole 
through which the mouse’s tail was suspended. Latency to immobile and time spent 
immobile were measured manually with the use of a computer software. 
 
Forced swim test (FST): This test utilizes a clear 25 cm x 20 cm acrylic cylinder filled 
¾ full with water at room temperature (25°C). Mice are placed in the beaker for 1 
minute to acclimate to the chamber, after which we tested the mice for 5 minutes. 
Latency to immobile and time spent immobile were measured. Mice were placed in a 
warm cage and toweled dried.  
 
 
Statistical analysis 
The results are presented as mean ± SEM after data were subjected to Student 
t-test, one- or two-way ANOVA test (Prism 5.0 software; GraphPad Software, Inc., 
San Diego, CA). Statistical significance was defined as a p value ≤ 0.05 and was 
analyzed using the Tukey or Bonferroni post hoc test. 
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RESULTS 
Overexpression of CRH in the CeA of adolescent mice 
We used the tetracycline-inducible system in combination with lentiviral 
vectors to specifically overexpress CRH in the CeA (Figure 3.1.).  Using a lentivirus 
containing GFP, we show accurate targeting of the CeA in mice at P28 (Figure 3.2. 
A). We overexpressed CRH in the CeA in adolescence by injecting LV-tetop CRH 
into wild-type (Control) or CamtTA (CeA CRH-OE) when mice were between P28-
P30. CRH in situ hybridization was evaluated 2 weeks after lentiviral injection, and 
demonstrated a 2-fold increase in CeA CRH-OE compared to control mice (Figure 
3.2. B) 
 
 
 
 
 
 
 
 
 
Figure 3.1. CRH overexpression model. Spatial and temporal restriction of CRH 
overexpression using the tetracycline-inducible system. In the absence of doxycycline, the 
tetracycline transactivator (tTA) binds to the tetracycline-responsive promoter (tetop) and 
drives CRH expression. In the presence of doxycycline, CRH overexpression is prevented. 
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Figure 3.2. CeA targeting and increased CRH mRNA expression. (A) Picture depicting 
accurate targeting of the CeA through GFP injection. (B) In situ hybridization quantification 
demonstrating a 2-fold increase in CRH mRNA expression in adolescent mice.  
 
 
Adolescent CeA CRH-OE mice display no anxiety or despair phenotypes 
To evaluate the effects of CeA CRH overexpression on behavior in adolescent 
mice, we tested control and CeA CRH-OE mice in a number of behavioral paradigms 
during the late adolescent period (P53-P73). We observe normal locomotor behavior 
in CeA CRH-OE mice in terms of distance traveled in the OF test (Figure 3.3. A).  
However we do not observe increased anxiety behaviors in the OF (Figure 3.3. B-D). 
The LD and EZM tests also reveal no differences in anxiety behaviors in CeA CRH-
OE mice compared to controls (Figure 3.4. A-F). When we evaluated the effects of 
amygdala CRH increase on despair-like behaviors in the TST and FST tests, we 
observed no differences between control and CeA CRH-OE mice (Figure 3.5. A-D).  
 
 
 
 
 
 
A B 
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Figure 3.3. Adolescent CeA CRH-OE mice display no locomotor or anxiety phenotypes 
in the OF test. Adolescent male CeA CRH-OE mice show normal locomotor activity (A) and 
no anxiety behavior in terms of time spent (B), latency (C) and number of entries (D) into the 
center zone. 
 221 
 
 
Figure 3.4. Adolescent CeA CRH-OE mice display no anxiety phenotypes in the LD and 
EZM tests. Adolescent male CeA CRH-OE mice show no anxiety behavior in the LD test in 
terms of time spent (A), entries (B) and latency (C) into the light zone. No anxiety behavior 
was observed in the EZM test in terms of time spent (A) and entries (B) into the open arm and 
no chance in the latency to enter the closed zone (C). 
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Figure 3.5. Adolescent CeA CRH-OE mice do not display any despair phenotypes in the 
TST and FST tests. Adolescent male CeA CRH-OE mice show no despair behavior in the 
TST test in terms of time spent (A) or latency (B) to the immobility. No despair behavior was 
observed in terms of time spent (C) or latency (D) to the immobility in the FST test. 
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DISCUSSION 
The amygdala plays a key role in generating emotional responses to stress and 
is coupled with HPA axis hyperactivity. One way the HPA axis responds to stress is 
through increasing levels of CRH in the CeA. The effects of persistent elevations in 
CeA CRH in mediating behavioral and neuroendocrine responses to stress remain 
unclear. Additionally, the effects of transient CeA CRH overexpression during 
developmentally critical periods, such as adolescence, are unexplored. We 
hypothesized that transiently elevated CeA CRH during adolescence will lead to 
anxiety and despair-like behaviors.  
The use of tetracycline-inducible transgenic mice models to overexpress CRH 
during specific periods of development, in combination with stereotaxic injections of 
viral vectors, allowed for the CeA-specific increases in CRH. Our model for CRH 
overexpression using CamtTA mice is limited by basal functional changes in CamtTA 
mice ((50), data not shown). Since we did not observed any behavioral difference in 
CeA CRH-OE mice compared to controls, it is possible that the elevated CeA CRH 
may cause adaptations or compensation in CRH signaling through regulation of the 
availably and activity of CRH receptors. By understanding region-specific functions 
of CRH in the stress response, the function of the CRH system can be elucidated to 
determine when a response will either cause a return to homeostasis or a drive 
towards psychiatric disease.  
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